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Extracellular matrix (ECM) biomarkers are useful for measuring underlying molecular activity 
associated with cardiac repair following acute myocardial infarction (AMI). While promising as 
predictive tools, integration into clinical practice has been hindered by discordant findings 
within the literature and investigations have largely been limited to single biomarker analysis. 
Thus, this thesis explored alternative strategies for examining circulating ECM biomarkers in 
AMI.  
 
Firstly, we examined the feasibility of combining circulating ECM biomarkers in a cohort of 140 
AMI patients. ECM biomarkers measured in this study included: fibroblast growth factor basic 
(FGFb), matrix metalloproteinase (MMP) -2, -3, -8, -9, osteopontin, periostin, N-terminal type 
I procollagen (PINP), transforming growth factor - beta 1 (TGF-β1), tissue inhibitor of matrix 
metalloproteinase (TIMP) -1, -4 and vascular endothelial growth factor (VEGF). Application of 
exploratory factor analysis (EFA), a mathematical technique to elucidate the underlying 
structure of variables, demonstrated collinearity between biomarkers. Combination of 
biomarkers using cluster analysis separated patients into three distinct clusters, with 
differential levels of peak high-sensitivity troponin T and global registry of acute coronary 
events (GRACE) scores. We demonstrate that complex interrelationships exist between ECM 
biomarkers and combination can distinguish ECM profiles associated with differential patient 
risk.  
 
Next, we explored the temporal variability of circulating ECM biomarkers in a prospective 
cohort of 23 AMI patients. When compared to levels in 12 healthy volunteers, MMP-8, MMP-
9, PINP and TIMP-1 were elevated in AMI patients at one or more of the time points measured, 
while MMP-3 and periostin were significantly decreased. Longitudinal profiles of these ECM 
biomarkers demonstrated some temporal variation, but no clear trend in maximal or minimal 
levels were identified. Furthermore, only weak-to-moderate correlations were observed 
between ECM biomarkers and baseline left ventricular ejection fraction (LVEF) and area under 
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the curve (AUC) high-sensitivity Troponin T, suggesting that biomarker variation was not 
primarily driven by indices of myocardial damage.  
 
Harnessing this panel of seven ECM biomarkers, we investigated the clinical utility of 
combined biomarker analysis to predict the development of systolic and diastolic dysfunction 
in patients with echocardiogram measurements within 1 year of AMI. Specifically, 
combination of MMP-3, MMP-8, MMP-9 and TIMP-1 using cluster analysis separated patients 
into two clustered groups. Assignment to Cluster One, as well as prescription of ACE inhibitors 
at discharge, peak high-sensitivity troponin T ≥ median levels and current smoking were 
independent predictors for development of systolic dysfunction. However, neither single nor 
combined biomarker analysis could predict development of diastolic dysfunction. Thus, these 
findings demonstrate both the advantages and limitations of combined ECM biomarker 
analysis for predicting LV remodelling processes.  
 
Potentially, novel biomarker approaches should be developed to represent ECM activity 
during AMI. Therefore, the final study in this thesis examined extracellular vesicle (EV) 
expression in cardiac fibroblasts stimulated under pro-inflammatory and pro-fibrotic 
conditions in vitro. Using RNA sequencing, we identified 12 EV microRNAs differentially 
expressed across stimulation conditions. To the best of our knowledge, this is the first study 
to investigate cardiac fibroblast-derived EVs under conditions representing early cardiac 
repair processes, and these may provide novel putative targets for future biomarker research. 
 
Together, findings from this thesis demonstrate the complexity of measuring ECM biomarkers 
in AMI. We have shown that combined biomarker analysis may more appropriately capture 
ECM activity than single biomarkers, and we have provided future potential targets for 
assessment of cellular activity in cardiac repair.  
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1.1 Cardiovascular Disease 
1.1.1 Burden of disease 
Cardiovascular disease (CVD) is the overarching clinical definition to describe disorders that 
affect the myocardium and blood vessels. The Global Burden of Disease (GBD) 2019 [1], a 
multinational collaborative study that estimates disease burden across 204 countries and 
territories worldwide, has demonstrated an increased prevalence of CVD from an estimated 
271 million cases in 1990 to 523 million in 2019. Globally, CVD accounted for an estimated 
18.6 million deaths in 2019 [1]. In the most recent Ministry of Health mortality statistics, CVD 
was responsible for approximately one third of total New Zealand deaths in 2017 [2]. In 
addition, death from CVD was twice as likely in Māori when compared to non-Māori [2]. 
Despite evolving treatment strategies and advances in medical therapies, CVD remains the 
leading cause of morbidity and mortality worldwide. 
 
1.1.2 Coronary artery disease 
Coronary artery disease (CAD) is a chronic inflammatory condition which results in the gradual 
narrowing of the coronary arteries due to long-term accumulation of fatty deposits [3]. 
According to the GBD 2019, CAD was responsible for an estimated nine million deaths in 2019, 
and this accounted for approximately 49.2% of all mortality in CVD [1]. The All of New Zealand, 
Acute Coronary Syndrome - Quality Improvement (ANZACS-QI) registry has demonstrated that 
160,109 New Zealand residents aged between 35-84 years were hospitalised for CAD between 
2005 and 2015 [4]. During this same decade, CAD was responsible for approximately 35,000 
deaths [4]. Overwhelming, Māori and Pacific people are disproportionally represented in CAD 
mortality statistics [5], and this further highlights ongoing risk and health inequities. 
Atherosclerosis is the principle underlying pathophysiology for CAD development, and is 
described in the following section.   
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1.1.3 Atherosclerosis 
Atherosclerosis is a chronic inflammatory condition characterised by the accumulation of 
lipids, inflammatory cytokines, fibrous elements and immune cells within the intima of the 
arterial wall [6, 7]. Lesion development is initiated when low density lipoprotein (LDL) particles 
accumulate in the arterial intima [6]. LDL accumulation is facilitated by a compromised 
endothelial barrier, which can be attributed to both haemodynamic strain and lipoprotein 
modification [8]. At sites of arterial curves and branches, low sheer stress and disturbed blood 
flow can increase endothelial microparticle release [9] and apoptosis [10]. In addition, LDL 
retained within the arterial wall can undergo oxidisation and enzymatic modification to 
release phospholipids which further propagate endothelial dysfunction [11]. 
 
Modified endothelial cells upregulate the expression of adhesion molecules [12, 13], which 
recruit circulating monocytes and immune cells to the disturbed endothelial monolayer. 
Infiltrating monocytes differentiate into macrophage cells and engulf lipoprotein as a 
protective mechanism to reduce arterial burden [14]. However, this process is a double-edged 
sword. While removal of fatty deposits is essential for preventing lipoprotein accumulation, 
continuous engulfment of lipoproteins causes the pathological transformation of macrophage 
cells to foam cells [15]. Simple lesions, known as fatty streaks, are characterised by the 
accumulation of these lipid-laden foam cells beneath the surface of the endothelium, and are 
precursors for the development of more advanced lesions [16]. Fatty streak formation can 
begin within the first decade of life, and largely remains subclinical within the population [16, 
17]. 
 
The atherosclerotic lesion is progressed by the accumulation of foam cells in the arterial 
intima, and the gradual development of a necrotic core due to excessive inflammation causing 
cell death [14, 18]. Resident and infiltrating vascular smooth muscle cells (VSMC) respond to 
this invasion by proliferating and synthesising elevated levels of extracellular matrix (ECM) [6]. 
Collagen-rich fibrous tissue produced by VSMC forms the fibrous cap of the growing plaque, 
which keeps the lesion structurally stable and isolated from the circulation [16]. However, 
chronic exposure to the pro-inflammatory environment and hemodynamic strain promotes 
VMSC apoptosis and the release of matrix-degrading enzymes that can compromise the 
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integrity of the fibrous cap. Exposure of the pro-thrombotic elements of the lesion to the 
external environment promotes platelet activation and thrombus formation, leading to the 
clinical manifestations of acute coronary syndromes (ACS) [3]. The evolution of atherosclerosis 
is schematically shown in Figure 1-1.  
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Figure 1-1. The pathological progression of atherosclerosis.  
This figure describes the initiation and progression of atherosclerosis. Beginning as an initial lesion, atherosclerosis is defined by gradual 
accumulation of lipids in the coronary arteries. This process is propagated by endothelial cell dysfunction and leukocyte activity, and can develop 
into the clinical manifestations of acute coronary syndromes. This figure was created on Biorender.com, Toronto, Canada. 
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1.1.4 Acute coronary syndromes  
1.1.4.1 Pathology 
ACS is the unstable presentation of CAD, and describes the clinical manifestations of partial or 
complete occlusion of the coronary arteries. The abrupt transition from atherosclerosis to ACS 
is most commonly caused by exposure of the thrombolytic elements of the vulnerable plaque 
to the external environment [3].  
 
Studies using computed tomographic (CT) angiography, a non-invasive methodology to 
evaluate the arterial wall and lumen, have demonstrated that reduced calcification and 
outward expansion of the artery wall are characteristics of a vulnerable plaque associated with 
ACS [19, 20]. There are two methods for acute thrombus formation at the site of an exposed 
atherosclerotic plaque: plaque rupture or erosion. Autopsy studies and in vivo optical 
coherence tomography (OCT) have shown that plaque rupture accounts for a majority of 
coronary thrombosis events, while plaque erosion occurs in approximately 30% of acute 
myocardial infarction (AMI) patients [21, 22]. Importantly, plaque rupture or erosion does not 
occur in isolation, and may not solely propagate an ACS. Instead, local flow dynamics, elevated 
inflammation and a high thrombogenicity of plaque components is required for plaque 
rupture or erosion to create a coronary event [3] 
 
Partial or complete coronary occlusion can impede perfusion, and is a process clinically 
identified as ischaemia. Prolonged ischaemia can lead to oxygen deprivation of localised 
cardiac tissue, and in some cases can cause mass cellular death, which is described clinically 
by infarction [23].  
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1.1.4.2  Clinical definitions 
ACS encompasses a spectrum of diseases categorised by ranging severity of ischaemia and the 
presence or absence of infarction [23]. Manifestations of ischaemia and infarction are 
commonly accompanied by symptoms which can include: anginal chest pain, dyspnoea 
(shortness of breath), diaphoresis (sweating) and nausea [24]. ACS is diagnosed and 
differentiated based on early clinical evaluation using a 12-lead electrocardiogram (ECG) and 
detection of cellular injury biomarkers, such as Troponin I and T [25]. Clinical definitions of 
ACS and their associated phenotypes are described in Figure 1-2. 
 
Unstable angina (UA) is identified by clinical presentation with chest pain at rest or under 
minimal exertion. UA patients demonstrate ECG changes consistent with myocardial 
ischaemia, but do not exhibit elevated levels of cardiac troponins due to negligible infarction 
[26, 27].  Non-ST-elevation myocardial infarction (NSTEMI) is clinically described by sub-
endocardial ischaemia, and presents with elevation of cardiac injury enzymes in the presence 
or absence of ischaemic ECG changes [25]. Guidelines commonly use the group term non ST-
elevation acute coronary syndrome (NSTE-ACS) to describe UA and NSTEMI [26, 27]. ST-
segment elevation myocardial infarction (STEMI) presents most commonly when ischaemia is 
transmural. STEMI is clinically identified by ST-segment elevation in at least two contiguous 
ECG leads and in combination with significant changes in cardiac injury biomarker levels  [25]. 
Collectively, the terms NSTEMI and STEMI define the two types of AMI. 
 
The Fourth Universal Definition of Myocardial Infarction [25] describes five classifications of 
myocardial infarction (MI). Type 1 MI is most commonly associated with CAD, and precipitated 
by atherosclerosis. Type 2 MI is associated with an imbalance between oxygen supply and 
demand that is not linked to plaque instability. Type 3 MI transpires in situations where 
suspicion of AMI is high, but cardiac enzyme biomarker testing has not occurred or been 
confirmed prior to patient mortality. Procedural complications, such as percutaneous 
coronary intervention (PCI) with or without stent thrombosis or restenosis, is linked to Type 4 
MI, while complications associated with coronary artery bypass graft (CABG) surgery is the 
main cause of Type 5 MI.  
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Figure 1-2. The spectrum of acute coronary syndromes.  
Schematic representation of clinical manifestations of acute coronary disease. Disease severity, degree of myocardial necrosis, symptom 
presentation and disease pathology are described in relation to unstable angina, non-ST-elevation myocardial infarction and ST-elevation 
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1.1.5 ACS treatment and management 
The main management goal for treating ACS is to reduce the amount of myocardial necrosis, 
and to preserve cardiac function. Two mainstay methods for ACS therapy include coronary 
revascularisation and pharmacological therapy. National [28, 29] and international [26, 27, 30, 
31] guidelines have been created to summarise evidence-based research. These guidelines 
inform decision making in order to provide the best management strategy for patients.  
 
1.1.5.1 Coronary revascularisation  
Coronary revascularisation in the context of AMI describes the restoration of perfusion to the 
heart following coronary artery occlusion [32]. The mainstay methods of coronary 
revascularisation include PCI, fibrinolytic therapy and CABG. Treatment strategies for ACS are 
personalised and based on multiple competing factors that include ACS classification, access 
to PCI, urgency for treatment, extent of vessel disease, presence of reduced left ventricular 
(LV) function or existence of multiple risk factors. Ultimately, a patient’s propensity for 
adverse outcomes, as well as access to procedural facilities, will determine the appropriate 
strategy for coronary revascularisation. 
 
In STEMI, reperfusion therapy should be administered to all eligible patients within 12 hours 
of symptom onset [31]. The two recommended revascularisation strategies for acute care of 
STEMI patients includes primary PCI or fibrinolytic therapy. Primary PCI describes a non-
invasive interventional procedure that unblocks and widens blood vessels by balloon 
angioplasty and insertion of a wire stent. In contrast, fibrinolytic therapy is a medical strategy 
that causes thrombus breakdown via activation of plasminogen, which cleaves fibrous clots. 
Primary PCI is the preferred reperfusion strategy for STEMI patients when time-to-treatment 
delays are short and a PCI-capable centre is available [30, 33, 34]. Primary PCI should be 
performed within 90 minutes of first medical contact. However, if patients are not located 
within 120 minutes of a PCI-capable hospital, fibrinolytic therapy is recommended and should 
be administered within 30 minutes of hospitalisation [30].  
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CABG is a cardiac surgery in which a section of blood vessel is grafted from the aorta or internal 
mammary arteries to bypass the blocked segment of coronary artery [35]. Urgent CABG has a 
limited role in the acute phase of STEMI and is only recommended in some patients with 
cardiogenic shock, or in cases where PCI has failed or could not occur due to unamenable 
coronary anatomy [30].  
 
The evidence supporting an early invasive strategy for the management of NSTE-ACS is less 
certain. TIMACS [36] and VERDICT [37],  two monumental randomised control trials assessing 
the benefit of an early invasive strategy in NSTE-ACS, demonstrated no additional 
improvement in overall long-term outcomes of patients who received early invasive treatment 
versus standard or delayed strategies. However, both studies observed a marked benefit for 
early invasive treatment in high-risk patients [36, 37]. Therefore, current guidelines 
recommend early invasive treatment for NSTE-ACS patients with refractory angina, 
hemodynamic or electrical instability, or for stabilised patients with elevated risk for clinical 
events [27]. PCI and CABG are both acceptable methods for coronary revascularisation in 
NSTEMI patients. The treatment strategy chosen will be dependent on patient risk-
stratification [27].    
 
1.1.5.2 Pharmacological management 
1.1.5.2.1 Aspirin 
Aspirin, also known as acetylsalicylic acid, irreversibly inhibits the synthesis of thromboxane 
A2 (TXA2) by inactivating platelet cyclooxygenase-1 (COX-1) activity [38]. This is of significance 
in the context of anti-platelet therapy, as TXA2 is important for platelet activation and 
aggregation processes. The role of aspirin in secondary prevention of CVD is well established 
in the literature, and has been demonstrated to significantly reduce mortality in ACS [39-41]. 
The New Zealand Guidelines for management of NSTEMI [28] and STEMI [29] patients 
recommends immediate loading with 150 - 300 mg of Aspirin, and chronic maintenance with 
a lower dose of 75 - 100 mg. This is in agreement with the American College of 
Cardiology/American Heart Association (ACC/AHA) [27, 30] and European Society of 
Cardiology (ESC) guidelines [26, 31].   
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1.1.5.2.2  P2Y12 receptor inhibitors 
While aspirin is critical for inhibiting TXA2-mediated platelet activation and aggregation, 
platelets can also be activated by alternative pathways that include adenosine diphosphate 
(ADP) [42]. Specifically, P2Y12 receptor inhibitors, such as Clopidogrel, Ticagrelor and 
Prasugrel, selectively bind to the P2Y12 receptor to inhibit ADP mediated platelet activation. 
In a New Zealand setting, ACS patients predominately receive Clopidogrel or Ticagrelor. 
 
Clopidogrel is a thienopyridine that irreversibly inhibits platelet activation through active 
metabolite binding of the pro-drug, metabolised by the hepatic cytochrome P 450 system, to 
the P2Y12 platelet receptor [42]. Clopidogrel paired with aspirin is more effective for secondary 
prevention than aspirin alone in ACS. Specifically, the CURE [43],  CREDO [44] and CLARITY [45] 
randomised control trials demonstrated reduced cardiovascular mortality, AMI, and stoke 
incidences in patients receiving DAPT with Clopidogrel when compared to aspirin alone.  
 
Ticagrelor is a non-thienopyridine, and directly and reversible changes the conformation of 
the P2Y12 receptor to inhibit platelet activation [42].  When compared to DAPT with 
Clopidogrel, patients receiving Ticagrelor in the PLATO trial [46] had significantly reduced 
cardiovascular-related mortality and AMI when measured individually and in combination 
with incidence of stroke. In addition, stent thrombosis and all-cause mortality were also 
reduced in the Ticagrelor arm of the trial [46]. Thus, Ticagrelor is the preferred P2Y12 receptor 
inhibitor in New Zealand, and a loading dose of 180 mg followed by a twice-daily 90 mg 
maintenance dose is recommended in AMI patients [28, 29]. These recommendations are 
supported by international guidelines [26, 27, 30, 31]. 
 
 
1.1.5.2.3 Renin-angiotensin system inhibitors 
The renin-angiotensin system (RAS) is a well-established regulator of cardiovascular 
physiology and pathophysiology. Specifically, conversion of angiotensin I to angiotensin II by 
the angiotensin-converting enzyme (ACE) modulates the autonomic nervous system through 
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interactive binding with the AT1 and AT2 receptors [47]. ACE inhibitors mediate the RAS by 
competitively blocking ACE to prevent angiotensin I conversion, while angiotensin receptor 
blockers (ARB) bind to the AT1 receptor to prevent angiotensin II signalling [47]. Systematic 
meta-analyses of large randomised control trials have demonstrated reduced mortality and 
morbidity in ACS patients on short-term [48] and long-term [49] ACE inhibitor therapy. 
Specifically, benefits were most pronounced in patients with LV dysfunction, an anterior MI, 
a heart rate ≥ 100 beats per minute or patients with heart failure. Therefore, ACE inhibitor 
therapy is recommended in patients with an anterior infarction or evidence of heart failure or 
LV systolic dysfunction (<40%), as well as patients presenting with co-morbidities such as 
diabetes mellitus or stable chronic kidney disorder [26, 31]. Patients intolerant to ACE 
inhibitors should be offered ARB as an alternative therapy.  
 
1.1.5.2.4 Beta-blockers 
Beta-blockers competitively inhibit the binding of the catecholamines, such as adrenaline, to 
beta-receptors and subsequently reduce myocardial oxygen consumption by lowering heart 
rate, blood pressure and myocardial contractility. Early randomised control trials assessing 
beta-blocker efficacy in patients with stable heart failure or LV systolic dysfunction 
demonstrated improved survival and patient outcomes when compared to placebo [50, 51]. 
Thus, guidelines recommend the initiation of beta-blockers in patients with heart failure or LV 
systolic dysfunction (<40%) [26, 31]. However, beta-blocker therapy is contraindicated in 
patients with acute heart failure, evidence of low-output state or those at high-risk for 
cardiogenic shock [27, 30]. 
 
1.1.5.2.5 Statins 
Statins are pharmacologically recognised as lipid-lowering agents [52]. The mechanism of 
action for statin therapy is associated with inhibition of 3-hydroxy-3-methylglutaryl-coenzyme 
A (HMG-CoA) reductase, which is enzymatically responsible for synthesising the main 
substrate for cholesterol production, mevalonate [52]. A meta-analysis by the Cholesterol 
Treatment Trialists Collaboration [53] investigating 14 randomised control trials that assessed 
statin therapy efficacy compared to no treatment, confirmed that statins reduced the 
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incidence of major adverse events, defined by cardiovascular-specific death, non-fatal MI, 
coronary revascularisation or stroke, by approximately one fifth per mmol/L LDL cholesterol 
reduced. Subsequently, guidelines recommend the initiation of high-intensity statin therapy 
immediately following NSTE-ACS or STEMI presentation [26, 31]  
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1.2 Adverse left ventricular remodelling 
1.2.1 Burden of adverse left ventricular remodelling 
While short-term and long-term survival following AMI has improved in recent decades, AMI 
patients still remain at increased risk for adverse cardiovascular events [54-56]. This statistic 
holds true for New Zealand, with longitudinal ANZAC-QI data demonstrating a small decline in 
mortality for NSTEMI patients between 2006 and 2016, although mortality risk remained 
unchanged for STEMI and UA [57]. Adverse LV remodelling underlies many cardiac conditions 
associated with poor health outcomes, and describes progressive geometric and functional 
changes to the myocardium in response to damage [58]. Bauters et al. [59] has demonstrated 
in two independent cohorts that LV remodelling persisted in approximately 30% of AMI 
patients when measured 1 year following index admission and despite optimal clinical 
therapy. Additionally, long-term follow-up demonstrated that LV remodelling patients were 
at increased risk of heart failure development and cardiovascular death [59]. Thus, despite 
improvement in medical therapy and evolving treatment strategies, LV remodelling persists 
in AMI patients and continues to remain an important risk factor for the development of 
adverse outcomes.  
 
1.2.2 Mechanisms of adverse left ventricular remodelling 
Ventricular remodelling is commonly initiated by infarct expansion [23]. Commenced within 
the first 24 hours following AMI, infarct expansion describes the thinning and dilation of 
infarcted myocardium resulting in increased segment length of the infarct [60]. Importantly, 
infarct expansion is not associated with additional cellular necrosis, and instead is caused by 
cardiomyocyte bundle rearrangement [61] and degradation of interstitial matrix by matrix 
metalloproteinases (MMPs) [62]. As infarct size increases, and the subsequent scar territory 
expands, there is increased myocardial wall stress and global ventricular contractile function 
[58]. In order to compensate for the dyskinetic infarcted tissue, non-infarcted tissue segments 
undergo volume-overload hypertrophy to preserve stroke volume [63]. This process is a 
critical compensatory mechanism that further exacerbates ventricular chamber enlargement 
and increases chamber volumes [58].  
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Another critical mechanism associated with adverse LV remodelling is accumulation of ECM in 
the myocardium, a process termed myocardial fibrosis [64]. Fibrosis stems from the necessary 
repair of myocardial tissue during collagen scar formation [64]. Specifically, replacement 
fibrosis describes the development of an organised scar following AMI, while reactive fibrosis 
accumulates in the interstitial and perivascular matrix and results in unique structural and 
metabolic changes to the myocardium [65]. The deposition of interstitial collagen has been 
shown in the infarcted and non-infarcted regions of the murine myocardium following AMI 
[66]. Clinically, myocardial fibrosis manifests as increased LV wall stiffness and hypertrophy 
that increases LV resistance and filling pressures.   
 
Adverse ventricular remodelling is diagnosed by cardiac imaging techniques, and is often 
undertaken in patients upon clinical indication. The gold-standard imaging technique for 
assessing structural myocardial abnormalities is cardiac magnetic resonance imaging (cMRI) 
[67]. While accurate and reproducible, this technique is not routinely undertaken in patients 
due to expensive overheads associated with staff experience and machine functionality. In 
comparison, transthoracic echocardiography is more commonly clinically implemented due to 
its availability, safety profile, portability and low cost [67]. 
 
1.2.3 Systolic and diastolic dysfunction 
Adverse LV remodelling manifests as systolic and diastolic dysfunction. Systolic dysfunction is 
characterised by impaired cardiac output and enlarged end-diastolic chamber volumes [68]. 
Systolic dysfunction can be determined by left ventricular ejection fraction (LVEF) 
measurements, which are calculated as a percentage of stroke volume over end-diastolic 
volume. The American Society of Echocardiography and the European Association of 
Cardiovascular Imaging (ASE/EACVI) have provided updated recommendations for cardiac 
chamber quantification in adults [69]. In these guidelines, a scale of severity is provided for 
LVEF that differs slightly between genders: normal range (female, 54-74%; male, 52-72%), 
mildly abnormal (female, 41-53%; male, 41-51%), moderately abnormal (both, 30-40%) and 
severely abnormal (both, <30%) [69].  
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Diastolic dysfunction is characterised by impaired LV relaxation, and increased chamber 
stiffness associated with increased ventricular filling pressures [70]. Diastolic dysfunction 
diagnosis is more complex than systolic, and involves measuring multiple parameters of LV 
function. The most recent ASE/EACVI guidelines recommend evaluation of the following four 
variables: annular e’ velocity, average E/e’ ratio, left atrial (LA) volume index, and peak 
tricuspid regurgitation (TR) velocity [70]. Threshold values are provided for each variable, and 
diastolic dysfunction is indicated if more than half of the thresholds are exceeded. Severity of 
diastolic dysfunction can be determined by the magnitude of E/A ratio, which represents the 
peak velocity of blood flow during LV relaxation (E wave) and LV contraction (A wave) [70].  
 
While systolic and diastolic dysfunction can present asymptomatically, the most common 
clinical manifestation of these disorders is heart failure. Systolic dysfunction is a key feature 
of heart failure with reduced ejection fraction (HFrEF), while heart failure with preserved 
ejection fraction (HFpEF) is primarily driven by diastolic dysfunction [71, 72]. These diseases 
share similar clinical presentations, but their pathophysiology remains distinct. Specifically, 
chamber dilation is a defining characteristic of HFrEF, while normal ventricular chamber sizes 
are commonly observed in HFpEF [73]. Instead, key features of HFpEF are chamber and 
myocardial stiffness associated with collagen accumulation [74]. Heart failure remains a key 
determinate of poor health outcome secondary to initial infarction [71].  
 
1.2.4 Circulating biomarkers of systolic and diastolic dysfunction 
Biomarkers are defined by the National Institute of Health’s Biomarker Working Group as any 
characteristic that can objectively evaluate normal biological process, a pathological process 
or a response to therapeutic intervention [75]. Since first described in 1989, biomarker 
research has advanced to include more sensitive screening methods and evolved to 
encompass a wider range of purposes such as screening, diagnosis and prognosis [76]. Well 
characterised guidelines exist for heart failure management by the ACC/AHA [72] and the ESC 
[71]. However, the clinical utility of biomarkers in heart failure remains poorly defined, and 
discordant recommendations exist between these leadings consortiums. A summary of 
guideline recommendations for biomarkers in the clinical management of heart failure 
patients is shown in Table 1-1. 
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Natriuretic peptides are the gold standard biomarkers in heart failure. Primarily synthesised 
in ventricular cardiomyocytes, natriuretic peptides are released as preprohormones that are 
modified to the functionally inert N-terminal pro-B-type natriuretic peptide (NT-proBNP) and 
biologically active B-type natriuretic peptide (BNP) [77]. NT-proBNP and BNP levels are 
increased in response to ventricular wall stretch, dilation and pressure [78, 79]. ACC/AHA and 
ESC both recommend the use of natriuretic peptide biomarkers in heart failure diagnosis [71, 
72], with multiple studies demonstrating clinical utility in establishing or excluding acute and 
chronic heart failure in patients [80-82]. The ACC/AHA [72], but not the ESC [71], also 
recommends the use of admission natriuretic peptide levels for establishing disease severity 
and prognosis in acutely decompensated and chronic heart failure. In addition, ACC/AHA also 
suggests a role for BNP and NT-pro-BNP in heart failure prevention, as well as pre-discharge 
levels for patient risk-stratification (Table 1-1).  
 
Despite widespread success, important limitations exist for the use of natriuretic peptides as 
biomarkers in heart failure. Large inter-individual heterogeneity exists for natriuretic peptide  
levels, which is driven by non-specific elevation in clinical features such as age or gender [83], 
and non-cardiac disease states such as renal dysfunction [84]. Thus, ESC guidelines suggest 
using the exclusionary thresholds of BNP < 100 pg/mL and NT-proBNP < 300 pg/mL to rule out 
heart failure rather than establish a working diagnosis [71]. Additionally, natriuretic peptides 
are limited in their ability to predict adverse ventricular remodelling processes, as levels 
become elevated as a consequence of damage [78]. Thus, natriuretic peptides have limited 
clinical utility for the prevention of structural remodelling.  
 
Troponin is a further biomarker recommended by the ACC/AHA for prognosis in heart failure 
when measured upon hospital admission [72]. Troponin is a cardiac enzyme routinely used for 
AMI diagnosis [30, 31], and similar to natriuretic peptides, is elevated in response to 
myocardial damage. Thus, identification of novel biomarkers that precede adverse 
remodelling is desirable for advancing biomarker research in this field. The ACC/AHA currently 
acknowledges two such biomarkers, known as soluble suppression of tumorigenicity 2 (ST2) 
receptor and galectin-3 [72]. These biomarkers are associated with myocardial fibrosis 
Page | 18 
 
pathophysiology, and early research has indicated their clinical utility in predicting 
hospitalisation and mortality in heart failure patients [85, 86].  
 
Overall, advancements in biomarker research for heart failure have progressed. However, 
development of biomarkers for prognosis and prevention of LV remodelling are still required. 
Biomarkers linked to the underlying molecular activity associated with remodelling processes 
remain promising and require further attention [76]. In addition, the ACC/AHA also 
acknowledges the potential benefit of developing sophisticated strategies to combine 
biomarkers for improved risk-stratification [72]. Potentially, the combination of multiple 
biomarkers that represent differential pathophysiological pathways in remodelling may be 
more powerful than a single representative biomarker measure. These avenues of research 
both require attention for the advancement of biomarker predictive tools in the setting of 
AMI.  
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Table 1-1. Biomarkers indicated for heart failure in clinical guidelines. 









Diagnosis I A 
Prevention IIa B-R 
Hospital admission 





Troponin T or I 
Hospital admission 
levels for prognosis 
I A 
sST2 











Diagnosis * Not stated Not stated 
Therapy guidance IIa C 
*Recommended as an initial investigation to rule out heart failure.  Abbreviations: AHA/ACC, American Heart 
Association/American College of Cardiology; ESC, European Society of Cardiology; BNP, B-type natriuretic 
peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sST2, soluble suppression of tumorigenicity 2.  
Class of recommendation: Class I benefit > > > risk/is recommended; Class IIa benefit > > risk/should be 
considered; Class IIb benefit ≥ risk/may be considered. Level of evidence: [A] data is derived from multiple 
randomized clinical trials or meta-analysis; [B-R] data is derived from a single randomised clinical trial; [B-NR] 
data is derived from a large non-randomised study; [C] consensus of opinion based limited population studies.  
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1.3 Extracellular matrix  
1.3.1 Homeostasis 
The cardiac ECM is a dynamic three-dimension network that is conceptually divided into two 
key components: the basement membrane and the interstitial matrix [87]. A commonality 
between these two structural components is a collagen scaffold that provides tensile strength 
and structural support to the myocardium [88]. The basement membrane is highly organised 
network of dense ECM proteins that surround cardiomyocyte cells, and provides an interface 
to facilitate cellular and ECM interactions. The basement membrane is primarily composed of 
a collagen type IV matrix and lamanin proteins, and has a multifaceted role in cellular function 
[87]. The interstitial matrix is primarily comprised of fibrillar collagens, with collagen type I 
forming thick rod-like fibres and collagen type III forming a thin fibre network [88, 89]. The 
interstitial matrix encompasses all myocardial resident cells, and is the ECM component that 
expands upon injury in order to preserve myocardial function [89]. While important for 
maintaining the structural integrity of the myocardium, the interstitial matrix also 
encompasses a host of non-structural proteins that comprise the ECM proteome and drive 
molecular signalling processes [87]. While the primary role of the ECM in homeostasis is 
providing structural support to the myocardium, molecular factors that comprise the ECM 
proteome also facilitate cellular migration, proliferation and activation processes.  
 
1.3.2 Injury 
The initiation of AMI begins with obstruction of the coronary arteries limiting perfusion and 
causing localised cardiac ischaemia. The largest consequence of myocardial ischaemia is mass 
cellular death, which can arise if perfusion is not re-established shortly following obstruction. 
The cardiomyocyte is particular sensitive to hypoxia, and is the main target for cellular 
damage.  
 
On a cellular level, a series of metabolic and ionic disruptions take place prior to initiation of 
cellular death. Under normal physiological conditions, cardiomyocytes participate in aerobic 
metabolism. Upon ischaemic injury, immediate cessation of oxidative phosphorylation occurs 
and alternative pathways for adenosine triphosphate (ATP) generation are initiated [23]. 
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While hypoxic cardiomyocytes initially contain high energy phosphate reserves to buffer 
oxygen deprivation [90],  these quickly deplete and anaerobic glycolysis becomes the main 
source of newly synthesised ATP [91, 92]. While immediately necessary, anaerobic 
metabolism is not sustainable for long-term cellular activity due to inefficient ATP synthesis, 
which is further hindered by supply shortages of metabolic substrates, such as glucose [23, 
93]. In addition, anaerobic glycolysis produces lactic acid as a by-product of metabolism [91], 
and this accumulates in the intracellular space to progressively lower pH levels in a process 
known as acidosis [94]. A consequence of acidosis is the functional inhibition of glycolytic 
enzymes responsible for anaerobic metabolism, as well as ionic disruptions causing profound 
electrophysiological consequences [23]. Enzyme inhibition, combined with insufficient ATP 
synthesis, eventually causes glycolysis and all metabolic activity to cease within injured cells. 
 
While these metabolic and ionic perturbations inhibit functional activity of cardiomyocytes in 
the ischaemic region, they are not indicative of cellular death. Indeed, a seminal study in this 
field demonstrated the reversibility of cellular injury in cardiomyocytes exposed to ischaemia 
for less than 15 minutes using a canine coronary ligation model [95]. If reperfusion is not 
established within this short window, cardiomyocytes can become irreversibly functionally 
damaged. Ultrastructural studies have demonstrated irreversible damage as soon as 40 to 60 
minutes following coronary occlusion [96]. Irreversible damage is signposted by mitochondrial 
swelling and the presence of amorphous matrix densities in conjunction with sarcolemma 
disruptions of the plasma membrane [96]. Irreversibly damaged cardiomyocytes are shuttled 
towards cellular death processes. 
 
There are three mechanisms of cell death associated with cardiac ischaemia: necrosis, 
apoptosis and autophagy. Cellular necrosis is defined by loss of membrane integrity, 
intracellular organelle swelling and ATP depletion [97]. Measured by MRI imaging of DNA-
binding gadolinium chelate, murine in vivo cellular necrosis has been detected as early as 2 
hours following ischaemic insult and is negligible by 72 hours [98]. These findings confirm 
previous histological reports [99], and suggests cellular necrosis is initiated swiftly in response 
to ischaemia but is a short-lived process. Following acute cardiac ischaemia, cardiomyocyte 
necrosis is mostly attributed to mitochondrial dysfunction. Metabolic acidosis, caused by 
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anaerobic glycolysis, creates ionic imbalances within the cardiomyocyte leading to an 
accumulation of H+. To restore equilibrium, ion pumps remove excess H+ in exchange for Na+ 
which is quickly shuttled out of the cell and replaced by Ca2+ via the Na+/Ca2+ exchanger. Ca2+ 
is less readily removed and subsequently accumulates in the cytosolic space. Ca2+ entry into 
the mitochondria triggers the opening of the mitochondrial permeability transition pore 
(mPTP) resulting in mitochondrial swelling which ultimately leads to cellular necrosis [97, 100].  
 
A further method of cell death following acute myocardial ischaemia is apoptosis. Defined as 
a programmed pathway, apoptosis is associated with cell shrinkage, fragmentation into 
apoptotic bodies and removal by phagocytosis [100]. Apoptosis is mediated through activation 
of both intrinsic pathways involving mitochondrial signalling [101] and extrinsic pathways 
mediated by death ligand and receptor binding [102]. The nexus of both pathways is the 
permeabilization of the outer mitochondrial membrane (OMM) which is facilitated by 
interactions between B-cell lymphoma 2 (Bcl-2) proteins [23, 100]. Disruption of OMM results 
in the release of mitochondrial specific proteins, such as cytochrome c, which binds with 
cytosolic caspase enzymes to trigger cellular apoptosis. While histological and ultrastructural 
studies have demonstrated an important role for apoptosis in cardiomyocyte death following 
ischaemia [99, 103], the individual contribution of apoptosis compared to necrosis remains to 
be elucidated. 
 
Autophagy is a further mechanism for cellular death, although its role in ischaemia is less 
straightforward than that of necrosis and apoptosis. A highly conserved process, autophagy is 
described by the delivery of intracellular components to lysosomes for degradation [104]. In 
ischaemia, this process is mediated through an AMP-activated protein kinase (AMPK)-
dependent pathway [105], and is hypothesised to be an adaptive response to preserve cellular 
energy. The role of autophagy in ischaemia is complex, and appears to have dual function in 
both self-preservation [105] and cell death [106].   
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1.3.3 Cardiac repair  
The absolute loss of cardiomyocytes in ischaemic injury is monumental due to the non-
regenerative capacity of the myocardium, and has profound implications for structural 
integrity and electrophysiological function. Surviving cardiac resident cells, as well as 
infiltrating leukocytes, play an important role in the complex cardiac repair process that 
follows myocardial injury. The established view of cardiac repair is largely based on animal 
models of MI and describes the replacement of damaged myocardium with non-contractile 
scar [23]. Cardiac repair is divided into three key stages of which include: the inflammatory 
phase, the proliferative phase and the maturation phase. A schematic representation of ECM 
repair is shown in Figure 1-3 and is described in detail below.  
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Figure Legend  
Figure 1-3. A schematic representation of cardiac repair following acute myocardial infarction.  
This diagram demonstrates the proposed three phases of repair following ischaemic injury in the myocardium. The inflammatory phase is associated with 
upregulation of inflammation and necrotic debris removal by infiltrating leukocytes. The proliferative phase is linked to transdifferentiation of the cardiac 
fibroblast to the myofibroblast cells, which synthesises ECM. The maturation phase is associated with collagen-scar formation and collagen cross-linking. This 
figure was created on Biorender.com, Toronto, Canada.  
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1.3.3.1 The inflammatory phase 
The inflammatory phase of myocardial repair begins immediately following AMI, and is 
associated with rapid activation of the innate immune system. The onset of inflammation is 
complex and comprised of multiple molecular factors including the complement cascade, 
reactive oxygen species (ROS) and damage associated molecular patterns (DAMPs). 
 
The complement cascade is a central component of innate immunity and initiates 
inflammation via three separate pathways that include classical, lectin and alternative [107]. 
Hill and Ward [108] were the first to demonstrate that C3 cleavage products of the 
complement cascade were induced by myocardial damage in a rat infarction model. 
Subsequent studies have since demonstrated the induction and upregulation of complement 
components in human patients following ischaemic injury [109, 110]. Experimental studies 
have demonstrated the importance of the complement cascade in mediating myocardial 
damage, with pharmacological inhibition of complement components reducing infarct size 
following ischaemia [111, 112]. Complement activation is also shown to be a potent 
chemotactic factor for recruitment of neutrophils and monocytes to ischemic myocardium 
[113, 114].  
 
In parallel to the initiation of the complement cascade, ROS production is a further mediator 
of inflammation post-MI. ROS are normal by-products of oxidative respiration processes, and 
are highly reactive molecules containing free radicals [115]. ROS are upregulated in the 
myocardium following ischaemic injury [116, 117], and are synthesised by mitochondria, 
xanthine oxidase and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [115]. 
ROS synthesis is a double edge sword in inflammation. While important for activating 
inflammatory pathways associated with cardiac repair [107], overactive ROS-signalling can 
also promote cellular apoptosis and uncontrolled degradation of ECM components [118, 119] 
 
DAMPs are further components of the initial inflammatory response, and serve as endogenous 
‘danger signals’ to active the immune system. DAMPs are rapidly upregulated post-MI [120, 
121], and comprise a number of molecules involved in signalling transduction and cellular 
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activation. The most well studied DAMP in the setting of CVD is the nuclear factor high mobility 
group box 1 (HMGB1). Released from necrotic cells [122], HMGB1 has a dichotomous role in 
cardiac repair. Previous experimental research has demonstrated that neutralisation of 
HMGB1 following murine coronary ligation is associated with reduced cytokine expression and 
increased LV remodelling [120]. However, observational cohort studies have indicated a link 
between increased circulating levels, increased mortality and impaired cardiac function post-
MI [123, 124]. Like ROS expression, these findings indicate both a beneficial and deleterious 
role for HMGB1 in cardiac disease. This dichotomy is associated with the multifaceted role of 
DAMPs in cardiac repair, and is likely linked to differences in signalling pathways between 
cells.  
 
Complement components, ROS and DAMPs activate inflammatory signalling pathways by 
binding to pattern recognition receptors (PRRs) on infiltrating leukocytes. Toll-Like Receptors 
(TLRs) are the most well characterised PRRs, and engage with a diverse range of inflammatory 
molecules [107]. While there are 12 identified members of the TLR family, murine gene 
deficient studies have highlighted TLR2 and TLR4 as central mediators of the post-MI 
inflammatory response. Specifically, inhibition of TLR2 and TLR4 is associated with reduced MI 
size and preserved cardiac function when compared to wildtype controls [125-127]. Activation 
of TLRs are associated with a myriad of pro-inflammatory activities including lymphocyte 
activation, macrophage polarization, cellular phagocytosis [107]. However, one of the most 
significant functions of TLR engagement in post-MI inflammation is the activation of nuclear 
factor Kappa B (NF-κB). In quiescent cells, cytoplasmic NF-κB is inactive. Upon stimulation, NF-
κB is activated and translocated to the nucleus where it initiates transcription of key 
inflammatory genes [107]. Specifically, NF-κB is associated with the transcription of pro-
inflammatory cytokines, and this process is essential for propagating the inflammatory 
response [23].  
 
Multiple pro-inflammatory cytokines and chemokines are upregulated after MI [128]. These 
inflammatory mediators participate in leukocyte recruitment, cellular activation and signal 
transduction pathways. Interkeukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α) are two 
essential cytokines in the inflammatory response. Experimental studies have demonstrated 
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their rapid upregulation following ischaemic injury [128, 129]. Genetic ablation of the type I 
IL-1 receptor (IL-1R1) in mice demonstrated that inhibition of IL-1 signalling post-MI supressed 
cytokine expression, markedly reduced neutrophil and macrophage infiltration and 
attenuated LV dilation [130]. These findings support the important role of these cytokines in 
propagating the immune response post-MI.   
 
In addition to chemokines and cytokines, ECM proteins also participate in the propagation of 
the inflammatory response. MMPs are proteolytic enzymes that are responsible for ECM 
degradation processes. Following AMI, MMPs are upregulated [131] and can be detected in 
the myocardium as early as 10 minutes following coronary occlusion [132]. The primary 
purpose of MMP activity during the inflammatory phase is to remove cellular debris and 
necrotic tissue. Consequently, MMP activity is critical for architectural changes required in 
preparation for scar formation during proliferative and maturation phases. Aside from their 
primary role in ECM degradation, MMPs also participate in proteolytic processing of cytokines 
and growth factors. 
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1.3.3.2 The proliferative phase 
A timely resolution of inflammation is critical for post-MI repair. Indeed, the transition from 
the inflammatory to the proliferative phase following AMI is driven by alterations in the 
myocardial environment, and upregulation of anti-inflammatory and pro-fibrotic factors are a 
hallmark of inflammation resolution [64, 128]. Neutrophils initiate this transition through 
apoptotic mechanisms. Specifically, neutrophils undergoing apoptosis release mediators, such 
as lactoferrin, that inhibit further neutrophil recruitment [133]. In addition, apoptotic 
neutrophils upregulate their expression of scavenger receptors, such as CCR5, which act as 
decoys to sequester residual chemokines from the microenvironment [134]. Apoptotic 
neutrophils also express phagocytic signals that facilitate cellular ingestion by infiltrating 
macrophages [135]. Macrophage phagocytosis is critical for inflammation resolution in the 
myocardium, as it not only removes residual cellular components but also activates a pro-
resolving macrophage phenotype associated with increased expression of IL-10 and 
transforming growth factor beta 1 (TGF-β1) [135]  
 
Elevated levels of soluble anti-inflammatory mediators are central in suppression of 
inflammatory signalling. IL-10 is predominately expressed by T lymphocytes and macrophages 
[23], and acts as a negative regulator by inhibiting cytokine synthesis of macrophage cells 
[136]. IL-10 is elevated shortly following ischaemic injury and remains elevated past the 
subacute repair phase [128]. TGF-β1 is a multifactorial growth factor with a myriad of 
signalling roles in myocardial repair. Much like IL-10, TGF-β is temporally elevated post-MI 
[128] and is linked to suppressed cytokine expression in early repair [137]. In addition, TGF-β 
has a central role in driving differentiation of cardiac fibroblasts to their matrix-synthetic 
phenotype required for synthesising most ECM proteins in the myocardium [138]. The global 
role of TGF-β in myocardial repair is multifaceted, and this complexity is likely linked to its 
universal role in stimulating multiple signalling pathways and cellular functions [139]. 
However, overall inhibition of TGF-β during early repair appears to be detrimental, with 
increased mortality, increased cytokine production and impaired cardiac function [137, 140] 
 
Expansion of the cardiac fibroblast population and transdifferentiation into the matrix-
synthetic myofibroblast phenotype is a signature hallmark of the proliferative phase. Cardiac 
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fibroblasts are resident myocardial cells that are resistant to ischaemic injury and become the 
predominant cell type in the healing infarct [141]. The phenotype of the cardiac fibroblast is 
plastic, and can be altered by external factors in the microenvironment. Transdifferentiation 
into the myofibroblast phenotype is primarily driven by TGF-β expression via SMAD-
dependent pathways [138, 142], and is characterised by expression of alpha smooth muscle 
actin (αSMA) and the upregulation of ECM proteins [138, 141]. As the major source of ECM 
synthesis post-MI, myofibroblast activity is intricately linked with appropriate scar formation.  
 
Along with expansion and differentiation of fibroblast cells, ECM specific proteins are also 
upregulated during the proliferative phase. Specifically, matricellular and tissue inhibitor 
proteins are rapidly upregulated post-MI to mediate ECM remodelling processes. Tissue 
inhibitors of matrix metalloproteinases (TIMPs) actively inhibit MMP activity, and are 
consequently important for transitioning from ECM degradation to deposition at the infarct 
site [87].  Unlike TIMPs, matricellular proteins do not actively participate in ECM modulation, 
instead they are non-structural proteins that facilitate cellular and molecular signalling to 
propagate repair. Osteopontin is a well-studied matricellular protein, and is expressed at basal 
levels in normal tissue and is rapidly upregulated post-MI [128, 143]. Osteopontin regulates 
matrix assembly, and is important regulator of collagen synthesis following AMI [64] 
 
 
1.3.3.3 The maturation phase  
Following the proliferative phase is the maturation phase of cardiac repair, which is 
characterised by progressive alterations to scar composition associated with stable scar 
formation. The most significant architectural change to the ECM is collagen cross-linking, 
which begins weeks following ischaemic injury and is associated with scar stabilisation and 
increased tensile strength [144]. Suppression of pro-fibrotic factors is also a hallmark for the 
maturation phase. Decreased expression of matricellular proteins, fibrotic growth factors and 
TIMPs are observed in the myocardium in the weeks and months following AMI. The most 
notable difference in cellular composition during the maturation phase is the marked 
reduction in myofibroblast cells [145]. As the collagen-based scar is formed, myofibroblasts 
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become quiescent. The mechanisms that drive this reduction in myofibroblasts remain poorly 
understood. There is some observational evidence that links apoptosis and myofibroblasts 
during the maturation phase [146], while other evidence suggests a gradual loss of the matrix-
synthetic phenotype but persistence within the infarcted tissue [147].  
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1.4 ECM proteome 
The ECM proteome is comprised of multiple molecular factors with multifaceted roles in 
myocardium [87]. These ECM factors contribute to structural and non-structural roles within 
the myocardium, and are important for cardiac repair and adverse remodelling processes.  
Evidence for the role of the ECM proteome in LV remodelling is shown in Table 1-2 and Table 
1-3 at the end of this section.  
 
1.4.1 Matrix metalloproteinases 
MMPs are zinc dependent proteolytic enzymes primarily responsible for ECM degradation 
processes during homeostasis and injury. This enzyme group shares a common structural 
framework that consists of a prodomain, a catalytic domain, a hinge region and a hemopexin 
domain [148]. Secreted in their latent form, proMMPs are activated by a ‘cysteine switch’ 
mechanism in which a zinc-cysteine motif is hydrolysed from the prodomain, exposing the 
catalytic region for substrate-specific binding [148]. MMP activation is mediated by 
inflammatory signals, oxidative stress and proteinase activity [149]. The cellular source of 
MMPs is diverse in the myocardium, and can be altered between health and disease. 
Specifically, infiltrating neutrophils and macrophages are an abundant source of MMPs [150, 
151], while resident cardiac cells such as fibroblasts, cardiomyocytes and VSMC have also been 
linked to MMP expression [152, 153].  
 
MMPs can be categorised into five major groupings based on the substrate affinity and 
domain homology:  collagenases, gelatinases, stromelysins, matrilysins and membrane bound 
MMPs [154]. MMP-2 and MMP-9 are the most well studied MMPs in the myocardium, and 
are members of the gelatinase family. Early experimental studies in MI demonstrated a role 
for these MMPs in cardiac remodelling processes. Specifically, mice deficient in MMP-2 or 
MMP-9 had improved survival with reduced cardiac rupture, as well as reduced leukocyte 
infiltration [155, 156]. In addition, MMP-9 deficient mice also have reduced collagen 
accumulation and attenuated LV dilation [157]. While ECM degradation is the primary role of 
MMPs, degradation-independent activities have also been identified that include: 
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macrophage polarization [158], auto-catalytic activation of proMMPs [159], and proteolytic 
activation of cytokines [160].  
 
1.4.2 Tissue Inhibitors of metalloproteinases 
TIMPs are a group of four tissue specific endogenous inhibitors that regulate the activity of 
MMPs, and subsequently mediate ECM deposition processes [87]. TIMP-1, -2 and -4 are 
soluble proteins measurable in circulation, while TIMP-3 is an ECM bound protein [161]. TIMPs 
have a highly conserved structure subdivided into N-terminal and C-terminal subdomains, 
each comprising three conserved disulphide bonds that create a looped structure [162]. 
Crystallographic x-ray images of TIMP/MMP complexes demonstrate that TIMPs inhibit MMP 
activity through binding of the wedge-shaped TIMP inhibitor to the active-site of MMP 
catalytic domain [163, 164]. TIMP substrate affinity for MMPs is broad, and TIMP inhibition is 
suggested to occur in a 1:1 molar ratio [165].  
 
The source of TIMPs in the myocardium is localised to resident cardiac cells, and is enriched 
in cardiac fibroblasts and cardiomyocytes [152, 153]. TIMPs are expressed in healthy 
myocardium and are significantly upregulated in ischaemic cardiac tissue [166]. The main 
function of TIMP activity is attributed to MMP regulation, as demonstrated in murine genetic 
TIMP deletion models that show adverse LV remodelling can be rescued by MMP inhibition 
[167]. However, TIMPs also have a role in ECM remodelling independent to MMP inhibition 
that is associated with cell proliferation,  inflammation and angiogenesis [168].  
 
TIMP-1 is the most well studied TIMP, and has been closely linked to ECM deposition 
processes. Specifically, TIMP-1 null mice have increased LV dilation post-MI that is associated 
with reduced fibrillar collagen deposition [169, 170]. These studies suggest a direct role for 
TIMP-1 in ECM proteolysis following MI, and indicate a critical role in preservation of 
myocardial structure and function. Unlike TIMP-1, relatively less research has been conducted 
on the activity of TIMP-4, which is highly expressed in the myocardium [171]. TIMP-4 null mice 
have increased mortality due to LV wall rupture when compared to wildtype mice [167], and 
circulating TIMP-4 is an independent predictor of adverse LV remodelling [172].  
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1.4.3 Collagens 
Collagen is a critical component of the cardiac ECM, and comprises more than 20 genetically 
distinct members that are integral to the composition of the interstitial matrix and basement 
membrane [87]. Fibrillar collagens are the most abundant in the myocardium, and primarily 
comprise type I (~85%) and type III (~11%) [89]. Fibrillar collagens serve many diverse 
functions in the ECM that include: providing structural architecture and tensile strength to the 
myocardium, scaffolding support to the cellular network, coordinating force to the ventricular 
chamber generated by cardiomyocytes, and maintaining tissue homeostasis to prevent 
cardiac hypertrophy or rupture [89]. In addition to their role in ECM homeostasis, fibrillar 
collagens also comprise the structural component of myocardial fibrosis. Indeed, an early 
study investigating rodent collagen remodelling following coronary ligation demonstrated 
increased collagen type I and III synthesis in both the infarcted and non-infarcted regions of 
the myocardium [66]. These findings are well accepted within the literature, and while both 
fibrillar collagens are critical for fibrosis post-MI, collagen type I appears to be the 
predominant form identified in infarcted and non-infarcted tissue [166, 173] 
 
Cardiac fibroblasts are the primary source of fibrillar collagens in the cardiac ECM [89, 141]. 
Fibrillar collagens are secreted as procollagens with peptide terminal ends that are cleaved to 
form the mature collagen fibril. The propeptide ends are released into the circulation as a by-
product of collagen maturation, and can be used as a surrogate marker of collagen synthesis. 
N-terminal type I procollagen (PINP) is a marker of newly synthesised collagen type I, and has 
been investigated in the setting of AMI and heart failure. In a study conducted by Manhenke 
et al. [174], baseline PINP levels in AMI patients were a significant independent predictor of 
LV volumes, LVEF and infarct size on cMRI analysis at 1 year post-MI.  
 
1.4.4 Matricellular proteins 
Matricellular proteins describe a diverse range of non-structural macromolecules that 
mediate cellular adhesion, migration, growth and signalling processes in the myocardium 
[175]. Matricellular proteins have a limited role in matrix architecture, but facilitate matrix- 
remodelling processes by acting as an interface between the cellular and ECM network. A 
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number of molecular factors have now been classed as matricellular proteins. Of these, 
osteopontin and periostin have been highlighted as important in cardiac repair processes 
following ischaemic injury.  
 
Osteopontin is a pleiotropic glycoprotein involved in a number of inflammatory processes in 
CVD [175]. Expressed at low levels under normal physiological conditions, osteopontin is 
significantly upregulated post-MI [176, 177]. In osteopontin deficient mice, Trueblood et al. 
[176] demonstrated that LV dilation was significantly increased following coronary ligation, 
and this was associated with decreased collagen accumulation and organisation in the 
myocardium. Furthermore, osteopontin deficient mice have increased LV volumes and 
impaired systolic function based on echocardiogram measurements following coronary 
ligation [178]. The role of osteopontin in adverse remodelling post-MI may be in part 
associated with mediation of MMP activity, with MMP inhibition improving LV function indices 
in mice lacking osteopintin [178]. Increased levels of osteopontin in AMI patients has also been 
linked to adverse cardiovascular outcomes [179] and reduced LV function [180]. Thus, despite 
not actively contributing to the structural matrix, osteopontin is a critical component of 
cardiac repair.  
 
Periostin is a collagen chaperone that is significantly upregulated in the myocardium following 
MI [175], and appears to be localised to cardiac fibroblast activity [181, 182]. Periostin 
deficient mice have increased cardiac rupture acutely following coronary ligation, and this 
phenotype is associated with reduced collagen formation and cross-linking, as well as 
decreased cardiac fibroblast infiltration in the infarcted and non-infarcted myocardial tissue 
[181, 182]. The dysregulation of collagen deposition processes could be rescued in periostin 
deficient mice by gene transfer of periostin [182]. Interestingly, while periostin deletion was 
deleterious acutely post-MI, surviving periostin loss-of-function mice had less evidence of 
fibrosis and improved LV function compared to wildtype controls [181, 182]. Thus, periostin 
has a dichotomous role in cardiac repair. Periostin expression is likely beneficial for early repair 
processes associated with scar-formation, although long-term expression appears to be 
associated with increased myocardial fibrosis mechanisms.   
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1.4.5 Growth factors 
Growth factors comprise a subset of molecules integral for initiating cellular proliferation, 
migration, adhesion and signalling mechanisms. As such, they are central components of the 
ECM, and master regulators of cellular interactions. A number of growth factors have been 
highlighted as important in cardiac repair, each with a unique function within the myocardium. 
Arguably, the most important growth factor for mediating cardiac repair processes is TGF-β. 
As described in Section 1.3.3.2, TGF-β is essential for driving the proliferative phase of 
myocardial repair. Previous studies have documented the potent effect of TGF-β on cardiac 
fibroblast activity, with in vitro stimulation driving ECM synthesis processes that are linked to 
myofibroblast transdifferentiation [138, 183]. In addition to its regulatory role in ECM repair, 
TGF-β expression is also central to myocardial fibrosis and hypertrophic remodelling [139].  
 
Fibroblast growth factor basic (FGFb) and vascular endothelial growth factor (VEGF) are two 
further growth factors associated with cardiac repair processes post-MI. Both FGFb and VEGF 
are elevated in AMI patients acutely when compared to levels in healthy controls [184]. In an 
experimental model of MI, Virag et al. [185] demonstrated FGFb deficient mice have minimal 
scar contraction, increased LV dilation and reduced cardiac fibroblast proliferation and 
collagen deposition when compared to wildtype controls. These findings suggest a key role 
for FGFb in regulation of cardiac fibroblast ECM synthesis. In comparison, VEGF is a mitogenic 
growth factor central to angiogenesis and vasculogensis in the myocardium. Increased 
circulating levels of VEGF have been linked to larger ventricular volumes following AMI [186, 
187]. 
Page | 36 
 
Table 1-2. Experimental evidence for involvement of the ECM proteome in LV remodelling processes following AMI. 
Target Model Methodology Disease Findings Ref. 
FGFb Murine 





↓ scar contraction, ↑ LV dilation, ↓ cardiac fibroblast proliferation and ↓ 
collagen accumulation in FGFb-/- mice compared to wildtype. Genetic 
overexpression of FGFb ↑ cardiac fibroblast proliferation and ↑ collagen 
deposition compared to wildtype. 
[185] 
MMP-2 Murine 





↑ survival, ↓ cardiac rupture and ↓ macrophage infiltration in MMP-2 
inhibited mice compared to wildtype 
[156] 
MMP-3 -- -- -- -- -- 
MMP-8 -- -- -- -- -- 
MMP-9 
Murine Gene deletion 
Left coronary 
artery ligation 
↓ collagen accumulation, ↓ LV dilation and ↓ macrophage migration to 
infarct site in MMP-9-/- mice compared to wildtype. 
[157] 
Murine Gene deletion 
LAD coronary 
artery ligation 
↓ cardiac rupture and ↓ leukocyte infiltration to the infarct site in MMP-
9-/- mice compared to wildtype. 
[155] 
Osteopontin 
Murine Gene deletion 
Left coronary 
artery ligation 
↑ LV dilation and ↓ collagen content and organisation in osteopontin-/- 









↑ LVEDV, ↑LVESV and ↓ LVEF in osteopontin-/- mice compared to 










↓ survival caused by ↑ cardiac rupture and ↓  LVEDD/LVESD due to  
↓ collagen and fibronectin accumulation in periostin-/- mice compared to 
wildtype. This phenotype was rescued by periostin gene transfer. 
[182] 
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Table 1-2 continued. Experimental evidence for involvement of the ECM proteome in LV remodelling processes following AMI. 
Target Model Methodology Disease Findings Ref. 
Collagen Type I* Rodent 
Observational 
study - tissue 
LAD coronary 
artery ligation 








↑ LV dilation, ↓ collagen accumulation, and ↑ MMPs in TGF-β knock-










↑ LV dilation in TIMP-/- when compared to wildtype and this could be 
attenuated by MMP inhibition. 
[170] 
Murine Gene deletion 
Coronary 
artery ligation 
↑ LV dilation and ↓fibrillar collagen accumulation in TIMP-1-/- mice 
compared to wildtype. 
[169] 
TIMP-4 
Murine Gene deletion 
LAD coronary 
artery ligation 
↑ mortality caused by ↑ LV rupture and ↓ collagen accumulation in TIMP-







↓ LV dilation, improved LV function and ↑ fibrillar collagen content in 









Dose-dependent ↑ LVEF, ↓ mid-ventricle infarct size, ↓ remote collagen 
accumulation in ventricle and ↑ vessel density in mice with intra-cardiac 
injection 1 week post-MI of low or high does VEGF-A compared to vehicle 
control.  
[189] 
↑ increase; ↓ decrease; -- not investigated in coronary ligation model; *PINP was not directly investigated; -/- genetic null. Abbreviations: AMI, acute 
myocardial infarction; LAD, left anterior descending artery; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-
systolic volume; LVEF, left ventricular ejection fraction; LVEDD; left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; 
mRNA, messenger ribosomal nucleic acid. Abbreviations for targets can be found in Section 1.4.  
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Table 1-3. Clinical evidence for involvement of the ECM proteome in LV remodelling processes following AMI. 
Target Population Imaging Technique Findings Ref. 





Admission MMP-2 levels were independent predictors of LVESV index 





MMP-2 levels were -ve correlated with LVEDV and LVESV at 6 weeks 






Δ = hospital discharge & follow-up 
(median 148 days IQR 90-378). 
MMP-3 levels were +ve correlated with LVEDV/LVESV and -ve 
correlated with LVEF at follow-up. MMP-3 levels were ↑ in patients 






↑ MMP-8 levels were observed in patients with >20% ↑ LVEDV at 1 
year compared to patients without LVEDV remodelling. This 






Peak MMP-9 levels were +ve correlated with LVESV at 6 weeks post-MI 





Δ = hospital admission & follow-up 
(median 176 days, IQR 138-262). 
Peak MMP-9 levels were +ve correlated with ΔLVEDV and trough MMP-






Δ = hospital admission & follow-up 
(median 314 days, range 1-619) 
Admission MMP-9 levels were -ve correlated with LVEF and +ve 






Peak osteopontin levels were +ve correlated with LVEDV/LVESV index 






Admission periostin levels were +ve correlated with LVESV/LVEDV, and 
were -ve correlated with LVEF at 3 months post-MI. 
[195] 
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Table 1-3 continued. Clinical evidence for involvement of the ECM proteome in LV remodelling processes following AMI. 





Admission PINP levels were correlated with ↓ LVEDV index, ↓ LVESV 
index,↓ infarct size, and ↑ LVEF measured at 1 year upon univariate 
and multivariate analysis. 
[174] 





Δ = hospital admission & follow-up 
(median 314 days, range 1-619) 
Admission TIMP-1 -ve correlated with LVEF, +ve correlated with LVESV 
and ΔLVESV/ΔLVEDV. TIMP-1 levels were an independent predictor of 






TIMP-4 levels correlated with ↑ ΔLVESV index and ↑ ΔLVEDV. TIMP-4 







Δ = Day 14 & 6 months or 2 years. 
 
Peak VEGF was -ve correlated with ΔLVESV/ΔLVEDV index. When 
dichotomised into ↑/↓ VEGF groups, ↑ VEGF had increased 
LVESV/LVEDV index values compared to ↓ VEGF group. 
[186] 
↑ increase; ↓ decrease; +ve positive; -ve negative; -- not investigated following acute myocardial infarction; Δ, change in measurement between specified time points. 
Abbreviations: Define: LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; cMRI, cardiac 
magnetic resonance imaging;  ceMRI, cardiac magnetic resonance imaging. Abbreviations for targets can be found in Section 1.4. 
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1.5 Cardiac fibroblasts 
1.5.1 Role in homeostasis 
Cardiac fibroblasts are a central cellular component of the myocardium, and have a key role 
in maintaining ECM homeostasis [141]. Under normal physiological conditions, cardiac 
fibroblasts are relatively inert cells. They are the primary source of structural and fibrillar 
collagens in the myocardium, and are critical for maintaining architectural integrity [196]. In 
addition, cardiac fibroblasts are also a rich source of the MMPs and their inhibitors, TIMPS 
[197]. Therefore, cardiac fibroblasts have a critical role in mediating ECM degradation and 
deposition processes.  
 
Cardiac fibroblasts are arranged into stands that run parallel to cardiomyocytes and between 
layers of the myocardium [198, 199]. Thus, in addition to ECM homeostasis, cardiac fibroblasts 
also have important physiological roles in mediating cell-to-cell and cell-to-matrix 
interactions. Specifically, cardiac fibroblasts are sensitive to mechanical ECM stretch, which 
can induce cellular proliferation [200] and collagen synthesis [201]. In addition, cardiac 
fibroblast activity also directly contributes to myocardial electrophysiology by coupling with 
cardiomyocytes and influencing electrical transduction via gap junction interactions [202].  
 
1.5.2 Myofibroblast phenotype 
Cardiac fibroblasts are a dynamic and diverse cell type with exceptional phenotypic plasticity. 
In response to myocardial injury, the quiescent cardiac fibroblast can undergo 
transdifferentiation into a myofibroblast phenotype that exhibits distinct characteristic 
features compared to its inert counterpart. Specifically, myofibroblasts develop expression of 
contractile specific proteins, such as αSMA, which confers increased tensile strength and 
contractility [203, 204]. In addition, myofibroblasts have increased ECM synthesis capabilities 
and are a major source of collagen and structural proteins in scar tissue formation [66, 205].  
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The cellular source of myofibroblasts in the injured myocardium remains controversial, with 
research significantly impeded by non-specific markers for cardiac fibroblast identification 
[141, 206]. Endothelial cells, circulating fibrocytes, infiltrating leukocytes and pericytes have 
all been linked to myofibroblast formation [207]. However, a recent study conducted by 
Kanisicak et al. [208] has suggested that tissue-resident fibroblasts are the main source of 
myofibroblasts in a murine model of MI using cre-recombinase genetic linage tracing. These 
findings are supported by a previous study using a cardiac pressure-overload model, which 
demonstrated that myofibroblasts in the remodelled myocardium mostly arose from resident 
fibroblast cells [209].  
 
 
Myofibroblast differentiation is a triggered by external factors, tightly regulated by the cardiac 
microenvironment. Early in vitro studies demonstrated the importance of TGF-β1 signalling in 
myofibroblast differentiation [183, 210]. Additionally, Hinz et al. [211] also defined a critical 
role for mechanical tension in stimulating and maintaining myofibroblast phenotype and 
activity in vivo. Careful regulation of the myocardial microenvironment is required in order to 
promote infarct healing but prevent adverse fibrosis. Thus, cardiac fibroblasts and their 
myofibroblast phenotype form the nexus of cardiac repair following myocardial injury.   
 
1.5.3 Role of cardiac fibroblasts in cardiac repair  
1.5.3.1 The inflammatory phase 
The levels of pro-inflammatory cytokines are significantly upregulated following myocardial 
infarction [128]. Cardiac fibroblasts both contribute to, and are mediated by, cytokines in the 
microenvironment. TNF-α is a central cytokine in myocardial repair process, and is a potent 
regulator of cardiac fibroblast activity. Specifically, in vitro studies have shown that stimulation 
of cardiac fibroblasts with TNF-α promotes inflammatory cytokine production [212], cellular 
proliferation and invasion [213], MMP secretion [213, 214] and reduces collagen synthesis 
[214]. This inflammatory cardiac fibroblast phenotype is suggested to dominate early cardiac 
repair, and significantly contributes to necrotic cell removal and propagation of the 
inflammatory response [141].  
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1.5.3.2 The proliferation phase 
Expansion of cardiac fibroblasts and differentiation into the matrix-synthetic myofibroblast 
phenotype is a hallmark of the proliferative phase in cardiac repair [141]. Myofibroblasts 
primarily occupy the infarct zone as well as the infarct border zone, and ECM synthesis by this 
cell type is the main driver of collagen-scar formation post-MI [66, 205]. As previously 
described, TGF-β1 is a critical stimulus for myofibroblast differentiation, and additionally 
drives over activation of myofibroblasts resulting in myocardial fibrosis processes [215].  
 
1.5.3.3 The maturation phase 
A major feature of scar maturation is collagen cross-linking. This process occurs in the weeks 
following infarction [144] and is performed by lysyl oxidase enzymes, which are upregulated 
following infarction and highly correlated with myofibroblast activity [216]. Hypoxia and TGF-
β1 stimulation in vitro have been shown as important stimuli for lysyl oxidase synthesis in 
myofibroblast cells [216]. As the scar matures, a dramatic reduction of myofibroblasts is 
identified in the scar [145]. However, histological examination of human tissue has 
demonstrated that myofibroblasts can persist in myocardial scars for years following initial 
infarction [203]. The functional significance of myofibroblast persistence remains unknown. It 
is postulated that the matrix-synthetic phenotype is important for maintaining ECM 
homeostasis and contractility of the scar, which is under continuous mechanical stress caused 
by ongoing contraction and relaxation of the surrounding myocardium [203]. The potential 
contribution of persistently activated myofibroblasts in the scar to the pathogenesis of heart 
failure remains to be determined.   
 
1.5.4 Measuring cardiac fibroblast activity in vivo 
The important role of cardiac fibroblasts and their matrix-synthetic phenotypes in facilitating 
and co-ordinating cardiac repair makes them a desirable prognostic and therapeutic target. 
However, cardiac fibroblasts are tissue-resident cells. Therefore, measuring their activity in 
human patients following AMI remains challenging. Thus, identifying surrogate markers to 
represent cardiac fibroblast activity remains an important, and underdeveloped, area of 
research.   
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1.5.4.1 Cardiac fibroblast-derived extracellular vesicles 
Extracellular vesicles (EVs) are lipid bilayer membrane-derived particles that are synthesised 
by all cells in the human body [217]. EVs contain cell-specific cargo enriched with small non-
coding RNA (sncRNA) that can participate in post-translational gene regulation [217]. 
Consequently, EVs can contribute to cell-to-cell signalling processes, and can also be 
harnessed as blood-based biomarkers. 
 
Cardiac fibroblasts synthesise EVs that have been shown to both participate in critical fibrotic 
processes [218, 219] and can be modulated by the extracellular environment [220, 221]. These 
recent findings suggest a potential role for cardiac fibroblast derived EVs to be altered in 
myocardial repair, which is driven by two distinct microenvironments. Indeed, the 
inflammatory phase following AMI is driven by pro-inflammatory cytokines, while the 
proliferative phase is driven primarily by TGF-β1. As previously described, cardiac fibroblast 
activity is sensitive to cytokine and TGF-β1 stimulus, and emerging research has indicated that 
these stimuli can alter fibroblast EV composition. Specifically, Lacy et al. [222] stimulated lung 
fibroblasts with IL-1β in vitro and demonstrated altered levels of prostaglandins in EVs, which 
were shown to participate in paracrine fibroblast signalling to inhibit myofibroblast 
differentiation and ECM synthesis when compared to EVs from unstimulated cells. Similarly, 
Basma et al. [223] stimulated cardiac fibroblasts with TGF-β and demonstrated differential 
messenger ribonucleic acid (mRNA) in EVs when compared to EVs from unstimulated cells. 
EVs from TGF-β stimulated cardiac fibroblasts were shown to induce a heart failure phenotype 
in cardiomyocytes when co-cultured and this effect was not observed with EVs from 
unstimulated cells. These findings demonstrate that EV composition from fibroblast cells can 
be altered in inflammatory and fibrotic conditions. However, what remains to be determined 
is how EVs specifically change between repair states in cardiac fibroblasts, and how this could 
be utilised to provide a novel approach in measuring cardiac fibroblast activity in vivo.  
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1.6 Biomarker analysis  
1.6.1 Individual analysis versus combined analysis 
A number of circulating candidate biomarkers have been identified as predictors for adverse 
LV remodelling following AMI, and many of these high profile candidate biomarkers are 
represented by the ECM proteome [224]. However, to date, no overarching consensus has 
been reached regarding a gold-standard biomarker for LV remodelling prediction. This is partly 
due to contradictory results within the literature, with inconsistent findings existing between 
studies [172, 174, 194]. Furthermore, the ECM response following AMI is complex and 
comprises a number of molecular factors that have biologically diverse activity. As previously 
described, MMPs are upregulated during early myocardial repair to remove necrotic cellular 
debris from the infarct site, while structural proteins and inhibitory enzymes, such as collagens 
and TIMPs, are upregulated later during repair to replace ECM [64]. Therefore, identifying a 
single biomarker to represent ECM activity largely oversimplifies a complex pathophysiological 
process that is comprised of many individual components. Indeed, this argument has been 
highlighted by leading investigators in the field [224, 225], and thus, the investigation of more 
complex statistical methodologies to combine biomarkers is warranted. A number of 
methodologies exist within the literature, some more appropriate for biological research than 
others, and a description of techniques most relevant to this thesis are described below.  
 
1.6.2 Molar ratios and multivariate combination. 
The most statistically simplistic method to combine biomarkers reported in the literature is 
the molar ratio. Referring to the binary combination of biologically linked biomarkers, the 
molar ratio has the capacity to measure a specific physiological process. For example, López 
et al. [226] measured the molar ratio of carboxy-terminal telopeptide of collagen type I (CITP) 
and MMP-1 in a cohort of hypertensive heart failure patients. As CITP is a measurement of 
collagen degradation that occurs via MMP activity, this study argued that diminished cleavage 
of CITP, demonstrated by a decreased ratio, could represent increased collagen cross-linking 
resistance. Indeed, this study demonstrated that a lower CITP:MMP-1 ratio could  accurately 
identify high myocardial collagen cross-linking in cardiac tissue samples. In addition, a 
CITP:MMP-1 ratio of ≤ 1.968 was demonstrated as an independent predictor of hospitalization 
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for heart failure. Additional studies have also utilised molar ratios to examine ECM turnover 
in ACS through combination of type III procollagen peptide (PIIINP) and type I collagen 
telopeptide (ICTP) [227] or MMP-8 and TIMP-1 [228]. While successful in the literature, a 
strong limitation for this methodology is the limited number of biomarker combinations that 
can be examined.  
 
To navigate this limitation, further studies in the literature have combined multiple 
biomarkers using multivariate analysis methods. Indeed, Reinstadler et al. [229] demonstrated 
that combined measurement of peak NT-proBNP, high-sensitivity troponin T, high-sensitivity 
C-reactive protein (CRP), aspartate aminotransferase, alanine aminotransferase and lactate 
dehydrogenase in the sub-acute phase of AMI could significantly distinguish between patients 
with LV remodelling at 1 year when compared to peak NT-proBNP measurement alone. A 
further study conducted by Huttin et al. [230] demonstrated improved prediction of  left 
ventricular hypertrophy and diastolic dysfunction in AMI patients when the HOMAGE score 
(age, body mass index [BMI], systolic blood pressure, heart rate, serum creatinine, smoking, 
diabetes mellitus, history of CAD and use of antihypertensive medication) was combined with 
BNP, Galactin-3, PIIINP and ST2. Combined, these studies demonstrate the prognostic benefit 
of combining biomarkers that represent different pathophysiological pathways in disease to 
predict adverse ventricular remodelling processes. However, multivariate combination of 
biomarkers has some important limitations. Specifically, this model type assumes 
independence between variables and cannot account for shared biological activity. 
Collinearity describes a significant association between covariates within a single model, and 
is a cofounding feature in biomarker research. Thus, while combined biomarkers show 
promising outcomes, more sophisticated statistical methods are required to account for 
shared biological pathways.  
 
1.6.3 Cluster analysis and multidimensional reduction 
Cluster analysis is an example of an unsupervised learning technique and describes the 
partitioning of objects into groups, appropriately termed clusters, based on a set of measured 
variables [231]. Specifically, cluster analysis partitions parsimonious objects together and 
dissimilar objects apart [232]. In the context of biomedical research, cluster analysis can be 
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applied to a patient cohort in order to separate patients into groups with homogenous 
expression of multiple measured biomarkers. The relationship between an outcome or risk 
can then be assessed to identify if patients from a specific cluster have more opportunity for 
adversity. In this sense, cluster analysis is a powerful statistical methodology to separate 
groups without preconceived biases, and in addition, can partition patients based on 
biomarker trends that could not be achieved using binary separation techniques alone. An 
example of cluster analysis for risk-prediction in the literature has been demonstrated by 
Scherzer et al. [233]. In this study of HIV-infected individuals, measurement of eight CVD-
related biomarkers could partition patients into three distinct clusters that demonstrated 
differential risk for diastolic dysfunction and all-cause mortality.  
 
In addition to cluster analysis, further statistical techniques using multidimensional reduction 
provide an opportunity to examine the intricate relationships between biomarkers. 
Specifically, exploratory factor analysis (EFA) is a data extraction procedure that can transform 
multiple variables into a reduced number of independent latent factors that best describe the 
original dataset [234, 235]. This statistical methodology is common within social sciences 
[234], and has recently been transferred to biomarker research. The key purpose of EFA is to 
explain the relationship between variables based entirely on statistical parameters, and 
remains unbiased to preconceived associations [235]. In the context of biomarker analysis, 
EFA represents an opportunity to elucidate the underlying structure of biomarkers. In 
addition, scores can be generated to describe an individual’s placement on each factor [236], 
and are an example of combined biomarker analysis while accounting for collinearity. Indeed, 
Manhenke et al. [237] employed EFA to examine the interdependencies between 37 
prospectively measured CVD-related biomarkers in a cohort of AMI patients. EFA separated 
biomarkers into five latent factors that represented specific pathophysiological pathways, and 
scores generated from Factor 1 could independently predict all-cause mortality and re-
infarction in patients.  
 
Combined, cluster analysis and EFA provide an exciting and relatively unexplored avenue for 
combined biomarker analysis. The benefit of both of these statistical techniques hinges on 
their capability to combine multiple biomarkers while accounting for collinearity. The 
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feasibility of applying these methodologies to an AMI cohort using exclusively ECM biomarkers 
remains to be undertaken, and is a potential avenue to improve prediction of adverse 
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1.7 Aims  
This thesis explores ECM biomarkers in AMI, and the potential prognostic significance for 
determining adverse ventricular remodelling following infarction. While candidate ECM 
biomarkers have shown promise in scientific studies, integration into clinical practice has been 
hindered by discordant findings in the literature and minimal benefit when compared to 
current risk-prediction strategies. We suggest that evaluation of combined biomarker 
methodologies, as well as novel biomarker assessment of cellular activity in cardiac repair, are 
the next steps for ECM biomarker analysis in AMI. In order to adequately examine ECM 
biomarkers in this context, we systematically explored four key areas within this thesis.  
 
Firstly, we were interested in investigating the feasibility of combining circulating ECM 
biomarkers in AMI patients. Implementation of statistical methodologies to account for 
combined biomarker analysis were examined in Chapter 2 with the following aims: 
• Use EFA to investigate the underlying structure and interrelationships of circulating 
ECM biomarkers. 
• Use hierarchical cluster analysis to identify whether distinct ECM profiles exist within 
the patient population based on the expression of these ECM biomarkers 
 
Secondly, we were interested in exploring variability of circulating ECM biomarkers in AMI 
patients, and identifying how levels changed temporally and compared to healthy controls. 
Chapter 3 investigated the following aims: 
• To compare ECM biomarker levels between AMI patients and healthy controls.  
• To examine temporal changes in ECM biomarkers during hospital admission and at six 
months post symptom onset.  
• To identify which clinical characteristics and cardiac function parameters drive changes 
in ECM biomarker levels of AMI patients.  
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Thirdly, following the findings from Chapter 2 and Chapter 3, we were interested in examining 
the prognostic utility of a combined ECM biomarker approach in predicting adverse ventricular 
remodelling in AMI patients. This was examined in Chapter 4: 
• To determine if EFA analysis or cluster analysis of ECM biomarkers can predict systolic 
dysfunction in AMI patients. 
• To determine if EFA analysis or cluster analysis of ECM biomarkers can predict diastolic 
dysfunction in AMI patients. 
 
Finally, we were interested in identifying novel markers of cellular activity in cardiac repair. 
This was examined in Chapter 5: 
• To examine if the EV profile of cardiac fibroblasts changes under pro-inflammatory or 















 Investigating extracellular matrix 
biomarkers in acute myocardial infarction 
and the feasibility of applying combined 
biomarker techniques. 
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2.1 Introduction 
The ECM response post-MI is a coordinated process orchestrated by multiple cellular and 
molecular factors [64, 87, 238], and describes the replacement of damaged tissue with non-
contractile scar [239]. Measuring the ECM response in patients is challenging, as access to the 
myocardium is both invasive and not clinically applicable.  However, measuring circulating 
ECM biomarkers provides an opportunity to capture ECM activity with a simple blood test 
[87].  
 
While previous studies have demonstrated a link between individual ECM biomarkers and 
myocardial remodelling outcomes post-MI [191, 192, 240], no overarching consensus has 
been reached regarding a gold-standard biomarker. Indeed, a more comprehensive analysis 
of combined ECM biomarker activity has not yet been undertaken, and identifying techniques 
to capture the ECM response is required. Two potential statistical approaches to understand 
such complexity are EFA and cluster analysis. The primary purpose of EFA is to define the 
underlying structure of data based on correlations between variables [234, 241]. In this 
context, it is a powerful tool to investigate interrelationships between circulating ECM 
biomarkers without prior assumptions of likely associations. Complimentary to this technique 
is cluster analysis, which can organise patients into distinct groups based on ECM biomarker 
levels. While EFA identifies groupings of variables, cluster analysis can separate patients with 
similar biomarker profiles by maximising homogeneity within a cluster and heterogeneity 
between clusters [231, 242].  
 
Using these two techniques on a single AMI cohort provides an in-depth analysis of the ECM 
response in terms of both biomarker activity and patient profiles. This analysis will provide an 
opportunity to capture the complexity of ECM biomarker interrelationships and identify 
whether there are patients with distinct ECM biomarker profiles. We believe that such an 
approach is required prior to examining potential links to long-term LV remodelling, which is 
examined in Chapter 4. In total, 12 ECM biomarkers were selected for measurement in this 
study included: FGFb, MMP -2, -3, -8, -9, osteopontin, periostin, PINP, TGF-β1, TIMP -1, -4 and 
VEGF. The intricate role of these molecular factors in cardiac repair is described in detail in 
Chapter 1.  
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Thus, in this study we aimed to use combined statistical approaches to characterise ECM 
biomarkers in a cohort of AMI patients. This was achieved by investigating the following aims: 
• Use EFA to investigate the underlying structure and interrelationships of circulating 
ECM biomarkers. 
• Use hierarchical cluster analysis to identify whether distinct ECM profiles exist within 
the patient population based on combined ECM biomarker levels. 
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2.2 Methods 
2.2.1 Study population 
Patients diagnosed with ACS and undergoing invasive therapy (coronary angiography ± 
percutaneous coronary intervention) at Wellington Regional Hospital between January 2012 
and June 2018 were prospectively recruited into The Wellington ACS Registry. ACS was defined 
as having symptoms suggestive of myocardial ischemia for greater than 10 minutes, in 
conjunction with either troponin elevation or ≥1 mm of new ST-segment deviation or T wave 
inversion, as identified on an electrocardiogram in a minimum of two contiguous leads [243]. 
Patients were excluded from this registry if they had a platelet count less than 100 x 109 /L, a 
known platelet function disorder, administration of a fibrinolytic agent within 24 hours of 
enrolment or administration of a glycoprotein IIb/IIIa receptor agent within a week prior to 
enrolment. From this registry cohort, we included patients into the current study if they had 
a primary diagnosis of AMI and if blood samples were collected three days post-hospital 
admission. Patients were excluded from this study if they were documented as having had a 
previous AMI or a chronic heart failure diagnosis, had an active malignancy, had pulmonary 
fibrosis, or had renal insufficiency determined by estimated glomerular filtration rate (eGFR) 
< 30 or renal failure that was disclosed in the medical record. Patients with rheumatological 
diseases potentially influencing ECM turnover were also excluded from participation in the 
study. Participation was voluntary and patients gave informed written consent at the time of 
recruitment. This study was approved by the Lower South Regional Ethics Committee 
(LRS/11/09/035) and the New Zealand Central Health and Disabilities Ethics Committee 
(16/CEN/68). 
 
2.2.2 Data collection and blood sampling 
Demographic data, clinical characteristics, and aspects of clinical management were obtained 
prospectively from patient medical records. Whole blood was collected into sodium citrate 
tubes (0.109M, BD Vacutainer, New Jersey, USA) three days post patient admission to hospital. 
Blood was collected from the peripheral vein using a 21-gauge needle or from the radial or 
femoral artery immediately after catheter insertion and prior to heparin administration in the 
cardiac catheterisation laboratory. Citrated whole blood was centrifuged at 1500 x g for 15 
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minutes to generate platelet-poor plasma. Plasma was aliquoted and stored at -80°C for 
subsequent analysis.  
 
2.2.3 GRACE score 
The Global Registry of Acute Coronary Events (GRACE) is a prospectively studied scoring 
system to evaluate the in-hospital and 6-month mortality in patients hospitalised with ACS 
[244]. The GRACE score is calculated by assessing the following clinical parameters: age, heart 
rate, systolic blood pressure, creatinine, heart failure Killip class, cardiac arrest at admission, 
ST-segment deviation and abnormal troponin levels. All patients had a 6-month GRACE score 
calculated using Microsoft Excel software (Microsoft Corporation; Washington, USA).  
 
2.2.4 ELISA quantification 
Enzyme-linked immunosorbent assay (ELISA) is a sensitive and robust methodology to 
measure specific protein concentrations in complex solutions. A sandwich-based ELISA 
captures the analyte of interest between two analyte-specific antibodies which bind to non-
overlapping epitope regions. Specifically, the capture antibody is bound to the plate and 
immobilizes the antigen of interest, which is then complexed to a secondary detection 
antibody that is conjugated to horseradish-peroxidase (HRP). The addition of a substrate, such 
as 3,3’,5,5’-tetramethylbenzidine (TMB), creates a colour-based reaction in which the 
colourless TMB is oxidised by HRP to a blue solution. This reaction is stabilised by the addition 
of acid, and can be measured using a spectrophotometer. The protein concentration in the 
sample is directly proportional to the colour-change reaction. Four of the 12 biomarkers were 
measured using ELISAs in this study.  
 
2.2.4.1 PINP 
PINP is a surrogate marker for collagen type I synthesis. Peripheral levels of PINP were 
measured in plasma using a commercially available ELISA kit (Human Procollagen I N-Terminal 
Propeptide ELISA Kit, Abexxa, Cambridge, UK) according to manufacturer instructions. Briefly, 
the lyophilized human PINP standard was reconstituted in 1 mL Sample/Standard Diluent 
Page | 55 
 
Buffer, and a 2-fold serial dilution was performed to create a 7-point standard curve ranging 
from 1,000 to 15.6 pg/mL. Standards, and samples diluted 1:25, were added in duplicate to a 
96-well plate that was pre-coated with anti-human PINP capture antibody, and incubated for 
90 minutes at 37˚C. Liquid was discarded and the plate was incubated with biotin-conjugated 
antibody for 1 hour at 37˚C. Antibody solution was discarded, and the plate was washed three 
times with Wash Buffer. Streptavidin conjugated HRP (Strepavidin-HRP) was added to each 
well and incubated for 30 minutes at 37˚C. The liquid was discarded and the plate was washed 
five times before addition of TMB substrate to initiate the colour reaction. Following 
incubation in the dark for 15 minutes at 37˚C, the reaction was terminated by addition of Stop 
Solution. Absorbance was measured on the Multiskan GO microplate spectrophotometer 
(Thermo Fisher Scientific, California, United States) at 450 nm and 570 nm. The wavelength 
correction value (570 nm) was subtracted, and the levels of PINP were determined from the 
five-parameter logistic (5-PL) standard curve constructed on Prism v.7.04 (GraphPad Software 
Inc; California, USA). The intra-assay coefficient of variation was 10.00, and the inter-assay 
coefficient of variation was 11.27. 
 
2.2.4.2 TGF-β1 
The level of TGF-β1 in plasma samples was measured using the Quantikine® ELISA kit (Human 
TGF-beta 1 Quantikine ELISA Kit, R&D Systems, Minnesota, USA) according to manufacturer 
protocol. Briefly, the recombinant human TGF-β1 standard was reconstituted to 2,000 pg/mL 
using RD5-53 (diluted 1:4 in distilled water), and a 2-fold serial dilution was performed to 
create a 7-point standard curve. TGF-β1 is synthesised as an inactive (latent) protein and is 
comprised of a TGF-β1 dimer and a latency-associated peptide (LAP) which is bound to a latent 
TGF-β binding protein (LTBP). TGF-β1 can be measured by ELISA in its active form, which 
occurs when the TGF-β1 dimer is separated from the LAP/LTBP complex. In a biological system, 
this process is mediated by enzyme or receptor activation, but can also be achieved in vitro by 
sample acidification and neutralisation. Subsequently, TGF-β1 was activated in plasma by 
combining the sample with 1 N HCl and incubating for 10 minutes at room temperature 
followed by neutralisation with an equal volume of 1.2 N NaOH/0.5 M HEPES. Activated 
plasma samples were diluted 1:8 with RD5-53. Standards and diluted samples were added in 
duplicate to a monoclonal TGF-β1 pre-coated plate in a 1:1 ratio with RD1-73 for a total 
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volume of 100 µL per well. Following a 2 hour incubation at room temperature, liquid was 
discarded and the plate was washed four times with Wash Buffer. Polyclonal TGF-β1 
conjugated to HRP was added to each well for detection, and incubated for 2 hours at room 
temperature. The plate was washed a further four times before equal volumes of Colour 
Reagent A and Colour Reagent B were added as the substrate solution. The plate was 
incubated for 30 minutes at room temperature in darkness, before the reaction was 
terminated by the addition of Stop Solution. Absorbance was read at 450 nm and 570 nm on 
the Multiskan GO microplate spectrophotometer (Thermo Fisher Scientific). A four-parameter 
logistic (4-PL) standard curve was generated on Prism (GraphPad Software Inc), and was used 
to identify the biomarker concentrations. The intra-assay coefficient of variation was 3.14%, 
and the inter-assay coefficient of variation was 8.36%.  
 
2.2.4.3 TIMP-1 and TIMP-4  
Plasma concentrations of TIMP-1 were measured using a commercially available ELISA kit 
(Human TIMP-1 Duoset ELISA, R&D System, Minnesota, USA) according to manufacturer 
instruction. Briefly, a 96-well plate (Thermo Fisher Scientific, Massachusetts, United States) 
was pre-coated with 2 ug/mL purified mouse anti-human TIMP-1 capture antibody diluted in 
Phosphate-buffered saline (PBS) and incubated overnight at room temperature. Liquid was 
discarded and the plate was washed five times in 1x Wash Buffer (see Appendix 1). To 
minimise non-specific binding, the plate was blocked with 1x Blocking Buffer (see Appendix 1) 
and incubated for 2 hours at room temperature. The plate was washed a further five times 
with 1x Wash Buffer prior to sample addition. The standard protein concentrate for TIMP-1 
was reconstituted with Reagent Diluent (see Appendix 1) and a 2-fold serial dilution was 
executed to create a 7-point standard curve ranging from 2,000 - 31.3 pg/mL. Plasma samples 
were diluted 1:250 with Reagent Diluent, and all samples and standards were measured in 
duplicate. Following a 2 hour incubation at room temperature, liquid was discarded and the 
plate was washed five times. Biotinylated anti-human TIMP-1 detection antibody was 
reconstituted with Reagent Diluent to a working concentration of 50 ng/mL, and incubated 
for 2 hours at room temperature. After liquid was discarded and the plate was washed a 
further five times, steptavidin-HRP was added to each well and incubated in darkness for 30 
minutes at room temperature. Following a final wash step, the colour reaction was initiated 
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by adding Substrate Solution (see Appendix 1) and incubating in darkness for 20 minutes at 
room temperature.  Stop Solution (see Appendix 1) terminated the reaction, and optical 
density was measured at 450 nm, with wavelength correction set to 570 nm. A 4-PL standard 
curve was generated to determine the sample concentration. The intra-assay coefficient of 
variation was 3.41%, and the inter-assay coefficient of variation was 4.86%.  
 
The same protocol was followed for TIMP-4 detection (Human TIMP-4 Duoset ELISA, R&D 
System, Minnesota, USA). Specifically, 4ug/mL of mouse anti-human TIMP-4 capture antibody 
was diluted in PBS for capture, samples were diluted 1:4 with Reagent Diluent, and 100 ng/mL 
of biotinylated goat anti-human TIMP-4 detection antibody was diluted in Reagent Diluent for 
detection. The intra-assay coefficient of variation for TIMP-4 measurement was 1.96%, and 
the inter-assay coefficient of variation was 1.92%. 
 
2.2.5 Cytometric Bead Array quantification 
BD™ cytometric bead array (CBA) assays comprise capture beads of a known size and 
fluorescence that can quantify soluble proteins in samples using flow cytometry. Specifically, 
capture beads conjugated with an analyte specific antibody bind to soluble protein in a sample 
and form a sandwich complex when incubated with phycoerythrin (PE)-conjugated detection 
antibodies. This analyte complex can be measured using a dual-laser flow cytometry, with the 
bead region detected by the red laser and the PE fluorescence detected by the yellow-green 
laser. The bead region describes the analyte of interest, while PE fluorescence intensity is 
directly proportional to analyte concentration in a sample. This technology allows for 
multiplexing due to distinct fluorescent signatures of capture beads.  
 
2.2.5.1 FGFb and VEGF 
BD™ CBA Human Soluble Protein Flex Set System was used to quantify levels of FGFb 
(#558327, BD Biosciences, California, United States) and VEGF (#558336, BD Biosciences, 
California, United States) in plasma samples. Lyophilized standards for FGFb and VEGF were 
pooled, and reconstituted in Assay Diluent to create the top standard of 2,500 pg/mL. A 2-fold 
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serial dilution was performed to create an 8-point standard curve. Samples were diluted 4-
fold in Assay Diluent, while capture beads were diluted in Capture Bead Diluent for a final 
concentration of 50 µL beads per test measurement. Standards and samples were combined 
with diluted capture beads in a 1:1 ratio for a final volume of 100 µL per well in a 96-well plate. 
The plate was mixed for 5 minutes on an orbital shaker at 200 rpm, before incubating at room 
temperature for 1 hour. Detection reagent containing PE-conjugated antibodies was diluted 
in PE Detection Reagent to a concentration of 50 uL per test measurement, and added to the 
samples. The plate was mixed for 5 minutes at 200 rpm, and incubated for 2 hours at room 
temperature. The plate was centrifuged at 200 x g for 5 minutes to pellet the capture beads, 
and supernatant was removed. The plate was washed by adding Wash Buffer to each well, 
mixing for 5 minutes at 200 rpm, and centrifuging at 200 x g for 5 minutes. Pellets were 
resuspended in Wash Buffer, and incubated overnight at 4˚C. The mean fluorescent intensity 
(MFI) of capture beads in samples was measured using the FACSCanto™ II flow cytometer (BD 
Biosciences; California, United States). The data was analysed using FlowJo® (FlowJo, Oregon, 
United States) and FCAP Array Software v3.0 (BD Biosciences, California, United States). The 
concentrations of FGFb and VEGF were calculated using a 5-PL standard curve. Samples that 
had MFIs below the lowest standard (10 pg/mL) were given a value of zero.  
 
2.2.6 Human Magnetic Luminex® quantification 
Magnetic Luminex® is a quantification platform that simultaneously measures the levels of 
multiple analytes in a single sample using magnetic bead technology. Magnetic microparticles, 
pre-coated with analyte-specific capture antibodies, are combined with sample to capture the 
analyte of interest. Biotinylated detection antibodies are combined and form an antibody-
antigen complex specific to the analyte of interest. The addition of Streptavidin-phycoerythrin 
conjugate (Streptavidin-PE) binds to the biotinylated detection antibody and fluorescent 
intensity can be measured using dual-laser flow-based detection. The first laser identifies the 
analyte of interest, while the second laser determines the magnitude of PE-derived signal that 
is directly proportional to the amount of bound analyte. The remaining six biomarkers were 
measured using this technology.  
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2.2.6.1 MMP-2, MMP-3, MMP-8, MMP-9, osteopontin and periostin 
ECM biomarker levels were quantified in plasma using two Human Magnetic Luminex® panels 
(R&D Systems, Minnesota, USA) and were divided based on the expected concentration in the 
samples: MMP-2 , MMP-3 and MMP-9 (Panel 1; Lot L125985) and MMP-8, osteopontin and 
periostin (Panel 2; Lot L125986). Standards specific for each analyte in a panel were 
reconstituted with RD6-52, and combined in a 10-fold dilution to create the top standard. A 
3-fold serial dilution was performed to create a 6-point standard curve. Samples measured in 
Panel 1 were diluted 1:25 with RD6-52, while samples measured in Panel 2 were diluted 1:2. 
The microparticle cocktail, containing the analyte-specific capture antibodies, was diluted 10-
fold in RD2-1. Samples and standards were added to the 96-well plate in duplicate, and the 
diluted microparticle cocktail was added in 1:1 ratio for a final volume of 100 µL per well. The 
plate was incubate for 2 hours at room temperature while shaking at 200 rpm to ensure 
continuous mixing of sample with microparticles. Following incubation, a magnetic device 
(Luminex® Magnetic Plate Separator, R&D Systems, Minnesota, United States) was applied to 
the bottom of the microplate and acclimatised for 1 minute before the standards and samples 
were discarded. Wash Buffer was added and incubated for 1 minute before liquid was expelled 
and the magnetic device was removed. This wash procedure was repeated three times. 
Human Premixed Biotin-antibody Cocktail was diluted in RD2-1, added to each well, and 
incubated at room temperature for 1 hour while shaking at 200 rpm.  The plate was washed 
as previously described, and incubated with Streptavidin-PE diluted in Wash Buffer for 30 
minutes at room temperature while shaking at 200 rpm. The plate was washed a further three 
times and microparticles were resuspended in 150 µL of Wash Buffer and stored overnight at 
4˚C. The MFI  for each analyte was measured using dual-lasers on the Luminex® 200 analyzer 
(Sigma-Aldrich, Massachusetts, USA). Intra-assay coefficient of variations were between 4.6% 
and 11.2%, and inter-assay coefficient of variations were between 7.3% and 13.2%. 
Experimental data was analysed by fitting a 5-PL curve to the standard analyte curves.  
 
2.2.7 Statistical analysis 
A population size of 140 patients was considered appropriate for this initial study, as this 
sample size exceeded many of the previous studies conducted in this field. Specifically, Webb 
et al. [131] measured a combination of seven MMPs and TIMPs in a cohort of 32 AMI patients, 
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while Manhenke et al. [174] measured nine ECM turnover biomarkers in 42 first-time STEMI 
patients. Currently, the only other study within the literature to measure a large number of 
ECM-associated biomarkers was conducted by Fertin et al. [192] who measured eight MMPs 
and TIMPs in 246 AMI patients. While this sample size is the largest, it was a prospective multi-
centre study that recruited across a 2.5 year time period, which was beyond a realistic time 
scope for this thesis.   
Continuous variables were assessed for normality using the Shapiro-Wilk test. Parametric 
continuous variables were reported as mean ± standard deviation (SD) and non-parametric 
continuous variables were reported as median (interquartile range; IQR). Categorical variables 
were reported as frequencies (percentages). Univariate correlations were performed using 
Spearman’s Rank Correlation. Statistical tests to compare medians of continuous and 
categorical variables were performed using Mann-Whitney U and Kruskal-Wallis H Test, 
respectively. Chi Square tests were used to compare categorical variables. Statistical 
significance was determined in this study by p<0.05.  All basic statistical analysis were carried 
out in either GraphPad Prism Software v.7.04 (GraphPad Software Inc; California, USA) or SPSS 
v.24 (IBM; New York, USA).  
 
2.2.7.1 Exploratory Factor Analysis 
Exploratory Factor Analysis (EFA) was performed on 10 log-transformed ECM biomarkers 
using principle axis analysis with Oblimin rotation using R version 4.0.2 [245]. Eigenvalues 
were used to determine the number of factors extracted for this solution. Derived from matrix 
correlations between analysed variables, eigenvalues describe how well a single factor 
explains the variance in a solution. An initial analysis demonstrated that five out of 10 factors 
met Kaiser’s criterion of 1 (eigenvalue ≥ 1). A scree plot, which plots factors against respective 
eigenvalues, indicated a two-factor solution was most appropriate. A two-factor solution was 
further confirmed by parallel analysis [246]. A factor represents a group of variables which are 
highly interrelated. The strength in association between a variable and the corresponding 
factor can be determined by the factor loading score. Like any form of correlation, a factor 
loading closer to ± 1 demonstrates a strong relationship, and the squared factor loading is the 
amount of total variance that is accounted for by the factor. In this study, we have presented 
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all variables which have factor loadings > 0.3, which accounts for approximately 10% of total 
variance.  
 
2.2.7.2 Cluster analysis 
Cluster analysis was performed exclusively on ECM biomarker data and did not include clinical 
characteristics or patient risk factors. Prior to cluster analysis, biomarker data was log-
transformed to normalise distribution and each biomarker was standardised to the same scale 
(mean=0, SD=1) to account for large variance between biomarkers which could influence 
cluster assignment. Subjects were partitioned using agglomerative hierarchical clustering in R 
version 4.0.2 [245] using Ward’s method of minimum variance and the Euclidean distance 
metric. Identification of optimal number of cluster groups was determined using the NbClust 
package in R [247]. This methodology uses a series of 30 indices to determine optimal cluster 
number, with the majority rule determining the most optimal cluster size. One of these indices 
investigates within cluster sum of squares which measures compactness of clustering. The 
“elbow method” graphical plots the within sum of squares as a function of cluster number. 
The bend in the graph is the optimal cluster choice, and this validation plot is shown in 
Appendix Figure 1. This methodology, alongside a majority of the other measured indices, 
confirmed a cluster size of two.   
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2.3 Results 
2.3.1 Baseline demographics and clinical characteristics 
Baseline demographics and clinical characteristics of the 140 AMI patients are summarised in 
Table 2-1. The study population was 76.4% male with a mean age of 61 years and a mean BMI 
of 28.4. Of the patients in this cohort, 84.3% identified as European, 11.4% identified as Māori 
and Pacific, and a further 4.3% identified as ‘Other’. Upon index admission, 44.3% of patients 
had hypertension, 54.3% had dyslipidaemia, 15.0% had diabetes and 22.9% were current 
smokers. Patients in this AMI cohort presented as NSTEMI (73.6%) and STEMI (26.4%). 
 
2.3.2 Extracellular matrix biomarker measurements 
Circulating levels of ECM biomarkers are shown in Table 2-1 and in Figure 2-1. Of the 12 ECM 
biomarkers measured, 10 had detectable levels for all 140 AMI patients. Both FGFb and VEGF 
had values below the detectable limit of their protein assays for a substantial number of 
patients. These patients were given a value of zero, as described in the methodology (Section 
2.2.5.1). For FGFb, detectable levels were recorded in 38 (27.1%) patients (median 89.30 
pg/mL, IQR 70.17 - 101.30). For VEGF, detectable levels were recorded in 88 (62.9%) patients 
(42.13 pg/mL, 38.61 - 49.00). Due to the inability to measure these biomarkers in the majority 
of the patient cohort, FGFb and VEGF were excluded from further analysis in this chapter.   
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Table 2-1. Baseline demographics of the study population. 
Characteristics Patients (n = 140) 
Age (mean, years) 61 ± 11 
Male (n) 107 [76.4] 
BMI (median,  kg/m2) 28.4 [25.7 - 32.8] 
Ethnicity  
European 118 [84.3] 
Māori and Pacific 16 [11.4] 
Other 6 [4.3] 
Risk Factors  
Hypertension 62 [44.3] 
Dyslipidaemia  76 [54.3] 
Diabetes 21 [15.0] 
Current Smoker 32 [22.9] 
Classification  
NSTEMI 103 [73.6] 
STEMI 37 [26.4] 
Biochemical Measurements  
FGFb (pg/mL, detectable=38) 0.00 [0.00 - 56.53] 
MMP-2 (ng/mL) 106.92 [94.12 - 134.38] 
MMP-3 (ng/mL) 10.15 [7.77 - 15.07] 
MMP-8 (ng/mL) 0.41 [0.14 - 0.74] 
MMP-9 (ng/mL) 17.31 [11.78 - 28.69] 
Osteopontin (ng/mL) 36.71 [27.14 - 47.26] 
Periostin (ng/mL) 85.25 [69.39 - 107.15] 
PINP (ng/mL) 0.53 [0.30 - 0.97] 
TGF-β1 (ng/mL) 4.41 [3.10 - 6.14] 
TIMP-1 (ng/mL) 71.83 [54.37 - 85.37] 
TIMP-4 (ng/mL) 2.70 [2.04 - 3.53] 
VEGF (pg/mL, detectable=88) 37.74 [0.00 - 43.67] 
Peak hs Troponin T (ng/L) 382 [133 - 1,583] 
Parametric continuous variables were expressed as mean ± SD and non-parametric continuous 
variables were expressed as median (IQR). Categorical variables were expressed as frequencies 
(percentages). Abbreviations: BMI, body mass index; NSTEMI, non-ST-elevation myocardial 
infarction; STEMI, ST-elevation myocardial infarction.  












































































Figure 2-1. The ECM biomarker concentrations in 140 AMI patients. 
The levels of ECM biomarkers measured three days post hospital admission in 140 AMI 
patients. Data is shown as median (IQR). All biomarkers are shown as ng/mL, except for 
FGFb and VEGF which are shown as pg/mL. Biomarkers with low concentrations (MMP-8, 
PINP, TGF-β1 and TIMP-4; outlined in red) are represented by an additional graph with 
smaller concentrations recorded on the y-axis. 
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2.3.3 Correlations between extracellular matrix biomarkers 
The relationships between the remaining 10 ECM biomarkers were examined using 
Spearman’s Rank correlation. Of the 45 pairs examined, 13 significant correlations were 
observed (Figure 2-2). These correlations were weak-to-moderate in strength, with the 
strongest correlation observed between MMP-8 and MMP-9 (rs=0.571, p<0.0001). Of 
the 13 significant correlations, two inverse relationships were observed between 
osteopontin and PINP (rs =-0.225, p<0.05) and TGF-β1 and MMP-2 (rs =-0.267, p=0.001).  
 
  





Figure 2-2. Correlation matrix between extracellular matrix biomarkers.  
Spearman’s Rank correlation was conducted between extracellular matrix biomarker pairs. Red shading 
indicates positive correlations and blue shading indicates negative correlations. Significance is shown by 
white asterisk symbols. *p<0.05, ** p<0.001, *** p<0.0001.  
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2.3.4 Relationship between clinical risk factors and extracellular matrix biomarkers 
Correlations between clinical characteristics and patient risk factors are shown in Tables 
2-2 to 2-6.  
 
When biomarkers were correlated with age, seven of the 10 pairs were statistically 
significant. These significant correlations were weak-to-moderate in strength, with the 
strongest correlation observed between age and TIMP-4 (rs =0.429, p<0.01). A significant 
inverse relationship was also observed between age and PINP (rs=-0.197, p<0.05). No 
significant correlations were observed between BMI and ECM biomarkers. Female 
patients had higher levels of PINP, TIMP-1 and TIMP-4 (all p<0.05) when compared to 
male patients. In comparison, male patients had increased MMP-3 levels (p<0.001) 
compared to females.  
 
Patients presenting with NSTEMI had lower circulating levels of osteopontin (p<0.05) 
compared to patients who presented with STEMI. Patients diagnosed with hypertension 
had increased levels of periostin (p<0.05) and TIMP-4 (p<0.01) when compared to non-
hypertensive patients. Higher levels of TIMP-4 (p=0.05) were observed in diabetic 
patients and higher levels of PINP (p<0.05) were observed in patients diagnosed with 
dyslipidaemia. In this cohort, no differences were observed in ECM biomarker levels 
across ethnicities.  
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MMP-2 0.295++ -0.010 104.19 [93.92 - 134.21] 117.09 [94.57 - 139.30] 
MMP-3 0.216+ -0.133 11.55 [8.44 - 17.04] 7.75 [5.52 - 9.68]*** 
MMP-8 -0.067 -0.004 4.31 [1.69 – 7.46] 4.0 [0.99 – 6.33] 
MMP-9 -0.140 -0.003 17.47 [11.85 - 29.46] 16.49 [11.65 - 25.91] 
Osteopontin 0.298++ -0.028 34.95 [27.45 - 45.63] 39.23 [26.10 - 49.51] 
Periostin 0.231* 0.061 82.71 [67.34 - 101.78] 91.40 [77.22 - 116.94] 
PINP -0.197+ -0.010 0.48 [0.26 – 0.87] 0.69 [0.37 – 0.69]* 
TGF-β1 -0.018 -0.010 4.45 [3.08 - 6.13] 4.12 [3.06 - 6.20] 
TIMP-1 0.194+ 0.078 71.35 [53.64 - 82.2] 80.06 [63.14 - 94.77]* 
TIMP-4 0.429++ -0.049 2.60 [2.02 - 3.33] 3.33 [2.10 - 4.67]* 
Continuous variables are reported as median [IQR].  Spearman’s Rank correlation was used to 
measure the association between continuous variables. +p<0.05, ++p<0.01. Mann-Whitney U testing 
was used to detect differences in ECM biomarker levels between male and female patients. *p<0.05, 









None (n=78) Diagnosed (n=62) 
MMP-2 103.63 [90.09 - 126.44] 111.28 [96.95 - 146.11] 
MMP-3 9.82 [6.86 - 15.01] 10.53 [8.11 - 15.18] 
MMP-8 0.39 [0.11 – 0.72] 0.450 [0.18 – 0.78] 
MMP-9 16.98 [11.57 - 27.81] 17.78 [12.30 - 28.94] 
Osteopontin 34.85 [24.37 - 47.27] 38.69 [29.90 - 47.48] 
Periostin 80.31 [66.04 - 99.64] 94.08 [71.96 - 116.15]* 
PINP 0.55 [0.29 - 1.11] 0.52 [0.33 – 0.91] 
TGF-β1 4.31 [3.04 - 6.18] 4.55 [3.08 - 6.09] 
TIMP-1 71.35 [55.77 - 82.51] 74.74 [52.26 - 91.25] 
TIMP-4 2.55 [1.94 - 3.28] 3.04 [2.19 - 3.76]** 
Continuous variables are reported as median [IQR].  Mann-Whitney U testing was performed to detect 
differences in ECM biomarker levels between patients with a hypertension diagnosis. *p<0.05, **p<0.01. All 
biomarker concentrations are recorded in ng/mL. 
 
Page | 69 
 





None (n=64) Diagnosed (n=76) 
MMP-2 106.85 [94.34 - 128.14] 107.54 [94.03 - 140.52] 
MMP-3 9.95 [7.40 - 14.74] 10.92 [7.83 - 15.66] 
MMP-8 0.41 [0.17 - 0.70] 0.41 [0.11 - 0.77] 
MMP-9 17.27 [12.23 - 27.94] 17.32 [11.01 - 29.31] 
Osteopontin 35.76 [23.90 - 46.63] 37.48 [28.68 - 48.75] 
Periostin 82.52 [66.43 - 107.16] 86.29 [70.83 - 107.96] 
PINP 0.38 [0.26 - 0.82] 0.67 [0.42 - 1.15]* 
TGF-β1 4.68 [3.42 - 6.18] 4.16 [3.03 - 5.88] 
TIMP-1 71.92 [54.75 - 84.79] 71.09 [53.07 - 86.49] 
TIMP-4 2.80 [2.02 - 3.69] 2.60 [2.05 - 3.40] 
Continuous variables are reported as median [IQR]. Mann-Whitney U testing was performed to detect 
differences in ECM biomarker levels between patients with a dyslipidaemia diagnosis. *p<0.05. All biomarker 
concentrations are recorded in ng/mL. 
 
 





None (n=119) Diagnosed (n=21) 
MMP-2 106.89 [94.99. - 134.21] 111.12 [85.70 - 146.12] 
MMP-3 10.44 [7.75 - 15.16] 9.37 [7.34 - 13.54] 
MMP-8 0.41 [0.13 – 0.73] 0.52 [0.19 – 0.84] 
MMP-9 17.38 [12.03 - 29.08] 14.73 [9.66 - 26.42] 
Osteopontin 36.65 [25.74 - 45.63] 39.59 [27.48 - 54.80] 
Periostin 83.81 [67.49 - 104.49] 95.91 [78.09 - 126.57] 
PINP 0.54 [0.33 - 1.09] 0.53 [0.17 – 0.87] 
TGF-β1 4.34 [3.04 - 5.83] 4.75 [3.63 - 6.87] 
TIMP-1 71.80 [56.15 - 84.35] 75.26 [52.93 - 102.90] 
TIMP-4 2.63 [1.99 - 3.39] 3.29 [2.31 - 4.16]* 
Continuous variables are reported as median [IQR]. Mann-Whitney U testing was performed to detect 
differences in ECM biomarker levels between patients with a diabetes diagnosis. *p<0.05. All biomarker 
concentrations are recorded in ng/mL. 
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Table 2-6. The relationship between ECM biomarkers and AMI classification 
ECM Biomarker  
AMI Classification 
 
NSTEMI (n=103) STEMI (n=37) 
MMP-2 106.89 [94.16 - 131.80] 107.70 [91.07 - 144.15] 
MMP-3 10.18 [7.53 - 14.42] 9.92 [7.98 - 19.12] 
MMP-8 0.37 [0.11 – 0.73] 0.52 [0.24 – 0.79] 
MMP-9 17.25 [12.04 - 29.46] 18.03 [10.85 - 24.65] 
Osteopontin 34.79 [25.74 - 43.97] 39.99 [31.55 - 56.13]* 
Periostin 82.73 [67.49 - 104.49] 88.06 [70.82 - 114.49] 
PINP 0.53 [0.30 – 0.88] 0.55 [0.31 - 1.15] 
TGF-β1 4.38 [3.03 - 5.83] 4.62 [3.61 - 6.20] 
TIMP-1 71.28 [52.64 - 83.29] 76.63 [58.58 - 91.91] 
TIMP-4 2.60 [1.99 - 3.37] 3.05 [2.25 - 3.93] 
Continuous variables are reported as median [IQR]. Mann-Whitney U testing was used to detect differences 
in ECM biomarker levels between AMI classifications. *p<0.05. All biomarker concentrations are recorded in 
ng/mL. Abbreviations: AMI, acute myocardial infarction; NSTEMI, non ST-elevation myocardial infarction; 
STEMI, ST-elevation myocardial infarction. 
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2.3.5 Correlations between patient risk and extracellular matrix biomarkers 
In this study, patient risk was assessed by examining peak high-sensitivity Troponin T and 
GRACE scores. When peak troponin T levels were compared to ECM biomarkers, weak-to-
moderate significant correlations were observed and are shown in Figure 2-3. These were 
between peak troponin T and MMP-8 (rs=0.172, p<0.05), osteopontin (rs=0.341, p<0.0001) 
and TIMP-1 (rs=0.206, p<0.05). For GRACE scores, four positive and significant correlations 
were observed between MMP-2 (rs=0.250, p<0.01), MMP-3 (rs=0.232, p<0.01), osteopontin 
(rs=0.304, p<0.001) and TIMP-4 (rs=0.277, p=0.001) (Figure 2-4). In addition, MMP-9 levels 
were inversely correlated with GRACE scores (rs=-0.208, p<0.05) (Figure 2-4).   
 
  












































































Figure 2-3. Relationship between ECM biomarkers and peak troponin T. 
Spearman’s Rank Correlation was conducted to assess the relationship between ECM biomarkers and peak 
high-sensitivity troponin T (hs-TnT). Significant correlations were identified between peak troponin and 
MMP-8, osteopontin and TIMP-1.  
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(rs=0.304,p<0.001) (rs=-0.208, p<0.05) 
(rs=0.277, p=0.001) 
Figure 2-4. Relationship between ECM biomarkers and GRACE scores.  
Spearman’s Rank correlation was conducted between ECM biomarkers and GRACE scores. Five significant 
correlations were identified and these were between GRACE scores and MMP-2, MMP-3, MMP-9, 
osteopontin, TIMP-4. Abbreviations: GRACE, global registry of acute coronary events.  
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2.3.6 Exploratory factor analysis 
EFA was performed on 10 log-transformed ECM biomarkers using principle axis analysis with 
Oblimin rotation. Model fit was assessed using the Kaiser-Meyer-Olkin (KMO) measure which 
verified sampling adequacy with a value of 0.6 which is greater than the required threshold of 
0.5. Bartlett’s Test for Sphericity, which assesses collinearity within a dataset, was significant 
for this study (p<0.0001) and suggests EFA is an appropriate method to examine meaningful 
relationships between variables.  
 
A factor represents a group of items that are highly interrelated. The strength in association 
between an item and the corresponding factor can be determined by the factor loading score. 
A factor loading closer to ± 1 demonstrates a strong relationship, and the squared factor 
loading is the amount of total variance that is accounted for by the factor. In this study, we 
have presented all variables which have factor loadings > 0.3, which accounts for 
approximately 10% of item variance. 
 
EFA identified a two-factor solution which best described the relationship between ECM 
biomarkers in this AMI cohort. The rotated factor matrix, which describes the composition 
and loadings for each factor, is shown in Table 2-7. Factor 1 clustered three biomarkers with 
factor loadings greater than 0.3. MMP-8 and MMP-9 were highly correlated with Factor 1, 
while TGF-β1 only moderately contributed to Factor 1 which was demonstrated by a smaller 
factor loading. Factor 1 accounted for 15.88% of variance in the model.  
 
In comparison, Factor 2 was comprised of five biomarkers with factor loadings greater than 
0.3. MMP-2 and osteopontin significantly contributed to Factor 2. Comparably, MMP-3, 
periostin and PINP only demonstrated mid-range factor loadings between -0.312 and 0.499. 
In this EFA, PINP was the only biomarker with a negative factor loading and this suggests that 
lower levels of PINP result in more positive factor loadings. No biomarkers were cross-
correlated across factors and TIMP-1 and TIMP-4 did not contribute to either factor despite 
being included in the input for the EFA. Factor 2 accounted for 12.33% of variance in the 
model.   
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Table 2-7. The rotated factor matrix for circulating ECM biomarkers using EFA. 
Variables Factor 1 Loadings Factor 2 Loadings 
MMP-8 0.919 - 
MMP-9 0.621 - 
TGF-β1 0.448 - 
MMP-2 - 0.606 
Osteopontin - 0.565 
MMP3 - 0.499 
Periostin - 0.408 
PINP - -0.312 
% of variance  
(rotated Sum of Squared loadings) 
15.88 12.33 
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2.3.7 Cluster analysis  
Using EFA analysis, we have shown that complex interrelationships exist between ECM 
biomarkers. To capture this complexity, we employed cluster analysis to investigate ECM 
profiles in the AMI population. Hierarchical cluster analysis identified three patient groups 
with different ECM biomarker profiles. A dendrogram of patient clustering is shown in Figure 
2-5. Differences in clinical characteristics between clustered groups are shown in Table 2-8, 
while differences in individual ECM biomarker levels are shown in Table 2-9 and Figure 2-6. 
 
Cluster One (n = 54) comprised the largest patient group. Patients in Cluster One had 
significantly elevated levels of MMP-8, MMP-9 and TGF-β1 when compared to all other 
clusters. Levels of PINP and TIMP-4 were also increased when compared to patients in Cluster 
Two, while MMP-3 levels were significantly decreased.  
 
Cluster Two (n = 43) comprised patients with an increased median age compared to Cluster 
One (p<0.01) and Three (p<0.001). Peak levels of MMP-2, MMP-3, osteopontin, periostin and 
TIMP-1 were observed in Cluster Two when compared to other clustered groups. Levels of 
MMP-8 and TIMP-4 were increased when compared to Cluster Three, while PINP levels were 
significantly decreased. Patients in Cluster Two had significantly elevated GRACE scores when 
compared to patients in Cluster One (p<0.01) and Cluster Three (p<0.05). The proportion of 
age contributing to the score was calculated and compared between groups. Cluster Three 
had a significantly lower age proportion when compared to Cluster Two (p<0.001) and no 
difference in age proportion was observed between Cluster One and other clustered groups. 
Peak high-sensitivity troponin T levels were also significantly elevated in Cluster Two when 
compared to Cluster Three (p<0.05). 
 
Patients in Cluster Three (n = 43) demonstrated significantly lower median levels of most ECM 
biomarkers as described above (Figure 2-8). 
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Figure 2-5. Dendrogram of hierarchical cluster analysis.  
Algorithmic hierarchical cluster analysis identified three distinct groups of AMI patients based on the levels 
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Table 2-8. Patient demographics and clinical characteristics of clustered groups. 
Characteristics Cluster One (n=54) Cluster Two (n=43) Cluster Three (n=43) 
Age [mean, years] 60 [9] 67.2 [11]** 57.2 [13]+++  
Male [n] 39 [70.2] 36 [83.7] 32 [74.4] 
BMI [median,  kg/m2] 28.3 [25.9 - 32.7] 28.4 [25.1 - 32.9] 28.4 [25.1 - 32.5] 
Ethnicity    
European 44 [81.5] 35 [81.4] 39 [90.7] 
Māori & Pacific 7 [13.0] 6 [13.9] 3 [6.9] 
Other 3 [5.6] 2 [4.7] 1 [2.3] 
Risk Factors    
Hypertension 28 [51.9] 21 [48.8] 13 [30.2] 
Dyslipidaemia 29 [53.7] 26 [60.5] 21 [48.8] 
Diabetes 8 [14.8] 8 [18.6] 5 [11.6] 
Current Smoker 15 [27.8] 10 [23.3] 7 [16.3] 
Classification    
NSTEMI 37 [68.5] 30 [69.8] 36 [83.7] 
STEMI 17 [31.5] 13 [30.2] 7 [16.3] 
Patient Risk    
hs-Troponin T [ng/L] 458 [127.0 - 1,527.5] 644.0 [163 - 2,700.0] 218.0 [105.5 - 683.5]+ 
GRACE score 117.1 ± 30.9 136.3 ± 31.7**  117.3 ± 33.2+ 
Proportion of 
age/total GRACE score 
0.40 ± 0.12 0.45 ±0.11 0.34 ± 0.15+++ 
Continuous variables are reported as median (IQR). Kruskal-Wallis test with Dunn’s correction and one-way 
ANOVA with Tukey’s correction were used to compare non-parametric and parametric continuous variables 
between clusters, respectively. *denotes significance compared to Cluster 1. **p<0.01. +denotes significance 
compared to Cluster 2. +p<0.05, +++p<0.001. Categorical variables are reported as frequency (percentage). Chi 
Square test was used to determine differences in categorical variables between clusters. Abbreviations: BMI, 
body mass index; NSTEMI, non ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.  




Figure 2-6. Extracellular matrix biomarker levels between clustered groups.  
Kruskal-Wallis test with Dun’s multiple comparisons was used to identify significant difference between 
biomarker levels of each patient cluster. *p<0.01, ****p<0.0001. Median + IQR is plotted for all graphs.  
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Cluster One Cluster Two Cluster Three 
MMP-2 97.69 (86.5 - 126.4) 139.4 (107.7 - 153.7)† 103.9 (91.5 - 154.3)^ 
MMP-3 8.31 (7.08 - 11.57) 15.19 (11.38 - 24.17)† 9.21 (5.52 - 12.25)^ 
MMP-8 0.75 (0.44 - 1.02) 0.38 (0.23 - 0.66)# 0.17 (0.08 - 0.71)‡ † 
MMP-9 27.89 (18.33 - 43.53) 13.12 (10.79 - 18.21)† 14.29 (10.94 - 17.55)† 
Osteopontin 33.78 (25.82 - 41.30) 48.53 (38.90 - 62.32)† 31.23 (22.07 - 37.4)^ 
Periostin 82.52 (70.91 -  100.50) 110.60 (92.26 - 132.60)# 71.17 (60.45 - 84.92)^ * 
PINP 0.72 (0.45 - 1.38) 0.36 (0.17 - 0.64)† 0.53 (0.30 - 1.30)‡ 
TGF-β1 5.41 (4.26 - 6.79) 4.13 (2.82 - 5.19)# 3.67 (2.74 - 5.20)† 
TIMP-1 71.75 (52.00 - 85.05) 81.01 (65.48 - 94.35)* 61.97 (52.54 - 74.47)§ 
TIMP-4 2.99 (2.14 - 3.75) 2.97 (2.40 - 3.76) 2.20 (1.53 - 2.59)# ^ 
Kruskal-Wallis test with Dunn’s multiple comparisons was performed to identify significant differences 
between ECM biomarker levels in clustered groups. Symbols denote significant differences between 
clusters. *Cluster One (p<0.05), #Cluster One (p<0.001), †Cluster One (p<0.0001), ‡Cluster Two 
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2.4 Discussion 
In this study, we have explored the complexity and heterogeneity of ECM biomarkers 
measured in AMI patients on day three following hospital admission. EFA demonstrated 
complex and collinear interrelationships between ECM biomarkers. Specifically, this study was 
best described by a two-factor solution, which comprised three biomarkers strongly 
correlated in Factor 1 and five biomarkers with weak-to-moderate relationships in Factor 2. 
To account for this complexity, we applied cluster analysis to our AMI population and 
identified three subgroups of patients that exhibited distinct ECM biomarker profiles. These 
findings suggest that AMI patients can be partitioned into phenotypically distinct groups based 
on ECM biomarkers alone, and this provides an opportunity to discriminate between patients 
using a combined biomarker methodology.  
 
Upon initial investigation, each individual biomarker demonstrated considerable variation and 
the correlations between each biomarker were modest, weak or not evident within the 
patient cohort. To understand the complexity of interrelationships between measured ECM 
biomarkers in-depth, we employed EFA. This is an advanced statistical technique with the 
primary purpose of defining the underlying structure of data based on the correlations 
between variables [241]. This approach takes multidimensional data and reduces it to 
overarching latent variables, known as factors. Variables with high collinearity are grouped 
together in a single factor, and their loading value represents the strength of their relationship 
within a factor [234].  
 
In this study, a two-factor solution best described ECM biomarkers in our AMI cohort. Factor 
1 was comprised of three ECM biomarkers. In this factor, MMP-8 had the highest loading 
value, and this was followed by MMP-9 and then TGF-β1. This composition could suggest that 
Factor 1 represents an ECM degradation phenotype, as MMPs are responsible for mediating 
the removal of cellular debris at the infarct site [248], while TGF-β1 can activate these 
pathways as a multifunctional growth factor [249]. In comparison, Factor 2 comprised a larger 
number of ECM biomarkers with weak- to mid-range loadings. This suggests that a 
combination of ECM biomarkers jointly contributed to the composition of Factor 2, unlike 
Factor 1, which was mostly described by a single biomarker. Biomarkers with the strongest 
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loadings in Factor 2 were MMP-2 and osteopontin, closely followed by MMP-3, periostin and 
PINP. Consequently, deciphering the latent variable represented by Factor 2 is more 
challenging due to the combination of ECM biomarkers included which were not separated 
solely based on biological function.  
 
This segues into the most important findings from EFA in this study. Firstly, EFA has confirmed 
that collinearity exists within the ECM biomarkers measured in this patient cohort. This is 
shown by the significant Bartlett’s Test for Sphericity which confirms interrelationships exist 
between measured variables and by the inclusion of multiple biomarkers within each factor. 
EFA has also importantly demonstrated that ECM biomarkers are not grouped solely based on 
biological function. This is particularly evident in the distribution of MMPs, which are evenly 
spread across both factors. Overall, these findings suggest that ECM biomarker relationships 
are entwined and consequently measuring multiple ECM biomarkers may be important for 
capturing the complexity of these interrelationships.  
 
Total variance accounted for by the EFA model was 28.21 across both factors. While this value 
is less than half of all variance, it must be acknowledged within the context of EFA. Unlike 
principle component analysis (PCA), which is another data extraction procedure that accounts 
for the maximal variance between variables, EFA only measures common variance among 
variables [234]. The distinction between these two similar, yet diverse, techniques is the 
purpose of their use. While PCA aims to represent as much variance in as few components as 
possible, EFA aims to describe the relationships between variables and latent factors in smaller 
underlying dimensions. Thus, the variance observed in this study is unsurprising, and the use 
of EFA over PCA is justified for the purpose of this research.  
 
While included in the analysis, both TIMP-1 and TIMP-4 were not represented by either factor 
upon EFA. All biomarker measurements recorded for this study were collected three days 
following hospital admission, as this is the latest measurement collected from hospital 
inpatients and provides an opportunity to capture ECM activity in the sub-acute phase of 
repair. However, this time point may favour cardiac ECM degradation processes as tissue 
Page | 83 
 
clearance dominates early repair [64]. Indeed, Factor 1 and Factor 2 both comprised 
biomarkers that represented ECM degradation activity. As TIMPs are associated with ECM 
deposition mechanisms due to their active role in MMP inhibition [87], this may be a biological 
explanation for why these were not captured by the EFA factors.  
 
While 10 ECM biomarkers were included in EFA, 12 biomarkers were measured in this study. 
Both FGFb and VEGF levels were not detectable in a significant number of patient samples. 
These biomarkers are both growth factors essential for regulating repair processes following 
AMI. Specifically, FGFb is required for cell proliferation, collagen synthesis and correct scar 
formation [250], while VEGF is a potent mitogen with a central role in vasculogenesis and 
angiogenesis [251]. Interestingly, a previous study measuring VEGF in AMI patients also 
identified dichotomised groups that separated VEGF measurements above and below the 
lowest detectable limit of the assay [186]. While dichotomised groups have not been reported 
in the literature for FGFb, studies in serum have consistently shown low expression levels for 
this biomarker in AMI patients [184, 252]. The BD™ CBA assay used in this experiment has a 
lowest standard of 10 pg/mL, and this is more sensitive than other commercially available 
ELISA kits on the market currently. Therefore, measurement of this biomarker in a clinical 
setting may be impeded by assay sensitivity. Potentially, the timing of biomarker 
measurements may influence the levels of detectability, with peak levels occurring before or 
after three days post-hospital admission. This is an avenue for future research that is further 
addressed in Chapter 3.    
 
Patients included in this study were retrospectively selected from the Wellington ACS Registry, 
which is a pre-existing biobank of prospectively recruited ACS patients presenting to 
Wellington Regional Hospital. Patients were included if they were diagnosed with AMI and 
had blood collected three-days following hospital admission. The purpose of this study was to 
capture ECM repair processes following AMI, and exclusion criteria was carefully applied to 
this patient cohort to remove confounding co-morbidities which were likely to influence ECM 
biomarker levels beyond post-MI repair. Alongside common exclusion criteria for biomarker 
research, such as renal insufficiency and active malignancy, patients were also excluded if they 
had a prior AMI or CHF diagnosis. These patients are likely to have undergone adverse cardiac 
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remodelling processes associated with their initial ischaemic injury, and therefore, ECM 
biomarker levels measured in this study would not likely be reflective of their current AMI 
event. For similar reasons, patients with active rheumatological disease or pulmonary fibrosis 
were also excluded from this study, as ECM biomarkers are not cardiac specific and can be 
influenced by systemic remodelling processes. While this exclusion criteria narrows down the 
patient population, findings from this study are still applicable to a broader AMI population, 
as patients with these co-morbidities will likely have an exaggerated ECM response that is still 
captured by measurement of these biomarkers.  
 
Following EFA findings that demonstrated collinearity existed between circulating ECM 
biomarkers, we employed cluster analysis to identify whether patients could be partitioned 
based on ECM biomarker levels exclusively. Cluster analysis is an unsupervised classification 
technique that groups objects with similar characteristics together, and dissimilar objects 
separately [232]. This study carried out agglomerative hierarchical cluster analysis on the 
patient population. This is a common method utilised in cluster analysis, and involves the 
successive combination of cases into groups until an optimal grouping is identified [253]. In 
this study, AMI patients were clustered into three groups based on the levels of 10 ECM 
biomarkers. These findings suggest that the ECM response following AMI is not homogenous, 
and distinct ECM biomarker profiles can be identified within the patient population. These 
findings are of significance in this setting, as they suggest that patients with similar clinical 
characteristics and AMI presentations have altered ECM biomarker levels that can be 
categorised using cluster analysis. More specifically, ECM biomarker levels were not uniformly 
increased or decreased within clustered groups, but instead displayed a combination of 
changes that could not be identified using a single biomarker approach. 
 
For simplicity in understanding the potential biological relevance of clustered groups, we have 
described clusters based on peak biomarker levels. Cluster Two had the largest number of 
peak biomarkers with increased levels of MMP-2, MMP-3, osteopontin, periostin and TIMP-1 
when compared to other cluster groups. Cluster One had increased levels of MMP-8, MMP-9 
and TGF-β1, while no peak biomarker levels were observed in Cluster Three. Levels of TIMP-4 
and PINP were increased in Cluster One compared to Cluster Two, and but were not different 
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when compared to Cluster Three. We suggest that ECM biomarker levels are representative 
of intra-cardiac changes in molecular function. As such, we postulate that patients in Cluster 
Two have greater ECM activity than patients in Cluster One or Three. We also suggest that 
patients in Cluster Three had decreased global ECM activity, as demonstrated by collectively 
lower concentrations.  
 
Previous studies have demonstrated the ability of cluster analysis to capture disease 
heterogeneity [254, 255]. Furthermore, the relationship between clustered groups and 
patient risk has been well documented in the literature [233, 255]. In a recent study of HIV-
infected patients, Scherzer et al.[233] demonstrated that patients could be partitioned into 
three distinct groups based on the levels of serum-derived biomarkers only. Of the three 
groups, one was classified as a cardiac phenotype, one was classified as an inflammatory 
phenotype and one remained undefined. The two defined phenotypes were shown to be 
predictive of mortality in patients, demonstrating the significance of profiling patients based 
on biomarker levels. Similar to these studies, we chose to create clusters based on biomarkers 
only. However, this is not the only approach to cluster analysis, as clinical variables and patient 
characteristics can also be included to strengthen patient subgroups [254, 256]. 
 
While we could not link ECM activity with direct measures of LV function in this study, we have 
examined the ability for cluster-based ECM profiles to differentiate patients based on two 
indices of cardiovascular risk. Peak troponin T is a clinically useful biomarker and is routinely 
used for AMI diagnosis and estimation of infarct size [257]. In addition to its clinical utility, 
peak troponin T is also associated with patient risk, with increased levels linked to LV 
remodelling and adverse long-term outcomes [258]. In this study, we have shown that peak 
high-sensitivity troponin T levels are significantly elevated in patients from Cluster Two 
compared to Cluster Three, and levels are numerically higher when compared to Cluster One. 
In addition, GRACE scores were significantly higher in Cluster Two when compared to other 
groups. While age, which is a component of the GRACE score, appears to be driving some of 
this variation between cluster groups, it is not the only contributing factor. Indeed, the 
proportion of age contributing to the total GRACE score was similar between Cluster One and 
Cluster Two, despite a significant increase in score values for patients in Cluster Two. Higher 
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GRACE scores are associated with increased mortality risk at six months post-MI [244], and 
this score has also been shown to hold value for predicting longer term mortality outcomes 
[259]. Combined, these findings suggest that clustered groups can differentiate patients into 
distinct risk categories based on ECM biomarker profiles despite similar clinical presentation. 
Identifying how ECM biomarker profiles relate to long-term indices of LV remodelling is an 
appropriate next step and is assessed in Chapter 4.  
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2.5 Limitations 
Firstly, the current study measured a number of circulating biomarkers that represent key 
processes in the ECM response post-MI. While these biomarkers are well-linked to repair 
processes and are known to change post-MI [87], we cannot conclude for certain the 
measured levels directly reflect intra-cardiac composition. However, direct measures of 
biomarker levels within the heart are not possible without invasive procedures, and would be 
unachievable within a clinical setting. Secondly, we measured biomarkers at a single 
standardised time point in the acute phase of AMI. While standardisation reduces variability 
between patients as a consequence of time differences, it does not allow us to examine the 
dynamic nature of biomarker levels which have been shown to change across time [192, 237]. 
However, this was not a question we directly assessed in this study, and instead has been 
addressed in Chapter 3. Thirdly, this study measured a number of correlations between 
biomarker levels without compensating for multiple comparisons. While this may influence 
the number of significant correlations captured in our analysis, this does not greatly influence 
the outcome of our results as we were interested in maximising the number of significant 
correlations. Finally, we chose to use cluster analysis as a method for combining biomarker 
measurements. While this approach overcomes collinearity, selecting an appropriate cluster 
size can be difficult. To overcome this limitation, we employed the NBClust package[247] in R 
that analyses optimal cluster size based on 30 well-established indices within the literature. 
This analysis provided an in-depth and extensive examination of optimal cluster size.  
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2.6 Conclusion 
In this study, we have demonstrated that variation exists in the levels of ECM biomarkers 
measured in our patient population, and this can only be modestly described by patient 
characteristics and clinical presentation. We have shown complex interrelationships exist 
between ECM biomarkers using EFA, and measuring multiple biomarkers may more accurately 
capture the ECM biological process post-MI. Using cluster analysis, we identified three groups 
of patients which had distinct ECM profiles. These clustered groups provide an opportunity to 
discriminate between patients during early myocardial repair.  
 
  













 Examining variation and temporal 
dynamics of extracellular matrix biomarkers 
following acute myocardial infarction. 
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3.1 Introduction 
An appropriate ECM response following AMI reduces myocardial damage and initiates a well-
orchestrated repair process that is facilitated by the ECM proteome [87]. In Chapter 2, we 
investigated statistical techniques for combining ECM biomarker measurements and 
demonstrated that differential ECM profiles existed in our AMI population. Biomarker levels 
were measured at a single standardised time point in order to account for sampling 
heterogeneity. While this time point was strategically selected to target early myocardial 
repair, further investigation into biomarker dynamics is required to ascertain optimal 
biomarker measurement. 
 
It is our contention that in order to identify prognostic biomarkers for patient risk, we must 
first have a basic understanding of biomarker activity in healthy and AMI conditions.  
Specifically, we are interested in examining temporal variation of biomarker levels in AMI 
patients when compared to a healthy reference range. This provides an opportunity to identify 
biomarkers with levels that exceed the variation observed in healthy biological processes, and 
provides an initial insight into pathological processes that may be of interest for future 
biomarker research.  
 
The groundwork for this research has begun, although current studies have largely focused on 
ECM turnover biomarkers [131, 174]. ECM turnover describes degradation and deposition 
processes in the myocardium [64], and is one part of a very complex pathophysiological 
system. We build upon previous research by investigating an expanded panel that was used 
in Chapter 2 which includes: MMPs, TIMPs, collagen peptides, growth factors and matricellular 
proteins. In addition, we are interested in understanding what relationships exist between 
ECM biomarkers and what cardiac risk factors drive differences in biomarker levels. 
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Thus, the aims for this study were as follows: 
• To compare ECM biomarker levels between AMI patients and healthy controls.  
• To examine temporal changes in ECM biomarkers during hospital admission and at 
six months post symptom onset.  
• To identify which clinical characteristics and cardiac function parameters drive 
changes in ECM biomarker levels of AMI patients.  
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3.2 Methods 
3.2.1 Study population. 
3.2.1.1 Acute myocardial infarction patients 
We prospectively recruited 23 patients diagnosed with AMI presenting to Wellington Regional 
Hospital between March and December 2018. Patients were eligible for inclusion in this study 
if they were: diagnosed with AMI according to the Third Universal Definition of Myocardial 
Infarction [243], presented to hospital within 24 hours of symptom onset, resided in the 
Wellington region, and were scheduled to have invasive therapy (coronary angiography ± 
percutaneous coronary intervention). Patients were excluded from this study if they were 
unable to provide informed consent, had chronic heart failure, had symptoms of ventricular 
tachycardia or ventricular fibrillation, were defibrillated, were diagnosed with an active 
malignancy, were on immune-modulating medications, or were diagnosed with renal 
insufficiency as previously described in Section 2.2.1. In addition, patients with cardiogenic 
shock or LVEF < 35% were excluded from this study as they were considered the most 
haemodynamically unstable group, making them unfit for ethical recruitment. This study was 
reviewed and approved by the Health and Disabilities Ethics Committee (17/CEN/212), and all 
participants provided voluntary written and informed consent prior to recruitment.  
 
3.2.1.2 Healthy volunteers 
This study included 12 healthy volunteers with no known cardiovascular disease, or other 
acute illness in the preceding six weeks prior to recruitment. Other exclusion criteria included 
diabetes, smoking, pregnancy and patients who were on regular cardiovascular or immune-
modulating medication and who had received antiplatelet therapy or non-steroidal anti-
inflammatory drugs (NSAID) within seven days prior to blood collection. All healthy volunteers 
provided informed written consent, and the study was reviewed and approved by the Central 
Health and Disability Ethics Committee (13/CEN/29).  
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3.2.2 Data collection and blood sampling  
Demographic data and clinical characteristics were obtained prospectively from patient 
medical records during hospitalisation and at routine outpatient clinics. Echocardiogram 
measurements that were conducted during hospital admission were collected from patient 
medical records. Whole blood was collected into EDTA tubes (1.8 mg/mL, BD) from the 
peripheral vein of AMI patients using a 21-guage needle or from the radial or femoral artery 
immediately after catheter insertion and prior to heparin administration in the cardiac 
catheterisation laboratory. Blood samples were collected at routine intervals during hospital 
admission, with the earliest sample collected within 24 hours of symptom onset (Day 1) and 
the final sample collected at hospital discharge (Day 3). A single additional blood sample was 
collected from patients six months following AMI (6 Month) during clinical follow-up. Blood 
samples were centrifuged at 1500 x g for 20 minutes to extract plasma. Plasma samples were 
aliquoted and stored at -80˚C for subsequent analysis.  
 
3.2.3 ELISA quantification 
Plasma concentrations of TGF-β1, TIMP-1 and TIMP-4 were measured in AMI and healthy 
volunteers using ELISAs as previously described in Section 2.2.4. The intra-assay coefficient of 
variance was 2.11% and inter-assay coefficient of variance was 2.61%.  
 
3.2.3.1 PINP measurement 
PINP levels were measured using an alternative ELISA kit to Chapter 2, as the previous kit 
supplied by Abexxa was discontinued. Thus, plasma samples were instead measured using the 
Human PINP ELISA Kit (MyBioSource, California, United States) according to manufacturer 
instructions. Briefly, the PINP standard was reconstituted in 1 mL Standard Diluent, and a 7-
point standard curve was generated by performing a 2-fold serial dilution (1,000 - 15.15 
pg/mL). Samples were diluted 1:640 with Sample Diluent, and plated alongside standards in a 
96-well plate pre-coated with PINP antibody. Following a 90 minute incubation at 37˚C, 
samples were removed and Biotinylated Detection antibody diluted 100-fold in Detection 
Antibody Diluent was added. Samples were incubated for 1 hour at 37˚C. Liquid was removed, 
and the plate was washed three times in Wash Buffer. Avadin-HRP solution was diluted 1:100 
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with HRP Diluent, and was added to each well and incubated for 30 minutes at 37˚C. The plate 
was washed a further five times with Wash Buffer, prior to the addition of Substrate Reagent. 
Following a 15 minute incubation at 37˚C, Stop Solution was added and the plate was read on 
the MultiSkan Go (Thermo Fisher Scientific) at 450 nm and 570 nm. The correction wavelength 
was subtracted from 450 nm, and the sample concentrations were interpolated from a 5-PL 
curve generated on Prism v.7.04 (Graphpad software Inc). The intra-assay variation was 
7.91%, and the inter-assay variation was 7.36%.  
 
3.2.4 Cytometric bead array quantification 
Levels of FGFb and VEGF were measured in plasma samples from AMI patients and healthy 
volunteers using BD™ CB Soluble Protein assay, as previously described in Section 2.2.5. 
 
3.2.5 Human magnetic luminex® quantification 
Peripheral levels of MMP-2, MMP-3, MMP-8, MMP-9, osteopontin and periostin were 
measured in plasma samples using Magnetic Luminex Kits, as previously described in Section 
2.2.6. The intra-assay coefficient of variation was 8.75%, and the inter-assay coefficient of 
variation was 14.16%.  
 
3.2.6 Statistical analysis 
Parametric continuous variables were reported as mean ± SD and non-parametric continuous 
variables were reported as median (IQR). Categorical variables were reported as frequencies 
(percentages). Continuous variables were assessed for normality using the Shapiro-Wilk test, 
and all ECM biomarkers were shown to be non-parametric. Univariate correlations were 
performed using Spearman’s Rank correlation, and a heatmap of this data were generated 
using R version 4.0.2 [245] and the corrplot package [260]. Comparisons between median 
levels of healthy volunteers and median levels in AMI patients across time points was 
conducted using Kruskal-Wallis multiple comparisons test with Dunn’s correction. To assess 
temporal changes in the levels within each biomarker, Friedman multiple comparisons test 
with Dunn’s correction was performed. Mann Whitney-U tests were conducted to identify 
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differences between ECM biomarkers and categorical variables. With a cohort of 35, we had 
an effect size (Cohen’s d) of 1.0 with a power of 0.8 and alpha error of 0.05. Statistical analysis 
was performed using SPSS v.26 (IBM) and GraphPad Prism v.7.04 (GraphPad Software Inc).  
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3.3 Results 
3.3.1 Baseline demographics and clinical characteristics 
The baseline demographic characteristics of the healthy volunteers (n=12) and AMI patient 
population (n=23) are shown in Table 3-1. The mean age of the healthy and AMI populations 
was 55 and 60 years, respectively. The healthy population was comprised of seven male 
volunteers (58.3%), while 17 male patients (73.9%) were included in the AMI cohort. All 
participants in the healthy cohort (12, 100%) and a majority of participants in the AMI cohort 
(16, 69.6%) identified as European. A further three AMI patients were Māori (3, 13.0%) and 
four additional patients identified as either Pacific, Asian, Indian or African (each 4.3%). Upon 
index admission, nine patients (39.1%) had hypertension, 16 patients (69.6%) had 
dyslipidaemia, three patients (13.0%) had prior myocardial infarction, two patients (8.7%) 
were diabetics and eight patients (34.7%) were current smokers. Seven (30.4%) patients in 
this cohort presented NSTEMI and 16 (69.6%) presented as STEMI.  
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Table 3-1. Baseline demographics of healthy volunteers and AMI patients. 
Baseline Statistics Healthy (n =12) AMI (n=23) 
Age (years) 55 ± 8 60± 11 
Male 7 [58.3] 17 [73.9] 
Ethnicity   
European 12 [100.0] 16 [69.6] 
Māori -- 3 [13.0] 
Pacific -- 1 [4.3] 
Other -- 3 [13.0] 
Risk Factors   
Prior MI -- 3 [13.0] 
Hypertension -- 9 [39.1] 
Dyslipidaemia -- 16 [69.6] 
Diabetes -- 2 [8.7] 
Family History -- 1 [4.3] 
Current Smoker -- 8 [34.8] 
Classification   
NSTEMI -- 7 [30.4] 
STEMI -- 16 [69.6] 
Continuous variables are shown as mean ± SD and categorical variables are shown as frequency 
(percentage). -- indicates that the category is N/A.  Abbreviations: AMI, acute myocardial 
infarction; BMI, body mass index: NSTEMI, non-ST elevation myocardial infarction; STEMI, ST-
elevation myocardial infarction. 
 
.   
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3.3.2 Extracellular matrix biomarker measurements 
Of the 12 ECM biomarkers measured in AMI patients, nine had detectable levels for all 
patients and time points. For MMP-8, there were eight samples (6.8%) with undetectable 
levels. In comparison, FGFb and VEGF had undetectable levels in a majority of measured 
samples (FGFb, n=117, 100.0%; VEGF, n=109, 93.2%) and for this reason, were excluded from 
further analysis.  
 
3.3.3 Extracellular matrix biomarker measurements in healthy and AMI patients 
A summary of biomarker levels in healthy volunteers and AMI patients is shown in Figure 3-1. 
Seven out of 10 biomarkers demonstrated an altered distribution across time when compared 
to median levels of healthy volunteers.  
 
Six of the seven biomarkers demonstrated altered levels within the acute phase, which 
included biomarker measurements recorded on Day 1 to Day 3 post symptom onset. Elevated 
biomarker levels were observed for MMP-8 (Day 1, p<0.0001, Day 2, p<0.0001, Day 3, 
p<0.001), MMP-9 (Day 1, p<0.0001; Day 2, p<0.0001; Day 3, p<0.001), PINP (Day 1, p<0.05; 
Day 2, p<0.05; Day 3, p<0.01) and TIMP-1 (Day 1, p<0.05; Day 2, p<0.01; Day 3, p<0.01). 
Comparably, periostin (Day 1 - Day 3, all <0.01) and MMP-3 (Day 1, <0.001; Day 2, p<0.05; Day 
3, p<0.01) were both significantly reduced in AMI patients compared to healthy volunteer 
levels.  
 
At the 6 Month time point measurement, three ECM biomarkers demonstrated elevated 
levels in AMI patients compared to healthy volunteers. These biomarkers were MMP-2 
(p<0.0001), MMP-8 (p<0.05) and TIMP-1 (p<0.05).  
 
No changes in osteopontin, TGF-β1 and TIMP-4 levels were observed between healthy 
volunteers and AMI patients.




Figure 3-1. Differences in longitudinal profiles of ECM biomarkers compared to healthy volunteers. 
Kruskal-Wallis test with Dunn’s multiple comparisons was performed to identify differences in biomarker levels in AMI patients compared to healthy controls. 
Median (IQR) of ECM biomarkers is shown. Grey shaded area is the IQR of healthy controls *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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3.3.4 Longitudinal profiles of extracellular matrix biomarkers  
Longitudinal profiles were examined for all biomarkers that demonstrated altered levels in 
AMI patients compared to healthy volunteers. Specific biomarker concentrations are shown 
in Table 3-2. Within ECM biomarkers, acute measurements of MMP-2 (Day 1, p<0.0001; Day 
2, p<0.0001; Day 3, p<0.05), MMP-3 (Day 1, p<0.01; Day 2, p<0.01; Day 3, p<0.05) and 
periostin (Day 2, p<0.05) were significantly lower when compared to the 6 Month time point. 
In comparison, MMP-8 (Day 1, p<0.001, Day 2, p<0.001), MMP-9 (Day 1, p<0.0001; Day 2, 
p<0.0001; Day 3, p<0.05) and PINP (Day 3, p<0.05) levels were elevated during acute 
measurements and decreased at the 6 Month measurement. TIMP-1 displayed no dynamic 
changes in biomarker levels across time. 
 
 
3.3.5 Relationship between extracellular matrix biomarkers across time. 
A correlation matrix demonstrating ECM biomarker relationships across time is shown in 
Figure 3-2. Within each biomarker, moderate-to-strong positive relationships were identified 
for most acute time point measurements. The strongest correlation was identified between 
Day 1 and 6 Month MMP-8 measurements (rs=0.859, p<0.01). Periostin shared significant 
moderate correlations with multiple biomarkers that included: MMP-2, MMP-3, MMP-9 and 
TIMP-1. MMP-8 and MMP-9 also shared some positive moderate correlations.  Two inverse 
relationships were observed between MMP-2 and MMP-9 (Day 2, rs=-0.488, p<0.05) and 
MMP-9 and periostin (Day 3 & 6 Months, rs=-0.458, P<0.05).  
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Biomarkers Day 1 Day 2 Day 3 6 Months 
MMP-2 166.80 [151.0-184.0] 172.9 [144.70-197.20] 165.90 [152.00-174.20] 217.30 [181.40-235.80] ‡ † ¢ 
MMP-3 8.98 [6.64-11.99] 9.71 [8.11-13.95] 9.31 [6.42-14.44] 12.78 [9.49-14.86] # ^ ¥ 
MMP-8 0.58 [0.32-0.81] 0.56 [0.29-0.69] 0.44 [0.21-0.66] 0.33 [0.20-0.55] ‡ † 
MMP-9 58.60 [43.00-94.21] 63.83 [49.13-101.20] 56.16 [39.02-69.27] 36.43 [28.53-50.39] § Ø ¥ 
Periostin 71.60 [60.74-94.75] 75.79 [66.39-89.92] 72.42 [60.78-90.24] 88.54 [64.98-112.90] ^ 
PINP 81.32 [69.89-93.68] 82.31 [73.39-99.00] 90.72 [79.03-100.00] * 81.94 [71.22-90.31] ¥ 
TIMP-1 75.04 [67.81-83.97] 80.78 [64.47-101.00] 78.08 [66.47-93.50] 77.08 [64.53-87.08] 
Friedman’s test with Dunn’s multiple comparison correction was performed to identify longitudinal changes in biomarker levels of AMI patients. 
Symbols denote significant differences between time points. *Day 1 (p<0.05), # Day 1 (p<0.01), Day 1 ‡ (p<0.001), §Day 1 (p<0.0001), ^Day 2 












Figure 3-2. Correlation matrix measuring ECM biomarkers across time.  
Spearman’s Rank correlation coefficients are reported for the pairing of variables indicated on the 
y-axis and x-axis. Biomarker measurements were collected from 23 AMI patients on Day 1 (D1), 
Day 2 (D2), Day 3 (D3) and 6 Months (M6) post symptom onset. The colour scale ranges from blue 
(rs= -1.0) to white (rs= 0.0) to red (rs=1.0). Significant correlations are indicated by *p<0.05 and 
**p<0.01. 
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3.3.6 Relationship between extracellular matrix biomarkers and patient demographics. 
To assess which clinical characteristics may drive temporal changes in ECM biomarkers of AMI 
patients, we examined the relationship between biomarkers and patient demographics at 
acute and chronic measurements. As little dynamic change occurred in biomarker levels 
between acute time point measurements, we have chosen Day 1 levels to represent an acute 
time point. The chronic time point is represented by the 6 Month measurement. A summary 
of relationships between clinical characteristics and ECM biomarkers is shown in Table 3-3. 
 
Three of the measured ECM biomarkers demonstrated significant relationships between 
patient demographics and Day 1 measurements. Levels of MMP-2 were positively correlated 
with age (rs=0.615, p<0.01). MMP-3 levels were lower in female patients compared to male 
patients (p<0.05), while TIMP-1 levels were increased in females (p<0.05).  
 
Three ECM biomarkers had significant relationships with clinical characteristics at 6 Months. 
MMP-2 levels were correlated with both age (rs=0.605, p<0.01) and BMI (rs=-0.472, p<0.05), 
and were also significantly higher in non-smokers compared to current smokers (p<0.01). 
MMP-3 levels were inversely associated with BMI (rs=-0.432, p<0.05), and were increased in 
male patients compared to female patients (p<0.05). Periostin was significantly increased in 
non-smokers compared to smokers (p<0.01), while TIMP-1 was higher in females compared 
to male patients  
 
Hypertension and dyslipidaemia did not influence ECM biomarkers. This study was 
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Gender Smoking Status 




Day 1 0.615** -0.203 170.2 [154.6-184.1] 166.8 [150.4-186.5] 173.54 [152.12-188.96] 156.76 [134.14-169.22] 
Month 6 0.605** -0.472* 213.05 [158.97-236.20] 217.30 [184.11-236.94] 225.49 [214.84 - 238.13] 169.46 [148.36-201.29] ^^ 
MMP-3 
Day 1 -0.168 0.073 5.59 [3.38-9.80] 9.51 [8.10-12.19]^ 9.51 [5.50-11.99] 8.10 [6.87-12.79]? 
Month 6 0.180 -0.432* 7.17 [5.30 -12.50] 13.64 [12.11- 14.95] ^ 13.76 [9.49-14.93] 12.65 [9.28-13.63] 
MMP-9 
Day 1 0.024 0.026 50.80 [42.37-112.74] 62.13 [45.44-104.23] 52.85 [42.08-79.74] 83.15 [61.14-192.13] 
Month 6 0.021 -0.096 55.09 [22.22-71.86] 33.78 [29.42-49.14] 36.43 [28.53-50.39] 35.09 [25.89-61.68] 
Periostin 
Day 1 -0.168 -0.048 63.57[46.80-98.42] 71.60 [63.77-90.40] 73.83 [64.57-100.49] 63.85 [52.06-85.87] 
Month 6 -0.019 -0.168 72.57 [54.97-102.63] 95.87 [73.90-113.34] 109.58[84.10-114.85] 61.90 [53.40-81.73] ^^ 
PINP 
Day 1 -0.009 0.310 82.41 {63.12-107.13] 81.32 [70.66-93.03] 81.32 [71.13-93.68] 85.79 [58.27-102.77] 
Month 6 0.158 0.229 86.02 [69.85-90.51] 79.79 [69.68-95.63] 81.94 [73.92-88.98] 81.21 [62.69-103.90] 
TIMP-1 
Day 1 0.306 0.120 82.95 [76.90-88.86] 69.64 [64.67-80.45]^ 75.04 [67.81-83.97] 75.89 [64.87-85.27] 
Month 6 0.324 -0.101 78.06 [68.50-85.44] 71.33 [63.97-89.07] 71.89 [65.07-87.08] 78.01 [62.72-85.51] 
Continuous variables shown as median [IQR] ng/mL. Spearman’s rank order correlation was conducted to measure the association between continuous variables. *indicates 
significant correlation. *p<0.05, **p<0.01. Man Whitney-U test was used to detect differences between extracellular matrix biomarkers and categorical variables. ^indicates 
significant differences. ^p<0.05, ^^p<0.01. Abbreviations: BMI - body mass index, MMP-2 - matrix metalloproteinase-2, MMP-3 - matrix metalloproteinase-3, MMP-9 - matrix 
metalloproteinase-9, PINP – procollagen type I, TIMP-1 - tissue inhibitor of matrix metalloproteinase-1.  
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3.3.7 Relationship between extracellular matrix biomarkers and cardiac function parameters. 
A summary of significant relationships between ECM biomarkers and parameters of cardiac 
function are shown in Table 3-4. When correlated with AUC high-sensitivity Troponin T, only 
MMP-3 had a significant positive correlation observed at 6 Months (rs=0.555, p<0.01). MMP-
2 had a weak-to-moderate inverse relationship with LVEF at 6 Months (rs=-0.466, p<0.05), 
while periostin demonstrated an inverse association with LVEF for both Day 1 (rs=-0.553, 
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Day 1 0.089 -0.370 
Month 6 0.202 -0.466* 
MMP-3 
Day 1 0.333 -0.098 
Month 6 0.555** -0278 
MMP-9 
Day 1 0.086 0.036 
Month 6 -0.079 0.299 
Periostin 
Day 1 0.239 -0.553* 
Month 6 0.236 -0.571** 
PINP 
Day 1 -0.226 -0.159 
Month 6 -0.122 -0.090 
TIMP-1 
Day 1 -0.148 -0.083 
Month 6 -0.136 0.009 
Spearman’s rank order correlation was conducted to measure the association between 
continuous variables. *indicates significant correlation. *p<0.05, **p<0.01. Abbreviations: hs, 
high-sensitivity; LVEF, left ventricular ejection fraction.  
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3.4 Discussion 
In this prospective repeated-measures study, we examined 12 ECM biomarkers measured 
between hospital admission and six months following AMI. When compared to median 
biomarker levels of healthy volunteers, seven ECM biomarkers demonstrated significant 
changes at one or more of the time points measured. Temporal profiles were unique to each 
biomarker, with no obvious trend in maximal and minimum levels. In addition, few 
interrelationships were observed between biomarkers and this combined indicates that each 
biomarker represents a distinct biological process. The changes in ECM biomarker levels 
observed in AMI patients compared to healthy volunteers were not well described by clinical 
characteristics or parameters of cardiac function, and this suggests the drivers for this 
variation remain unknown. 
 
Similar to Chapter 2, 12 ECM biomarkers were measured in this study. These biomarkers 
comprised growth factors, matricellular proteins, MMPs, TIMPs and a collagen peptide. To the 
best of our knowledge, this is the largest combination of ECM biomarkers to be investigated 
in the setting of AMI. While we acknowledge that cardiac repair is shaped by both 
inflammation and the ECM response (see Section 1.3.3), we chose to only include ECM 
biomarkers in this thesis for two important reasons. Firstly, ECM molecular factors are strongly 
associated with changes to the cardiac tissue matrix, as described in Tables 1-2 and 1-3, and 
consequently may more directly represent adverse remodelling processes post-MI. Secondly, 
measurement of inflammatory biomarkers in addition to our large ECM biomarker panel 
would inflate sample sizes significantly, and this was already a limitation for this current study  
 
Biomarker levels could be measured across all time points for nine of the 12 ECM biomarkers 
in AMI patients. MMP-8 levels could be measured for most samples, with eight out of 117 
below the lowest assay standard. A value of zero was given to these measurements, which all 
occurred at the 6 Month time point except for one patient that had undetectable levels across 
all measurements. In Chapter 2, we identified low detectability of FGFb and VEGF at a single 
sample measurement taken three days post-hospital admission. We hypothesised that this 
time point may have been suboptimal for FGFb and VEGF measurements, and a greater range 
of sampling may increase biomarker detectability. However, we observed similar results for 
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FGFb and VEGF in this study, with undetectable levels observed for most samples. A clinically 
useful biomarker requires reliable and robust measurement, and for this reason FGFb and 
VEGF were excluded from further analysis in this thesis.  
 
Seven of the remaining 10 ECM biomarkers demonstrated altered levels at one or more 
measured time points in AMI patients compared to healthy volunteers. MMP-2, MMP-8, 
MMP-9, PINP and TIMP-1 demonstrated elevated levels, while MMP-3 and periostin were 
decreased in AMI patients. These findings demonstrate that most, but not all, ECM biomarkers 
have variation that exceeds healthy levels, and further supports their use as biomarkers in 
disease by demonstrating that peripheral levels may be sensitive to intra-cardiac changes.  
ECM turnover following AMI describes the process of degradation and deposition at the 
infarct site and surrounding regions, and is largely modulated by the activity of MMPs and 
TIMPs [261]. Differences in MMP and TIMP levels between AMI and healthy cohorts has been 
widely investigated in the literature [131, 174], with a majority of research focused on MMP-
2, MMP-9 and TIMP-1. Previous studies have robustly reported elevated levels of MMP-9 and 
TIMP-1 following AMI [131, 262-264], and our study supports these findings. The literature 
surrounding MMP-2 levels in the first year post-MI is less clear, with some studies indicating 
decreased expression [131, 174], and others showing no change [263], or increased levels 
[264]. In our study, MMP-2 levels remained unchanged from healthy volunteers during acute 
time points but increased sharply at the 6 Month measurement.  
 
Historically, MMP-3, MMP-8 and TIMP-4 have been less studied then the aforementioned 
enzymes, but recent investigations have shone a light on their potential role in adverse 
remodelling processes [172, 191, 192]. In accordance with previous findings, we observed a 
decrease in MMP-3 levels [174] and no change in TIMP-4 levels when compared to a healthy 
reference range [131, 174]. Parkkonen et al. [265] demonstrated elevated levels of MMP-8 in 
ACS patients compared to healthy controls, and our findings support this pattern in an AMI 
exclusive cohort. In our AMI cohort, PINP was increased during acute measurements but 
returned to within a healthy reference range at six months post-MI. These findings suggest 
collagen type I synthesis may be most pronounced during early cardiac repair in AMI patients. 
These findings are in contention with previous literature that demonstrated no change in PINP 
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levels between AMI patients and healthy controls between Day 1 and 1 year post-MI [174]. 
Biologically, scar formation is driven by collagen accumulation, and this process is initiated 
days following infarction as shown in a murine model of AMI [66]. Thus, despite not matching 
the current literature, we suggest our findings are reflective of intra-cardiac biological 
processes 
 
While widespread studies have focused on biomarkers of ECM turnover, less research is 
available regarding changes in growth factors and matricellular proteins in AMI patients 
compared to healthy volunteers. In this study, we measured two matricellular proteins 
involved with cardiac repair, periostin and osteopontin. Matricellular proteins are non-
structural components of the ECM that mediate crucial cellular processes such as cell 
adhesion, growth, migration and differentiation [87, 261]. Our findings demonstrate a 
sustained reduction in periostin levels across acute measurements in AMI patients when 
compared to healthy volunteers. While these results negate the animal literature, which 
suggests periostin levels are negligible in healthy myocardial tissue and increase 3 days post-
MI [266], this data is supported by a previous study which measured periostin levels following 
angiography and at 3 months post-MI [267]. Potentially, periostin is sequestered to the 
myocardium during early repair instead of being released into the circulation, and this would 
be one reason for the results identified in this study. However, further research is required to 
determine if this holds true in a larger prospective cohort.  
 
Both osteopontin and TGF-β1 remained unchanged in AMI patients compared to healthy 
volunteers. Along with TIMP-4, these were the only biomarkers that did not exceed healthy 
variation and this potentially negates their clinical use as a prognostic biomarker. Prior 
research has shown elevated osteopontin levels in STEMI patients on Day 1 and Day 3 post-
hospital admission compared to healthy controls [177]. A key difference between our study 
and this prior research is the AMI cohort under investigation. In our study, all patients received 
primary PCI or CABG, while more than fifty percent of the AMI population in Okyay et al. [177] 
underwent thrombolytic therapy and may potentially be the source of the difference. TGF-β1 
levels also remained unchanged in this study. Previous studies have demonstrated decreased 
levels of plasma TGF-β in CAD patients compared to healthy controls [268], and have linked 
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increased TGF-β levels to worse outcomes in CAD patients [269]. However, confounded 
research also exists which has shown increased levels of serum TGF-β1 in AMI patient 
compared to healthy controls [270]. Differences in sample type may be responsible for these 
discrepancies, as well as the TGF-β isotype measured.   
 
When investigating temporal patterns in biomarker levels, we did not observe a universal time 
point in which all ECM biomarkers were at maximal or minimum levels. Furthermore, the 
temporal profile across time points, as well as between AMI and healthy volunteers, was 
unique to each biomarker. This suggests that no single time point is more appropriate to 
measure than any other and this is of significance in the context of this thesis, as it suggests 
there is no optimal time point during hospital admission in which to measure these biomarkers 
in patients.  
 
The ECM repair response can be divided into three distinct but overlapping phases: the 
inflammatory phase, the proliferative phase and the maturation phase [64]. The inflammatory 
phase is characterised by rapid upregulation of inflammatory cytokines released by infiltrating 
immune cells, as well as the degradation of ECM by proteolytic enzymes in response to mass 
myocyte necrosis [271]. The proliferative phase is characterised by cardiac fibroblast 
expansion and increased synthesis of ECM that positively contributes to scar deposition, while 
the maturation phase describes scar maturity and long-term LV remodelling processes [64]. 
Changes observed in ECM biomarkers during acute time point measurements are likely 
associated with aspects of the inflammatory and proliferative phases, while sustained changes 
at the remote 6 Month measurement likely represent activity beyond early repair. Temporally, 
there did not appear to be a distinct pattern in biomarkers associated with ECM degradation 
and deposition processes. For example, while we observed peaks in MMP-8 and MMP-9 levels 
during acute measurements, MMP-2 levels were significantly elevated at six months. In 
addition, TIMP-1 levels were also significantly elevated across all time points, so qualitatively 
there was no early trend for MMPs and later trend for TIMPs. These findings suggest that 
measurement of circulating ECM biomarkers may not appropriately distinguish the transition 
between the inflammatory and  proliferative phases and further highlight the complexity of 
the ECM response post-MI. Thus, investigating the relationship between biomarkers, as well 
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as the characteristics that drive their variation, will aid in identifying potential biomarkers for 
clinical use.  
 
To further investigate the complex relationship between ECM biomarkers across time, we 
undertook a correlation matrix. Within each ECM biomarker, we observed moderate-to-
strong correlations between all acute time points measured. This further suggests that no 
single time point within the first three days post-MI is more appropriate to measure than 
another. When biomarkers were compared to each other, we identified very few meaningful 
correlations. These results suggest two key points. Firstly, despite representing similar 
processes, roles for each ECM biomarker appear to be distinct and this supports the notion of 
measuring a panel of ECM biomarkers in order to capture the complexity of ECM repair. 
Secondly, the most significant relationships were observed between periostin and other ECM 
proteins, which supports its role as a regulatory protein [272]. Specifically, periostin levels 
were associated with multiple biomarkers of ECM turnover. The most pronounced 
interrelationship was observed with MMP-3, with multiple moderate positive correlations 
across acute time point measurements.  
 
In this study, the relationship between patient clinical characteristics and ECM biomarker 
levels were examined to assess their influence on biomarker variation. Age was only 
correlated with MMP-2 levels and no other ECM biomarkers. Male patients had higher levels 
of MMP-3 and TIMP-1, while BMI was inversely correlated with MMP-2 and MMP-3. Non-
smokers had higher levels of both periostin and MMP-2. This suggests that while there may 
be a slight influence of demographic features on ECM biomarker levels, these are not strong 
and the majority of variance in ECM biomarkers is not driven by these factors.  
 
Similar to Chapter 2, we were interested in investigating the association biomarker levels to 
troponin T. As troponin T measurements were available at all acute time points, AUC troponin 
measurements were used. In this Chapter, only one significant correlation was observed and 
this was between AUC troponin T and Day 1 measurements of MMP-3. These findings indicate 
that ECM biomarker levels are not especially associated with troponin levels and this suggests 
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their expression may be driven by processes independent to myocardial damage. A further 
indices important for assessing patient risk acutely is LVEF, which is a central measure of LV 
systolic function [273]. Indeed, reduced baseline LVEF has been linked to the development of 
major adverse cardiovascular events (MACE) post-MI [274], and is associated with a 
compensatory mechanism to mediate mass cellular death. In this study, MMP-2 and periostin 
measurements were inversely correlated with baseline LVEF measurements. Specifically, 
periostin was moderately correlated at both Day 1 and 6 Month time points, while MMP-2 
was only weak-to-moderately correlated at the 6 Month measurement. Once again, these 
findings indicate that myocardial damage is not well linked to biomarker levels, and 
independent processes are likely influencing temporal biomarker changes. Combined, these 
findings suggest that clinical characteristics and parameters of cardiac function are not strong 
drivers of the dynamic change observed in ECM biomarkers. Thus, while dynamic differences 
exist across time points and between AMI and healthy cohorts, the main factors contributing 
to this variation remain unknown.  
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3.5 Limitations 
There are a few limitations to this research that should be appropriately addressed. Similar to 
Chapter 2, we have measured circulating levels of ECM biomarkers. While this study cannot 
prove that these levels represent intra-cardiac expression profiles, we have demonstrated 
that changes to ECM biomarkers do occur post-MI when compared to healthy subjects, and 
temporal profiles do exist in these patients. The ELISA platform used to measure PINP was 
different in this Chapter when compared to Chapter 2. This was due to discontinuation by the 
previous supplier, and this was beyond our control. The replacement kit was a commercially 
validated ELISA and in-house testing using spike-and-recovery assays and linearity-of-dilution 
suggested that this ELISA was appropriate for measuring PINP in our samples. In addition, we 
demonstrated changes between healthy and AMI patients as well as longitudinal changes 
across time, suggesting PINP measurement was unaffected by change in ELISA. This research 
represents a small sample size with in-depth analysis. We recognise that this is a limitation to 
this study, and had endeavoured to include more patients in the final cohort size. While 43 
patients were initially recruited into this research, early discharge, change in diagnosis from 
AMI and missing follow-up time points reduced this sample size to 23 patients. While this 
prevents us from linking biomarker levels to meaningful patient outcomes, it does provide an 
opportunity to investigate basic biomarker profiles and associations and this was the purpose 
of this research. We selected four time points to represent acute and chronic biomarker 
measurements in AMI patients. We cannot confirm that these time points represent peak 
biomarker levels in patients, and that measuring levels during the subacute phase (1 week 
post-MI) would provide greater resolution of biomarker dynamics. However, all samples were 
collected from patients during hospital admission or at clinical follow-up appointments. Thus, 
these time points are most appropriate for implementation if these biomarkers were to be 
utilised in a clinical setting. In addition, our chronic measurement was selected as six months 
post-MI to represent a remote time point from the index event. While long-term remodelling 
can continue well beyond six months, we selected this time point based on previous studies 
which have used six months or less for temporal biomarker studies [131, 267]. Finally, as an 
indicator of biomarker activity in normal biological processes, we measured ECM biomarkers 
in a single sample from 12 healthy volunteers. While this does not provide insight into the 
temporal changes of biomarker levels in healthy processes, it does indicate levels of normal 
variation that exist in biomarkers of healthy participants.   
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3.6 Conclusion 
In conclusion, we have identified a panel of seven ECM biomarkers that may be useful for 
measuring the ECM response following AMI. We have demonstrated that these biomarkers 
exhibit changes across time points in AMI patients compared to healthy volunteers, and have 
demonstrated longitudinal profiles that may be associated with their activity during the ECM 
response. Clinical characteristics and indices of cardiac function were not well correlated with 
biomarker levels, and this suggests that changes in ECM biomarkers may be independent of 
clinical characteristics and myocardial damage. Identifying if these ECM biomarkers are linked 
to parameters of adverse remodelling is the next step in establishing potential biomarkers of 
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In Chapter 2, we investigated combined statistical approaches that allowed for the 
examination of ECM profiles in AMI patients based on biomarkers that reflected ECM activity. 
Biomarkers included in Chapter 2 were then further explored in Chapter 3, by examining their 
temporal profiles and differences in levels between AMI patients and healthy volunteers. The 
product of these two chapters was understanding that a group of seven ECM biomarkers, 
MMP-2, MMP-3, MMP-8, MMP-9, periostin, PINP and TIMP-1, displayed variance over time 
and were changed in AMI patients when compared to a healthy reference range. In addition, 
we demonstrated that these biomarkers could be combined in a way that dealt appropriately 
with collinearity. What remains unknown is the prognostic utility of these combined 
biomarkers in prediction of LV remodeling processes following AMI.  
 
The ECM is central to compensatory cardiac repair mechanisms following infarction, and 
inefficient or excessive ECM activity can result in adverse changes to LV geometry and function 
[64, 87]. These ventricular changes manifest clinically as systolic and diastolic dysfunction [68]. 
Systolic dysfunction describes ventricular chamber dilation and reduced cardiac output, and 
can be diagnosed by abnormal LVEF measurements [275]. Comparably, diastolic dysfunction 
describes increased chamber resistance and elevated filling pressures, and can be diagnosed 
by measuring multiple parameters of impaired LV relaxation and increased diastolic stiffness 
[70]. Importantly, LV dysfunction does not occur in isolation and is commonly associated with 
the development of heart failure [71, 72]. 
 
Echocardiogram measurements taken from AMI patients during clinical follow-up provide an 
opportunity to measure systolic and diastolic dysfunction at a remote time point from the 
initial infarction. In particular, we are interested in assessing the prognostic utility of 
combining ECM biomarkers using strategies investigated in Chapter 2, EFA and cluster 
analysis, for predicting the development of LV dysfunction in AMI patients. We hypothesise 
that combined biomarker analysis may be more predicative for the development of LV 
dysfunction when compared to single biomarker analysis.  
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This will be addressed by the following study aims: 
• To examine if EFA or cluster analysis of ECM biomarkers can predict systolic 
dysfunction in AMI patients. 
• To determine if EFA or cluster analysis of ECM biomarkers can predict diastolic 
dysfunction in AMI patients. 
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4.2 Methods 
4.2.1 Study population 
The registry cohort used in this study was as previously described in Section 2.2.1. From this 
cohort, a subset of 120 AMI patients were selected who had no previous history of MI or atrial 
fibrillation, and who had echocardiogram measurements at a remote time point from index 
admission. Study sub-populations were assigned by grouping patients based on LV function 
measures. A flow diagram of study population selection is shown in Figure 4-1. This study was 
approved by the Lower South Regional Ethics Committee (LRS/11/09/035) and the New 
Zealand Central Health and Disabilities Ethics Committee (16/CEN/68).  
 
4.2.2 Data collection and blood sampling.  
Blood sampling and data collection was conducted as previously described in Section 2.2.2.  
 
4.2.3 Echocardiogram assessment 
A 2-dimensional transthoracic echocardiogram was performed on each patient during clinical 
follow-up within 1 year of AMI onset. Trained sonographers conducted all echocardiograms, 
and were blinded to patient LV function categorisation in this study. A standard transthoracic 
echocardiographic imaging protocol was used [276], with apical four-chamber and two-
chamber views; LV short axis were recorded from the left parasternal region at three levels: 
the mitral valve, the mid-papillary muscle, and the apex. All calculations and interpretations 
of echocardiogram reports were performed by cardiologists or cardiac sonographers who 
were blinded to patient LV function categorisation. All systolic and diastolic function 
categorisations were made based on recorded echocardiographic measurements. For any 
missing values, an advanced cardiology trainee retrospectively identified the correct 
measurements blinded to patient LV function categorisation.  
  




Figure 4-1. Flow diagram demonstrating patient selection and categorisation.  
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4.2.3.1 Systolic and diastolic function categorisation.  
Systolic function was dichotomised into two distinct groups: patients with preserved function 
(LVEF ≥ 50%) and patients with impaired function (LVEF < 50%). Normal and impaired function 
values were selected based on the updated recommendations by the ASE/EACVI [69]. Indices 
to measure LV systolic function were available for all 120 patients (100%).  
 
Diastolic dysfunction was diagnosed according to the current guidelines set out by the 
ASE/EACVI [70]. The diagnosis scheme is shown in Figure 4-2. In patients with LVEF ≥ 50%, the 
following parameters were examined: Average E/e’ > 14, Septal e’ velocity < 0.07 m/s or 
Lateral e’ velocity < 0.10 m/s, TR > 2.8 m/s and LA volume index > 34 mL/m2. Patients were 
diagnosed with normal diastolic function if less than 50% of these parameters were met. 
Patients were diagnosed with grade I diastolic dysfunction if more than 50% of these 
parameters were met. Diastolic function was identified as indeterminate in patients with 
exactly 50% of these parameters met.   
 
In patients with LVEF < 50%, E/A ratio was assessed to determine left atrial pressure (LAP). In 
patients with E/A ≤ 0.8, Normal LAP and grade I diastolic dysfunction was diagnosed. In 
patients with E/A ≥ 2, increased LAP and grade III diastolic dysfunction was diagnosed. In 
patients with E/A > 0.8  and  < 2, the following three criteria were evaluated: Average E/e’ > 
14, TR > 2.8 m/s and LA volume index > 34 mL/m2. Patients who met less than 50% of these 
parameters were diagnosed with normal LAP and grade I diastolic dysfunction, while patients 
who met more than 50% of these parameters were diagnosed with increased LAP and grade 
II diastolic function. LV diastolic function was determined in 100 patients (83.3%). Specifically,  
four patients were missing E/A measurements and 16 patients were missing E/e’ 
measurements.  
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Figure 4-2. Flow diagram demonstrating diastolic function diagnosis and categorisation. This figure has been adapted from the ASE/EACVI 
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4.2.4 Biomarker measurements 
A subset of ECM biomarkers were measured in this study based on the analysis conducted in 
Chapter 3. MMP-2, MMP-3, MMP-8, MMP-9, periostin, PINP and TIMP-1 levels were 
quantified in plasma samples blinded to LV function categorisation.   
 
 
4.2.4.1 ELISA quantification 
The levels of PINP and TIMP-1 were measured in plasma samples using commercially available 
ELISA kits as previously described in Section 3.2.3.1 and Section 2.2.4.3, respectively. The intra-
assay coefficient of variance was 6.7%, and the inter-assay coefficient of variance was 5.1%.  
 
 
4.2.4.2 Human magnetic luminex® quantification 
The plasma concentrations of MMP-2, MMP-3, MMP-8, MMP-9 and periostin were quantified 
using Magnetic Luminex Kits as previously described in Section 2.2.6. The intra-assay 
coefficient of variance was 5.8%, and the inter-assay coefficient of variance was 6.4%. 
 
 
4.2.5 Statistical analysis 
With a population of 120, we had an effect size (Cohen’s d) of 0.5 with a power of 0.8 and 
alpha error of 0.05. Continuous variables were assessed for normality using the Shapiro-Wilk 
test. Parametric continuous variables were reported as mean ± SD and non-parametric 
continuous variables were reported as median (IQR). Categorical variables were reported as 
frequencies (percentages). Statistical tests to compare medians of continuous and categorical 
variables were performed using Mann-Whitney U and Kruskal-Wallis H Test. Chi Square tests 
were used to compare categorical variables. To construct multivariate regression modelling, 
all demographics and clinical characteristics with a p-value <0.05 on univariate analysis were 
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included in binary logistic regression analysis. All basic statistical analysis were carried out in 
either GraphPad Prism Software v.7.04 (GraphPad Software Inc; California, USA) or SPSS v.24 
(IBM; New York, USA). EFA analysis was performed as described in Section 2.2.7.1. From EFA 
analysis, factor scores were generated using a Bartlett scoring system. Cluster analysis and 
cluster validation were performed as described in Section 2.2.7.2, and validation plots are 
shown in Appendix Figure 2 and Figure 3.   
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4.3 Results 
4.3.1 Baseline demographics and clinical characteristics 
A summary of baseline demographic data is shown in Table 4-1.  The population comprised 94 
male patients (78.3%) with a mean age of 62 years old and a mean BMI of 29.2 kg/m2. There 
were 94 patients (78.3%) who identified as European, 11 patients who identified as Māori 
(9.2%), 4 Pacific Island patients (3.3%) and 11 patients who identified as Asian, Indian or Latin 
(9.2%).  Within the population, 62 had hypertension (51.7%), 59 had dyslipidaemia (49.2%), 
22 were diabetic and also current smokers (each, 18.3%), and 2 patients had renal 
insufficiency (1.7%), as defined in Section 2.2.1. Less than half of the patient population 
presented as STEMI (44 patients, 36.7%), with 76 patients presenting with NSTEMI (63.3%). 
MMP-2, MMP-3, MMP-8, MMP-9, periostin, PINP and TIMP-1 were measured in all 120 
patients, and biomarker concentrations are shown in Table 4-2.  
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Table 4-1. Baseline demographics of the study population. 
Baseline Demographics Patients (n=120) 
Male  94 [78.3] 
Age (years) 62 ± 11 
BMI (kg/m2) 29.2 ± 5.8 
Ethnicity  
European 94 [78.3] 
Māori 11 [9.2] 
Pacific Islander 4 [3.3] 
Other (Asian, Indian, Latin) 11 [9.2] 
Cardiac Risk Factors  
Hypertension 62 [51.7] 
Dyslipidaemia 59 [49.2] 
Diabetes 22 [18.3] 
Current Smoker 22 [18.3] 
Renal Insufficiency 2 [1.7] 
AMI Classification  
NSTEMI 76 [63.3] 
STEMI 44 [36.7] 
Discharge Medications  
Aspirin 100 
P2Y12 inhibitor 100 
ACE Inhibitor 81 [67.5] 
Beta Blocker 96 [80.0] 
CA Channel Inhibitor  8 [6.7] 
Statin 113 [94.2] 
Echocardiogram Features  
Time to echocardiogram (days) 145 [89 - 252] 
Peak hs Troponin T (ng/L) 610.0 [214.0 - 2442.0] 
Parametric continuous variables were expressed as mean ± SD and non-parametric continuous 
variables were expressed as median (IQR). Categorical variables were expressed as frequencies 
(percentages). BMI, body mass index; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-
elevation myocardial infarction; hs, high-sensitivity.  
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Table 4-2. ECM biomarker concentrations of the study population. 
ECM biomarkers Concentration (ng/mL) 
MMP-2 110.7 [98.2 - 122.3] 
MMP-3 9.6 [7.1 - 14.2] 
MMP-8 0.52 [0.49 - 0.63] 
MMP-9 17.8 [12.8 - 29.8] 
Periostin 64.3 [48.3 - 74.4] 
PINP 42.2 [34.3 - 56.4] 
TIMP-1 81.0 [72.3 - 95.7] 
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4.3.2 Systolic function analysis 
4.3.2.1 Baseline demographics and clinical characteristics of patients with preserved and 
impaired systolic function.   
A summary of patient demographic data between systolic function groups is shown in Table 
4-3. Follow-up echocardiogram measurements were conducted for all patients within 1 year 
following AMI. The median time to echocardiogram was 145 days (IQR 88 - 251). Of the AMI 
population, 83 patients (69.2%) had preserved systolic function and 37 patients (30.8%) had 
impaired systolic function. When groups were compared, patients with impaired systolic 
function were less likely to be current smokers and were more commonly discharged on ACE 
inhibitors. No further baseline demographic features or cardiac risk factors were different 
between the groups. Parameters of LV end-systolic volume (LVESV) and LV end-diastolic 
volume (LVEDV) were increased in patients with impaired systolic function compared to 
patients with preserved systolic function (both, p<0.0001). A summary of ECM biomarker 
levels is shown in Table 4-4. Of the seven ECM biomarkers measured, only MMP-8 was 
significantly different between groups, with elevated levels observed in patients with impaired 
systolic function compared to preserved function (p<0.05; Table 4-4).  Patients with impaired 
systolic function also presented with higher peak high-sensitivity troponin T levels (p<0.001). 
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Table 4-3. Baseline demographics of patients with preserved and impaired systolic function. 
Baseline Demographics Preserved LVEF (n=83) Impaired LVEF (n=37) P value 
Male  62 [74.7] 32 [86.5] 0.148 
Age (years) 62 ± 12 61 ± 10 0.517 
BMI 28.7 ± 5.6 30 ± 6.5 0.320 
Ethnicity    
European 65 [78.3] 29 [78.4] 
0.238 
Māori 6 [7.2] 5 [13.5] 
Pacific Islander 2 [2.4] 2 [5.4] 
Other (Asian, Indian, Latin) 10 [12.0] 1 [2.7] 
Cardiac Risk Factors    
Hypertension 46 [55.4] 16 [43.2] 0.218 
Dyslipidaemia 41 [49.4] 18 [48.6] 0.940 
Diabetes 18 [21.7] 4 [11.1] 0.172 
Current Smoker 20 [24.1] 2 [5.4] 0.015 
Renal Dysfunction 1 [1.2] 1 [2.7] 0.554 
AMI Classification    
NSTEMI 57 [68.7] 19 [51.4] 
0.069 
STEMI 26 [31.3] 18 [48.6] 
Discharge Medications    
Aspirin 100 100 -- 
P2Y12 inhibitor 100 100 -- 
ACE Inhibitor 50 [60.2] 31 [83.8] 0.011 
Beta Blocker 66 [79.5] 30 [81.1] 0.843 
CA Channel Inhibitor  6 [7.2] 2 [5.4] 0.700 
Statins 79 [95.2] 34 [91.9] 0.478 
Indices of Systolic Function    
LVEF (%) 57.0 [53.0 - 64.0] 44.0 [38.2 - 46.3] <0.0001 
LVESV (mL) 40.6 [28.4 - 55.0] 79.0 [64.8 - 97.7] <0.0001 
LVEDV (mL) 107.8 [81.1 - 131.8] 139.2 [115.3 - 166.6] <0.0001 
Echocardiogram Features    
Time to Echocardiogram (days) 143 [80 - 245] 163 [91 - 296] 0.341 
Peak hs Troponin T (ng/L) 499.0 [163.0 - 1580.0] 2174.5 [561.3 - 4184.8] <0.001 
Continuous variables are expressed as median (IQR). Categorical variables are expressed as frequencies 
(percentages). Mann-Whitney U testing and Chi-Square testing was conducted to detect differences between 
continuous and categorical variables and systolic function categorisation, respectively. Significant p-values are 
bolded (<0.05). For abbreviations see Table 4-1.  
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Table 4-4. ECM biomarker concentrations of patients with preserved and impaired systolic function. 
ECM Biomarkers (ng/mL) Preserved LVEF (n=83) Impaired LVEF (n=37) P value 
MMP-2 110.8 [98.6 - 123.1] 109.9 [94.1 - 120.5] 0.576 
MMP-3 9.0 [7.0 - 13.8] 9.7 [7.3 - 16.5] 0.493 
MMP-8 0.51 [0.48 - 0.60] 0.56 [0.49 - 0.71] 0.047 
MMP-9 17.5 [12.2 - 26.2] 21.5 [14.0 - 38.9] 0.141 
Periostin 64.7 [51.8 - 75.6] 61.4 [43.9 - 71.9] 0.205 
PINP 42.2 [34.3 - 57.5] 43.7 [34.3 - 54.5] 0.748 
TIMP-1 80.2 [70.6 - 93.2] 87.1 [75.8 - 116.0] 0.097 
Continuous variables are expressed as median (IQR). Mann-Whitney U testing was conducted to detect 
differences between ECM biomarker levels and systolic function categorisation. Significant p-values are bolded 
(<0.05). 
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4.3.2.2 EFA analysis of the systolic function cohort.  
EFA was performed on log-transformed biomarkers using principle axis analysis with Oblimin 
rotation. Model fit was assessed using KMO, and was above the required threshold of 0.5 with 
a value of 0.6. Collinearity of the dataset was assessed using Bartlett’s Test for Sphericity, and 
was found to be significant (p<0.0001). Factor loadings were suppressed below a 0.3 threshold 
to only include meaningful variables.  
 
EFA identified a two-factor solution. The rotated factor matrix is shown in Figure 4-3A. Factor 
1 was comprised of MMP-8 and MMP-9 with high loading values > 0.6, and MMP-3 and TIMP-
1 with lower loading factors. Factor 2 was comprised of MMP-3, MMP-2, TIMP-1 and PINP all 
with moderate loading factors between 0.4 - 0.5. MMP-3 and TIMP-1 were cross-correlated 
between factors. Both factors had higher loadings on Factor 2, suggesting they contributed to 
the composition of this factor more than Factor 1. Despite being included in the EFA analysis, 
periostin did not contribute to either Factor.  
 
In Chapter 2, the primary purpose of EFA was to assess the underlying structure of biomarkers 
and to examine their interrelationships. In this Chapter, we aimed to investigate the 
relationship between ECM biomarkers and parameters of LV function. Thus, Factor scores 
were generated for each patient and these scores were compared between preserved and 
impaired systolic function. Factor 1 scores were significantly elevated in patients with 
impaired systolic function compared to patients with preserved function (-0.02 [-0.60 - 0.95] 
versus -0.46 [-0.69 - 0.21], p<0.05). No differences in Factor 2 scores were observed between 
patient groups (-0.05 [-0.91 - 0.80] versus 0.01 [-0.83 - 0.80]). Differences between Factor 
scores are shown in Figure 4-3B.   
  




Variables Factor 1 Factor 2 
MMP-8 0.979  
MMP-9 0.636  
MMP-3 0.396 0.525 
MMP-2  0.504 
TIMP-1 0.367 0.454 
PINP  0.418 
% of variance 
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Figure 4-3. EFA analysis of the AMI population and relationship with preserved and impaired systolic 
function.  
A) The rotated factor matrix of log-transformed ECM biomarkers in 120 AMI patients using EFA. B) 
Mann-Whitney U testing demonstrates a significant increase in Factor 1 scores in patients with impaired 
systolic function compared to preserved function. No differences in Factor 2 scores were observed. 
*p<0.05. 
B.  
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4.3.2.3 Cluster analysis of the systolic function cohort. 
Factor 1 scores derived from EFA analysis were significantly elevated in patients with impaired 
systolic function compared to preserved function. Consequently, hierarchical cluster analysis 
was performed using the biomarkers that encompassed this factor of which included: MMP-
3, MMP-8, MMP-9, TIMP-1. Cluster analysis identified two patient groups. A dendrogram of 
patient clusters are shown in Figure 4-4A. Differences in patient demographics and clinical 
characteristics are shown in Table 4-5, while ECM biomarker levels are shown in Figure 4-4B 
and described in Table 4-6.  
 
Patients in Cluster One (n=31) had decreased LVEF measurements (p<0.05) and elevated levels 
of MMP-3 (p<0.05), MMP-8 (p<0.0001) and MMP-9 (p<0.0001) compared to Cluster Two 
(n=89). Of the clinical characteristics assessed in this study, only gender was significantly 
different between clustered groups with more male patients in Cluster One compared to 
Cluster Two (p<0.05). Peak high-sensitivity troponin T levels were significantly elevated in 












































Figure 4-4. Cluster analysis of the AMI population based on MMP-3, MMP-8, MMP-9 and TIMP-1 
biomarker levels.   
A) A dendrogram of hierarchical cluster analysis identified two distinct groups of AMI patients based on 
ECM biomarkers. B) Mann-Whitney U testing was undertaking to identify significant differences between 
biomarker levels of each patient cluster. *p<0.05, ****p<0.0001. Median (IQR) is plotted. 
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Table 4-5. Baseline demographics of clustered groups (systolic function analysis). 
Baseline Demographics Cluster One (n=31) Cluster Two (n=89) P value 
Male  29 (93.5) 65 (73.0) 0.017 
Age (years) 61 ± 11 62 ± 12 0.362 
BMI 29.6 ± 6.4 29.0 ± 6.4 0.783 
Ethnicity    
European 24 (77.4) 70 (78.7) 
0.999 
Māori 3 (9.6) 8 (9.0) 
Pacific  1 (3.2) 3 (3.4) 
Other (Asian, Indian, Latin) 3 (9.6) 8 (9.0) 
Cardiac Risk Factors    
Hypertension 16 (51.6) 46 (51.7) 0.994 
Dyslipidaemia 15 (48.4) 44 (49.4) 0.920 
Diabetes 7 (22.6) 15 (16.9) 0.495 
Current Smoker 5 (16.1) 17 (19.1) 0.713 
Renal Dysfunction 0 (0) 2 (2.2) 0.400 
AMI Classification    
NSTEMI 21 (67.7) 55 (61.8) 
0.554 
STEMI 10 (32.3) 34 (38.2) 
Indices of Systolic Function    
LVEF (%) 50.0 (44 - 56.2) 55.0 (49.0 - 61.7) 0.014 
LVESV (mL) 58.1 (43.9 - 74.0) 50.1 (31.0 - 71.0) 0.122 
LVEDV (mL) 118.1 (105.1 - 135.5) 111.0 (88.8 - 142.0) 0.375 
Echocardiogram Features    
Time to Echocardiogram (days) 176.0 [96.0 - 328.0] 139.0 [84.0 - 244.5] 0.156 
Peak hs Troponin T (ng/L) 2049.0 [490.0-3468.0] 539.5 [158.0 - 2118.3] <0.001 
Continuous variables were expressed as median (IQR). Mann-Whitney U testing was used to compare 
continuous variables between clustered groups. Categorical variables were expressed as frequencies 
(percentages). Chi-Square testing was used to compare categorical variables between clustered groups. 
Significant p-values are bolded (<0.05). 
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Table 4-6. ECM biomarker concentrations of clustered groups (systolic function analysis). 
ECM Biomarkers (ng/mL) Cluster One (n=31) Cluster Two (n=89) P value 
MMP-2 111.8 [96.2 - 119.4] 109.9 [98.8 - 122.8] 0.706 
MMP-3 10.9 [8.4 - 17.2] 9.0 [6.4 - 13.4] 0.015 
MMP-8 0.78 [0.63 - 0.84] 0.50 [0.47 - 0.54] <0.0001 
MMP-9 48.5 [33.1 - 64.4] 15.6 [11.8 - 19.7] <0.0001 
Periostin 61.7 [42.6 - 67.7] 65.0 [52.5 - 76.1] 0.074 
PINP 47.1 [35.1 - 56.5] 42.2 [34.3 - 57.6] 0.700 
TIMP-1 87.9 [72.7 - 124.0] 80.0 [72.0 - 93.9] 0.164 
Biomarkers expressed as median [IQR]. 
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4.3.2.4 Multivariate analysis of the systolic function cohort 
Binary logistic regression analysis was undertaken to investigate the predictive potential of 
MMP-8 levels, Factor 1 scores and cluster assignment for the development of systolic 
dysfunction in AMI patients. In Section 4.3.2.1, we demonstrate that prescription of ACE 
inhibitors at discharge, current smoking status and peak high-sensitivity troponin T > median 
were predictors of systolic function development. Therefore, these clinical variables were 
included in the multivariate model.  As Factor 1 scores and cluster analysis assignment both 
contain MMP-8, three separate models were created. The Multivariate analysis outcomes are 
shown in Table 4-7. Model 1 included MMP-8 levels and clinical variables, Model 2 contained 
Factor 1 scores and clinical variables and Model 3 comprised cluster assignment and clinical 
variables. All clinical variables included in analysis remained significantly associated with 
systolic function across all three models. MMP-8 levels and Factor 1 scores were not predictive 
of systolic dysfunction development, while assignment into Cluster One remained an 
independent predictor of systolic dysfunction (OR 2.74 [95% CI 1.04 – 7.23], p = 0.042). 
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Table 4-7. Multivariate analysis for systolic function population. 
Risk Factor Model 1 OR [95% CI] P value Model 2 [95% CI] P value Model 3 [95% CI] P value 
Current smoker 0.19 [0.04 - 0.88] 0.034 0.19 [0.04 - 0.88] 0.034 0.19 [0.04 - 0.89] 0.026 
ACE inhibitor at discharge 3.15 [1.04 - 9.51] 0.042 3.15 [1.04 - 9.51] 0.042 3.65 [1.17 - 11.36] 0.035 
Peak hs troponin T > 610 (ng/L) 3.30 [1.28 - 8.54] 0.014 3.30 [1.28 - 8.54] 0.014 3.14 [1.24 -  8.00] 0.016 
MMP-8 (ng/mL) 3.43 [0.32 - 36.68] 0.308     
Factor 1 score   0.80 [0.53 - 1.22] 0.307   
Cluster One assignment     2.74 [1.04 - 7.23] 0.042 
Model 1 = Current smoking status, prescription of ACE inhibitor at discharge, hs-TnT > median 610 ng/L and MMP-8 concentrations; Model 2 = Current smoking status, 
prescription of ACE inhibitor at discharge, hs-TnT > median 610 ng/L and Factor 1 score; Model 3 = Current smoking status, prescription of ACE inhibitor at discharge, hs-TnT 
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4.3.3 Diastolic function analysis 
4.3.3.1 Baseline demographics and clinical characteristics of patients with normal diastolic 
function, diastolic dysfunction and indeterminate function.  
Of the 120 patients included in this study, 100 had echocardiograms with sufficient 
information to group patients into diastolic function categories based on the ASE/EACVI 2016 
guidelines [70]. The baseline demographic data for this cohort is shown in Table 4-8. There 
were 43 patients with normal diastolic function (43.0%), 37 patients with diastolic dysfunction 
(37.0%) and 20 patients were indeterminate (20.0%). Patients with diastolic dysfunction were 
more likely to present as a STEMI compared to other groups, and had increased peak high-
sensitivity troponin T levels when compared to normal diastolic function. No differences in 
discharge medications or time to echocardiogram were observed between groups. 
 
Differences in indices of diastolic function are shown in Table 4-9. When compared to normal 
diastolic function, patients with diastolic dysfunction had decreased E/A values, septal e’ 
values and lateral e’ values. Patients in the indeterminate group had increased left atrial size 
and decreased septal e’ values.  
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Male (n) 34 [79.1] 30 [81.1] 13 [65.0] 0.306 
Age 60 ± 13.9 60.5 ± 9.1 64 ± 11.8 0.494 
BMI 29.1 ± 5.5 30.7 ± 6.6 27.8 ± 6.8 0.255 
Ethnicity     
European 33 [76.7] 28 [75.7] 16 [80.0] 
0.730 
Māori 4 [9.3] 5 [13.5] 0 [0.0] 
Pacific  1 [2.3] 1 [2.7] 1 [5.0] 
Other (Asian, Indian, 
Latin) 
5 [11.6] 3 [8.1] 3 [15.0] 
Cardiac Risk Factors     
Hypertension 19 [44.2] 19 [51.4] 13 [65.0] 0.354 
Dyslipidaemia 17 [39.5] 18 [48.6] 11 [55.0] 0.477 
Diabetes 11 [25.6] 4 [10.8] 4 [20.0] 0.242 
Current Smoker 11 [25.6] 4 [10.8] 4 [20.0] 0.242 
Renal Dysfunction 0 [100.0] 1 [2.7] 1 [5.0] 0.389 
AMI Classification     
NSTEMI 33 [76.7] 16 [40.2] 14 [70.0] 
0.006 
STEMI 10 [23.3] 21 [56.8] 6 [30] 
Discharge Medications     
Aspirin 100 [100.0] 100 [100.0] 100 [100.0]  
Ace Inhibitor 27 [62.8] 30 [81.1] 12 [60.0] 0.163 
Beta Blocker 35 [81.4] 31 [83.8] 16 [80.0] 0.930 
CA Channel Inhibitor  1 [2.3] 2 [5.4] 3 [50.0] 0.147 
Statin 41 [95.3] 35 [94.6] 18 [90.0] 0.694 




135 [78 - 204] 138 [84 - 260] 213 [96 - 263] 0.326 
Peak hs troponin T 
(ng/L) 
328.0 [119.0 - 
845.0] 
2263.0 [569.8 - 
4618.0]*** 
501.0 [198.0 - 
1861.0] 
<0.001 
Continuous variables are expressed as median (IQR) & categorical variables are expressed as frequencies 
(percentages). Kruskal-Wallis testing with Dunn’s correction for multiple comparisons was conducted to 
compare continuous variables.*indicates a significant difference compared to normal diastolic 
function.***p<0.001. Chi-Square testing was conducted to detect differences between categorical variables.   
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LVEF (%) 58.6 [54.0 - 65.0] 45.0 [39 - 48.1]**** 59.4 [55.0 - 65.5] #### <0.0001 
E/A ratio 0.9 [0.8 - 1.4] 0.9 [0.7 - 1.5] 1.0 [0.8 - 1.5] 0.956 
E/e’ 8.3 [6.3 - 11.1] 11.9 [8.1 - 15.0] 11.2 [8.8 - 12.6] 0.0028 
LAVi mL/m2 30.8 [23.4 - 36.9] 35.9 [29.4 - 42.0] 38.5 [35.2 - 44.9]** 0.0017 
Septal e’ m/s 0.07 [0.06 - 0.10] 0.05 [0.04 - 0.07]*** 0.06 [0.05 - 0.06]** 0.0001 
Lateral e’ m/s 0.10 [0.09 - 0.11] 0.08 [0.05 - 0.10]** 0.08 [0.07 - 0.09] 0.0071 
Grade I -- 31 [83.7] -- -- 
Grade II & III -- 6 [16.2] -- -- 
Biomarkers are expressed as median (IQR). Kruskal-Wallis testing with Dunn’s correction for multiple comparisons was 
conducted to compare continuous variables between diastolic function. *indicates a significant difference compared 
to normal diastolic function. **p<0.01, ***p<0.001, ****p<0.0001. #indicates a significant difference compared to 
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4.3.3.2 Extracellular matrix biomarker concentrations in diastolic function cohort.   
ECM biomarker concentrations were assessed between diastolic function categorisations 
(Table 4-10) and across diastolic dysfunction severity (Table 4-11).  No significant differences 
in ECM biomarker levels were observed between normal diastolic function, diastolic 
dysfunction and indeterminate groups. TIMP-1 was significantly elevated in patients with 
Grade II and III diastolic dysfunction when compared to Grade I (p<0.05; Table 4-11).  
 
Table 4-10. ECM biomarker concentrations of patients with normal function, diastolic dysfunction 
and indeterminate function. 







MMP-2 105.1 [96.4 - 120.1] 109.9 [91.6 - 120.2] 117.6 [99.9 - 132.9] 
MMP-3 8.82 [7.0 - 11.4] 9.95 [6.6 - 16.5] 10.44 [7.5 - 17.1] 
MMP-8 0.5 [0.48 - 0.58] 0.54 [0.49 - 0.71] 0.52 [0.49 - 0.65] 
MMP-9 18.37 [12.2 - 37.6] 20.87 [14.1 - 38.9] 16.41 [13.4 - 25.9] 
periostin 64.26 [45.3 - 74.3] 59.99 [44.9 - 68.9] 69.03 [55.2 - 79.4] 
PINP 42.17 [35.3 - 56.5] 42.14 [33.9 - 55.7] 42.71 [34.5 - 191.3] 
TIMP-1 79.75 [62.9 - 234.8] 80.8 [72.7 - 204.1] 79.4 [73.1 - 94.7] 
Biomarkers expressed as median (IQR). Kruskal-Wallis testing with Dunn’s correction for multiple comparisons 
was conducted to identify differences between biomarker levels in diastolic function.  
 
 
Table 4-11. ECM biomarker concentrations across diastolic dysfunction severity. 
ECM biomarkers (ng/mL)  
Normal function 
(n=43) 
Grade 1 diastolic 
dysfunction (n=31) 
Grade II & III diastolic 
dysfunction (n=6) 
MMP-2 105.1 [96.4 - 120.1] 109.9 [91.6 - 121.1] 111.3 [99.7 - 117.2] 
MMP-3 8.82 [7.0 - 11.4] 9.7 [5.6 - 15.8] 13.7 [8.9 - 24.8] 
MMP-8 0.5 [0.48 - 0.58] 0.53 [0.49 - 0.66] 0.74 [0.53 - 0.95] 
MMP-9 18.37 [12.2 - 37.6] 20.9 [14.1 - 38.5] 20.9 [13.1 - 45.7] 
periostin 64.26 [45.3 - 74.3] 60.0 [44.1 - 68.2] 55.0 [41.0 - 70.8] 
PINP 42.17 [35.3 - 56.5] 42.2 [34.3 - 55.2] 40.8 [25.5 - 59.2] 
TIMP-1 79.75 [62.9 - 234.8] 79.6 [72.4 - 91.6] 134.3 [90.8 - 177.9]* 
Biomarkers expressed as median (IQR). Kruskal-Wallis testing with Dunn’s correction for multiple comparisons 
was conducted to identify differences between biomarker levels in diastolic function. *indicates a significant 
difference (p<0.05) compared to grade I diastolic function.  
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4.3.3.3 EFA analysis of the diastolic function cohort. 
All of the requirements for EFA were met, with a KMO value of 0.6 and a significant Bartlett’s 
test for Sphercitiy (p<0.0001). EFA identified a two-factor solution that mirrored a similar 
pattern to systolic function analysis. Factor 1 was comprised of MMP-8, MMP-9, MMP-3 and 
TIMP-1, while Factor 2 comprised MMP-3, MMP-2, TIMP-1, PINP and periostin. As observed 
in the systolic function EFA analysis, MMP-3 and TIMP-1 were both cross-correlated across 
factors. Comparably, periostin was included as a variable for Factor 2 with a low loading score. 
The rotated factor matrix is shown in Figure 4-5A. Factor scores were generated for each 
patient, and were compared across the diastolic function groups. No significant differences in 
Factor scores were observed (Figure 4-5B).  
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A.  Biomarker Factor 1 Factor 2 
MMP-8 0.973  
MMP-9 0.644  
MMP-3 0.456 0.456 
MMP-2  0.510 
TIMP-1 0.372 0.462 
PINP  0.427 
Periostin  0.393 
% of variance 
(rotated Sum of Squared loadings) 
25.91 11.83 
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Figure 4-5. EFA analysis of the AMI population and relationship with normal function, diastolic 
dysfunction and indeterminate function.  
A) The rotated factor matrix of log-transformed ECM biomarkers in 100 AMI patients using EFA. B) No 
significant differences in factor scores were identified between diastolic function groups. Median (IQR) 
is plotted.   
B.  
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4.3.3.4 Cluster analysis of the diastolic function cohort. 
Hierarchical cluster analysis was performed on all seven ECM biomarkers for 100 AMI patients. 
Cluster analysis identified two patient groups. A dendrogram of hierarchical clustering is 
shown in Figure 4-6. Differences in clinical characteristics between clustered groups is shown 
in Table 4-12, while differences in ECM biomarker levels are described in Table 4-13. 
 
Cluster One (n=29) was comprised of more male patients (p<0.05) with increased E/e’ and 
reduced septal e’ values (both, p<0.05) compared to Cluster Two (n=71). These parameters 
indicate impaired diastolic function, although no significant differences were identified 
between diastolic function categorisation. The only two patients with renal dysfunction were 
also sorted into Cluster One. All ECM biomarkers, except for periostin, were significantly 
elevated in patients in Cluster One when compared to patients in Cluster Two (Table 4-13).  
The levels of peak high-sensitivity troponin T were elevated in patients from Cluster One 
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Table 4-12. Baseline demographics of clustered groups (diastolic function analysis). 
Baseline Demographics Cluster One (n=29) Cluster Two (n=71) P value 
Male  26 [89.7] 51 [71.8] 0.055 
Age (years) 63 ± 11 61 ± 13 0.338 
BMI 29.9 ± 6.1 29.2 ± 6.3 0.579 
Ethnicity    
European 24 [82.8] 53 [74.6] 
0.794 
Māori 2 [6.9] 7 [9.9] 
Pacific  1 [3.4] 2 [2.8] 
Other (Asian, Indian, Latin) 2 [6.9] 9 [12.7] 
Cardiac Risk Factors    
Hypertension 18 [62.1] 33 [46.5] 0.157 
Dyslipidaemia 15 [51.7] 31 [43.7] 0.463 
Diabetes 7 [24.1] 12 [16.9] 0.403 
Current Smoker 3 [10.3] 16 [22.5] 0.159 
Renal Dysfunction 2 [6.9] 0 [0.0] 0.025 
AMI Classification    
NSTEMI 17 [58.6] 46 [64.8] 
0.562 
STEMI 12 [41.4] 25 [35.2] 
Echocardiogram Features    
Time to Echocardiogram 
(days) 
171.0 [92.5 - 313.5] 139.0 [80.0 - 244.0] 0.244 
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Table 4-12 continued. Baseline demographics of clustered groups (diastolic function analysis). 
Diastolic Function Cluster One (n=29) Cluster Two (n=71) P value 
LVEF (%) 53.0 [46.3 - 58.8] 55.0 [46.5 - 62.8] 0.313 
E/A ratio 1.0 [0.8 - 1.5] 0.90 [0.80 - 1.40] 0.426 
E/e’  11.3 [8.9 - 15.0] 9.1 [7.4 - 12.2] 0.016 
LAVi (mL/m2) 35.7 [28.0 - 40.9] 33.7 [28.5 - 41.5] 0.974 
Septal e’ (m/s) 0.05 [0.04 - 0.07] 0.07 [0.05 - 0.08] 0.034 
Lateral e’ (m/s) 0.08 [0.06 - 0.10] 0.09 [0.05 - 0.08] 0.132 
Grade I 10 [43.5] 21 [36.8] 
0.343 
Grade II & III 3 [13.0] 3 [5.3] 
Diastolic Function Category    
Normal function 10 [34.5] 33 [46.5] 
0.503 Diastolic dysfunction 13 [44.8] 24 [33.8] 
Indeterminate function 6 [20.7] 14 [19.7] 
Continuous variables were expressed as median (IQR). Mann-Whitney U testing was used to compare 
continuous variables between clustered groups. Categorical variables were expressed as frequencies 
(percentages). Chi-Square testing was used to compare categorical variables between clustered groups. 
Significant p-values are bolded (<0.05). 
 
 
Table 4-13. ECM biomarker concentrations of clustered groups (diastolic function analysis). 
ECM biomarkers (ng/mL) Cluster One (n=29) Cluster Two (n=71) P value 
MMP-2 117.7 [105.6 - 126.2] 105.1 [91.7 - 121.1] 0.013 
MMP-3 16.8 [10.0 - 21.7] 8.4 [6.4 - 10.2] <0.0001 
MMP-8 0.71 [0.63 - 0.83] 0.50 [0.47 - 0.54] <0.0001 
MMP-9 63.2 [46.8 - 68.3] 15.9 [12.2 - 20.5] <0.0001 
Periostin 63.2 [46.8 - 68.3] 64.6 [45.9 - 74.3] 0.823 
PINP 52.8 [39.5 - 63.3] 41.7 [33.7 - 52.8] 0.011 
TIMP-1 91.6 [74.1 - 136.3] 79.2 [69.1 - 91.3] 0.006 
Biomarkers expressed as median (IQR). 
  
















Figure 4-6. Cluster analysis of ECM biomarkers in 100 patients with diastolic function measurements.  
A) A dendrogram of hierarchical cluster analysis identified two distinct groups of AMI patients based on 
ECM biomarkers. B) Mann-Whitney U testing was undertaking to identify significant differences between 
biomarker levels of each patient cluster. *p<0.05, p<0.01, ****p<0.0001. Median (IQR) is plotted. 
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4.4 Discussion 
In this study, we examined the utility of combining biomarkers to predict systolic and diastolic 
dysfunction development in a cohort of AMI patients. On univariate analysis, MMP-8, Factor 
1 scores and cluster analysis partitioning were associated with systolic dysfunction along with 
ACE inhibitor medication at discharge, peak troponin T levels above the median, and current 
smoking.  When multivariate analysis was performed, we demonstrated that assignment into 
Cluster One was an independent predictor of impaired systolic function. When diastolic 
dysfunction was examined, neither single biomarkers nor combined biomarker analysis could 
differentiate between patients with normal function, diastolic dysfunction or indeterminate 
function.  
 
The pathology of systolic dysfunction following AMI is associated with impaired cardiac output 
due to ventricular dilation [68]. LV systolic function can be assessed using ejection fraction, 
with a measurement above 50% indicating normal function and measurements below 50% 
suggesting abnormal function [69]. Asymptomatic systolic dysfunction can progress into 
HFrEF, which is a major cause of adverse outcomes in patients post-MI [71]. In Chapter 3, we 
identified a panel of seven ECM biomarkers that were changed in AMI patients when 
compared to healthy volunteers. In this study, we have investigated the relationship between 
these biomarkers and LV function in AMI patients. Of note, this Chapter did not control for 
timing of biomarker measurements. Findings from Chapter 3 demonstrated that while 
temporal changes were present for biomarkers, these almost exclusively occurred between 
acute and six-month time points. With the exception of PINP, stable expression was observed 
between Day 1 and Day 3 measurements for all biomarkers, suggesting that opportunistic 
testing was appropriate going forward in this thesis.  
 
MMP-8 was the only biomarker that demonstrated significant differences between patients 
with preserved and impaired systolic function upon univariate analysis. Infiltrating leukocytes 
are considered a major source of MMP-8 following AMI, with MMP-8 activity associated with 
collagen degradation [277]. A previous study conducted by Fertin et al. [192] demonstrated 
that acute MMP-8 levels were an independent predictor of LV remodeling, defined as a > 20% 
increase in LVEDV from baseline to 1 year. This study also identified increased levels of MMP-
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8 and MMP-9 in patients with reduced LVEF at baseline, but it was unclear if this relationship 
continued to 1 year [192]. These findings are contested by Nilsson et al. [278] who 
demonstrated no association between acute MMP-8 levels and LVEF measured at four 
months. While the univariate relationship between MMP-8 and impaired systolic function are 
of interest, significance was not maintained upon multivariate analysis when the confounders 
of ACE inhibitor mediation at discharge, peak troponin T levels above the median,  and current 
smoking were taken into consideration. These findings support that single biomarker analysis 
is likely not sufficient to predict systolic dysfunction, and that alternative biomarker 
approaches may be required to assess the prognostic utility of ECM biomarkers in this context.  
 
In Chapter 2, we demonstrated two techniques capable of combing biomarkers together, EFA 
and cluster analysis. In this study, we used these techniques to investigate the predictive utility 
of combined ECM biomarkers in systolic dysfunction identification. Firstly, EFA analysis 
created a two factor solution. Factor 1 was composed of MMP-8, MMP-9, MMP-3 and TIMP-
1. Similarly to Chapter 2, MMP-8 had the highest loading on this factor and this suggests most 
of the variance for Factor 1 is captured by MMP-8 levels. Factor 2 was comprised of MMP-3, 
MMP-2, TIMP-1 and PINP, which all demonstrated mid-range positive factor loadings. TIMP-1 
was associated with both factors, although the low factor loadings suggest this impact is 
minimal at best. Scores can be generated from EFA analysis as a mechanism to study the 
relationship between clinical endpoints and EFA [236]. A factor score is created for each 
patient based on the levels of biomarkers that contribute to each factor. For example, patient 
with high levels of MMP-8 and MMP-9 will have a higher Factor 1 score then patients with 
lower levels of these biomarkers. As EFA created a two-factor solution, each patient received 
two scores that represented each factor. When factor scores were compared across systolic 
function, patients with impaired function had significantly elevated Factor 1 scores compared 
to patients with preserved function on univariate but not multivariate analysis. No differences 
were observed for Factor 2 scores. 
 
In Chapter 2, we demonstrated that AMI patients could be classified into distinct groups with 
differential patient risk based on ECM profiles alone. To investigate the predictive utility of 
this method in identifying patients with impaired systolic function, we conducted cluster 
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analysis on our patient cohort using biomarkers comprised in Factor 1. We chose to only 
include biomarkers from Factor 1, as we demonstrated that these were significantly altered 
in patients with differential systolic function at a univariate level. Cluster analysis produced a 
two-cluster solution that best characterised this cohort. Patients in Cluster One (n=31) were 
more likely to be male, had decreased LVEF and had significantly elevated levels of MMP-3, 
MMP-8 and MMP-9 when compared to patients in Cluster Two (n=89). Univariate analysis 
using Chi square testing demonstrated that patients were more likely to be sorted into Cluster 
One if they had impaired systolic function, while patients in Cluster Two were more likely to 
have preserved systolic function. When assessed using multivariate analysis, being partitioned 
into Cluster One remained predictive of having impaired systolic function alongside smoking 
and being discharged with ACE inhibitor medication. Unlike single biomarker analysis, we 
demonstrate that combining biomarkers using cluster analysis is clinically beneficial in 
predicting systolic dysfunction.  
 
In addition to Cluster One assignment, prescription of ACE inhibitors at discharge and a current 
smoking status remained significantly associated with systolic dysfunction upon multivariate 
assessment. Specifically, patients with impaired systolic function within 1 year of AMI were 
more likely to be prescribed with ACE inhibitors at discharge. These findings are to be 
expected, as ACE inhibitor prescription is specifically indicated in patients with chronic heart 
failure or LV systolic dysfunction upon index admission based on guidelines recommendations 
[26, 31]. In addition, current smoking was shown to be protective against the development of 
impair systolic function upon univariate and multivariate analysis. Smoking is a well-known 
risk factor in the setting of CVD, and consequently these findings were surprising. However, 
sample size must be considered when evaluating these results, as only 22 out of the total 120 
patients (5.5%) were self-reported current smokers. Thus, potentially a small sampling skewed 
these findings.    
 
Interestingly, we demonstrate that our combined biomarker analysis methods were not equal 
in their capacity to predict the development of systolic dysfunction. While we demonstrated 
both Factor 1 scores and cluster analysis were univariate predictors of systolic dysfunction, 
only cluster analysis remained predictive upon multivariate analysis. Differences in predictive 
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power are likely associated with the underlying statistical principles of each test and their 
practical purpose. Cluster analysis is well established in the literature as a methodology for 
combining variables and examining the relationship between cluster phenotype and outcome 
[233, 256]. While EFA scores have also been used in this context with success [237, 279], the 
underlying principles are different from cluster analysis and this may impinge on its potential 
scoring power. Specifically, EFA is a tool to examine underlying structure and relationships 
between data, and this is why it was selected in Chapter 2 to assess ECM biomarkers. 
Consequently, less total variation is captured by this technique and this may be a reason as to 
why EFA was less predicative than cluster analysis.  
 
While systolic dysfunction is characteristically defined by ventricular diastolic chamber 
dilation, diastolic dysfunction is associated with increased chamber resistance and elevated 
filling pressures [68]. Diastolic dysfunction can remain subclinical or can deteriorate into 
HFpEF [71]. The development and progression of diastolic dysfunction is complex, but at its 
most basic form is driven by cardiac fibrosis mechanisms [280]. Thus, examining the role of 
ECM biomarkers in diastolic dysfunction is a clinically meaningful endpoint.  
 
Unlike systolic dysfunction, which is diagnosed using LVEF measurements alone, diastolic 
dysfunction is estimated using a combination of indices to represent LV function. Specifically, 
annular e’ velocity is an index for myocardial relaxation, while average E/e’ ratio, average E/A 
ratio and LA volume index are indices for LV filling pressures [281]. In this study, we 
dichotomised patients into normal diastolic function, diastolic dysfunction and indeterminate 
function based on the most up-to-date consensus guidelines by ASE/EACI [70]. These 
guidelines were selected for three important reasons. Firstly, these recommendations are 
clinically applicable as they are routinely implemented for patient diagnosis. Secondly, they 
provide a standardised methodology to ensure reproducibility between laboratory groups 
when defining diastolic dysfunction in a patient cohort. Thirdly, relying on a combination of 
indices provides certainty in diagnosis, as some measurements may fall into a normal range 
despite the presence of diastolic dysfunction. For example, E/A ratio describes the relationship 
between passive and active filling. Under normal diastolic function, the E wave is higher than 
the A wave, as more blood fills the ventricle during passive filling. However, patients with 
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diastolic dysfunction II may present with a similar E/A ratio as progressive remodelling of the 
atrium can cause increased atrial pressures which act to compensate for decreased function 
[282]. Thus, this thesis only used guidelines recommendations to dichotomise patients into 
diastolic function groups and single indices of diastolic dysfunction were not investigated.  
 
In this study, we did not identify any significant correlations between individual biomarkers 
and diastolic dysfunction categorisation. However, we did identify increased levels of TIMP-1 
based on diastolic dysfunction severity. In a study investigating diastolic dysfunction in 
hypertensive patients, Lindsay et al. [283] demonstrated that TIMP-1 levels were increased in 
patients with evidence of diastolic dysfunction when compared to patients with normal 
diastolic filling. In addition, this study also demonstrated that elevated TIMP-1 measurements 
> 500 ng/mL could accurately predict diastolic function in patients. A further study confirmed 
these findings, by demonstrating that TIMP-1 levels were elevated in patients with HFpEF 
when compared to healthy subjects and patients with left ventricular hypertrophy (LVH) 
without heart failure. MMP-9 levels were also elevated in patients with HFpEF when 
compared to the reference control, and no changes were observed in MMP-2 levels [284]. 
These findings uniquely demonstrate a relationship with reduced ECM degradation processes 
and increased ECM deposition in patients with diastolic dysfunction. However, conflicting 
results exist within the literature. A study by Martos et al. [285] demonstrated elevated levels 
of MMP-2 and MMP-9 in HFpEF patients compared to hypertensive patients without HF. In 
addition, increased MMP-2 levels were associated with diastolic dysfunction severity. No 
significant differences were observed in TIMP-1 or PINP levels between groups. These findings 
are further supported by Collier et al. [286] who demonstrated elevated levels of MMP-2 and 
MMP-9 in HFpEF compared to hypertensive controls, and no significant changes were 
observed in TIMP-1 and PINP levels.  
 
Combined, these findings create a complicated picture regarding the predictive utility of ECM 
biomarkers and diastolic dysfunction. One cause for this disparity within the literature could 
be associated with the heterogeneous diastolic dysfunction populations described by 
asymptomatic and heart failure subjects. While the underlying pathology is similar, diastolic 
dysfunction within these patient groups is categorised differently and severity of disease is 
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not comparable. However, it is clear that this alone is not the sole issue for discordant results 
in the literature, as discrepancies also exist between studies involving asymptomatic patients 
only. As described previously, Lindsay et al [283] demonstrated elevated levels of TIMP-1 in 
hypertensive patients with diastolic dysfunction. Comparably, Chu et al. [287] demonstrated 
no change in TIMP-1 levels in patients without heart failure but with diastolic dysfunction. 
Thus, it may be the diagnosis of diastolic dysfunction that is causing discrepancies between 
studies.   
 
The diagnosis of diastolic dysfunction is based on consensus recommendations, with the most 
recent guidelines published in 2016 [70]. Significant differences exist between current and 
superseded guidelines [288], as well as previous diagnostic algorithms [289, 290]. A study 
comparing diastolic dysfunction prevalence in a community-based population demonstrated 
that current guidelines only identified diastolic dysfunction in 1.3% of the population, while 
the superseded guidelines diagnosed 5.9% of the same population. Indeed, the previous 
studies described in this Chapter used different diagnosis strategies which included: E/A ratio 
< 1 [283], LAVi > 34 mL/m2 [286], stratification based on the Canadian Consensus Classification 
system [287], and combined measures of E/A ratio, isovolumic relaxation time and 
deceleration time [285]. Thus, differences observed in the predictive potential of ECM 
biomarkers may be greatly influenced by diastolic dysfunction diagnosis, and this may be an 
explanation for the lack of consensus between studies and for the differences observed in this 
study. This further supports the use of a standardised methodology for diagnosing patients 
with diastolic dysfunction, and we suggest utilisation of the most up-to-date consensus 
guidelines as an appropriate strategy to ensure reproducibility between laboratory groups. 
 
Similar to systolic dysfunction, we were interested in combining biomarker measurements to 
capture the complexity of the ECM process in LV dysfunction. When biomarkers were 
combined to create a score using EFA, no significant differences were observed between 
diastolic function groups. This was similarly observed when using cluster analysis. Previous 
studies have demonstrated some utility in using multimarker approach in identifying 
parameters of diastolic dysfunction. Zile et al. [291] demonstrated that a combination of 
clinical covariates and MMP-2, MMP-8, TIMP-4 and PIIINP levels could predict HFpEF with AUC 
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of 0.79 (0.73 - 0.86) when compared to covariates alone (AUC 0.68 [0.60 - 0.76]). Similarly, a 
recent study investigating diastolic dysfunction and LVH in a community-based population 
demonstrated that combining Galectine-3, PIIINP, BNP, ST2 and HOMAGE scores was more 
predictive of diastolic dysfunction and LVH than each biomarker alone [230]. These studies 
support the use of multimarker analysis in diagnosing diastolic dysfunction. However, a flaw 
in both studies is the use of statistical techniques that do not account for overlapping 
biomarker function, and thus over representing potential molecular activity. While we have 
demonstrated the benefit of a model that takes into account collinearity for systolic function, 
we could not show the predictive utility in diastolic dysfunction development.  
 
We also identified significant associations between peak troponin T levels and LV dysfunction. 
Specifically, higher levels of peak troponin T were identified in impaired systolic function and 
diastolic dysfunction at a univariate level, and this relationship was maintained at multivariate 
level for systolic dysfunction. The ACC/AHA recognises troponin as a potentially useful 
biomarker for prognosis or additive risk stratification in acute or hospitalised heart failure 
patients [72]. Growing evidence exists within the literature to demonstrate that increased 
troponin levels measured during heart failure hospitalisation are associated with increased 
mortality risk and worse outcomes [292, 293]. Therefore, it is unsurprising that we found 
elevated levels in patients with increased ventricular dysfunction. Natriuretic peptides are the 
gold-standard biomarkers in heart failure. However, in clinical practice biomarker levels are 
most commonly measured when clinically indicated. As all patients in this cohort had 
asymptomatic LV dysfunction at their follow-up appointment, most patients did not have BNP 
or NT-proBNP measurements conducted. Thus, a comparison between natriuretic peptides 
and LV dysfunction could not be assessed in this Chapter.  
 
Overall, the findings of this study suggest a combined biomarker approach improves 
prediction of systolic dysfunction but not diastolic dysfunction. While these results are 
exciting, caution must be taken when interpreting these findings. We show that cluster 
analysis can modestly separate patients with impaired and preserved systolic function into 
distinct groups based entirely on levels of MMP-3, MMP-8, MMP-9 and TIMP-1. However, this 
separation is not homogenous and perfect division has not occurred. Consequently, some 
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patients with preserved systolic function remain in Cluster One, while some patients with 
impaired systolic function remain in Cluster Two. We also show that this combined biomarker 
approach is only beneficial in systolic function and does not transfer to predicting diastolic 
dysfunction development. While this remains unsurprising, as the pathophysiology of these 
disease processes are unique [294], aspects of ECM activity underpin both LV function 
mechanisms. Thus, the inability of single or combined biomarker analysis to separate patients 
into diastolic dysfunction diagnosis, suggests room for improvement in this technique and 
perhaps a more novel approach is required. As described Chapter 1, cardiac fibroblast activity 
underpins ECM remodeling processes and excessive or underactive fibroblast activity is 
associated with impaired scar formation and adverse remodeling [141]. Thus, measurement 
of cardiac fibroblast activity may be more accurate and useful than traditional protein 
biomarkers. This novel approach will be explored further in Chapter 5.  
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4.5 Limitations 
In this study, we examined LV function in AMI patients at clinical follow-up. While we 
standardised this study to only include patients with echocardiogram measures within 1 year 
of the index event, the median time was 145 days (IQR 89 - 252 days). This creates two 
potential limitations for this study. Firstly, timing is not standardised for patients and this may 
influence measures of LV remodelling, which is a progressive disease. However, we 
demonstrate in both cohorts that differences between groupings are not influenced by time 
to echocardiogram. Therefore, the effects of imaging time differences remain minimal. 
Secondly, the median time to echocardiogram was approximately five months. While LV 
remodelling has occurred at this time point, and this timing or earlier is commonly used [190, 
267], it may be a limitation for measuring advanced LV remodelling. This may have also 
contributed to the lack of changes observed between diastolic function categories, as 
myocardial fibrosis is also a progressive disease that occurs over time.  A further limitation of 
this study is the sample population measured, for which all were clinically indicated to receive 
echocardiogram measurements at their follow-up appointment. However, the reason for 
receiving an echocardiogram remains unknown, although most likely a suspicion for 
dysfunction may have existed. Thus, our study population is biased towards a group of 
patients with potential complications following their index event. However, we have 
demonstrated for systolic and diastolic function groups that a higher proportion of patients 
have normal function, and this suggests a minimal impact for this bias. This study was a 
retrospective analysis, and thus has less power than collecting a prospective cohort. In 
addition, the echocardiograms and the analysis of the echocardiograms were conducted by 
employed and trained technical staff at Wellington Regional Hospital. Thus, these aspects of 
methodology were not controlled by this study. While this mimics the real world of clinical 
research, we recognise that this may have increased the variation in measurements.   
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4.6 Conclusion 
In conclusion, we demonstrate that combining ECM biomarkers is useful for predicting systolic 
dysfunction, but not diastolic dysfunction, in patients within 1 year of AMI. We also show that 
combined biomarker analysis remains predictive at a multivariate level where single 
biomarker analysis does not. These findings demonstrate the utility of cluster analysis in risk 
stratification of AMI patients. However, caution must be taken when interpreting these 
results, as this technique is not a perfect predictor of impaired systolic function and is 
ineffective for predicting diastolic dysfunction. Future research should focus on developing 
novel biomarker approaches for risk stratifying patients at risk of LV remodeling processes.  
 
  











 Examining the genetic 
extracellular vesicle composition of cardiac 
fibroblasts under pro-inflammatory and pro-
fibrotic conditions in vitro 
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5.1 Introduction 
In Chapter 4, we demonstrated that the combination of MMP-3, MMP-8, MMP-9 and TIMP-1 
using cluster analysis could distinguish between AMI patients with preserved and impaired 
systolic function. While we demonstrated that combined biomarker analysis improved 
prediction in comparison to single biomarker analysis, group separation was not homogenous 
and neither single nor combined biomarker analysis could predict development of diastolic 
dysfunction in AMI patients. Thus, potentially more novel and specific targets should be 
examined as future prognostic biomarkers.   
 
Cardiac fibroblast activity in AMI underpins appropriate repair, and is the main cellular source 
for collagen-scar formation [141]. Early cardiac repair is described by an inflammatory phase 
followed by a proliferative phase in which the microenvironment is governed by pro-
inflammatory and pro-fibrotic factors, respectively. Indeed, cardiac fibroblasts are also 
sensitive to this microenvironment and polarize to differential phenotypes under in vitro 
stimulation [138, 212, 213]. Therefore, the measurement of cardiac fibroblast activity may 
provide an opportunity to capture repair effectiveness following AMI. However, this research 
has been impeded by the location of these resident cardiac cells.   
 
EVs are small anuclear vesicles comprised of lipids, metabolites, proteins, RNA and DNA that 
are encapsulated within a phospholipid bilayer membrane [217]. EVs are synthesised by 
cardiac fibroblasts, and participate in crucial cellular signalling [218]. Furthermore, sncRNA 
comprised within EVs can be harnessed as liquid biopsy biomarkers that have shown some 
success in CVD [295, 296]. Importantly, recent studies have demonstrated that in vitro 
stimulation with IL-1β or TGF-β1 can alter EV genetic composition in lung [222] and cardiac 
fibroblasts [223], respectively. These studies confirm that the external microenvironment can 
influence cardiac fibroblast EV synthesis. However, what remains to be determined is how the 
sncRNA composition of cardiac fibroblast EVs is altered under pro-inflammatory and pro-
fibrotic conditions, as no previous study has investigated the paired change within a single 
fibroblast population nor has a previous study investigated sncRNAs specifically. This is of 
significance in the setting of AMI, as these stimuli represent the microenvironment in cardiac 
repair and examination of EV sncRNA could provide novel putative targets to non-invasively 
Page | 160 
 
examine cardiac fibroblast activity in AMI. TNF-α and TGF-β1 are two molecular factors that 
represent pro-inflammatory and pro-fibrotic processes, respectively, and were selected as 
stimuli in this study.   
 
We hypothesise that the sncRNA composition of cardiac fibroblast-derived EVs will change 
under pro-inflammatory and pro-fibrotic stimulation in vitro. This hypothesis was addressed 
by examining the following aim. 
• To assess sncRNA composition of EVs isolated from human primary cardiac fibroblasts 
under pro-inflammatory (TNF-α) and pro-fibrotic (TGF-β1) stimulation in vitro by 
performing RNA-sequencing analysis.  
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5.2 Methods 
5.2.1 Cardiac fibroblasts 
5.2.1.1 Patient recruitment and tissue collection 
Right atrial appendage biopsies were obtained from 16 patients with coronary artery disease 
undergoing CABG at Wellington Regional Hospital with or without prior AMI. Cardiac tissue 
was collected at the time a patient was placed on perfusion, and prior to coronary grafting. Of 
the 16 samples collected in this study, eight were used for protocol optimisation, three were 
disposed during COVID-19 lockdown, and three were processed for RNA-sequencing. Two 
patients were withdrawn from the study following recruitment, due to transfer into private 
practice and identification of a previously undiagnosed malignancy. Patients were excluded 
from this study if they were: unable to provide informed consent, were diagnosed with an 
active malignancy, were on immune-modulating medication, were diagnosed with diabetes, 
had atrial fibrillation, or had impaired left ventricular systolic function (<35%) as determined 
by echocardiogram. This study was reviewed and approved by the Health and Disabilities 
Ethics Committee (19/CEN/57), and all patients provided voluntary written and informed 
consent prior to recruitment.   
 
5.2.1.2 Cardiac fibroblast isolation and culture 
Following tissue collection, right atrial appendage samples were washed with PBS and minced 
into 1-2 mm fragments. The extracellular matrix was digested in 10mL of 800 U/mL 
Collagenase Type II (Thermo Fisher Scientific, Massachusetts, United States) in Hanks’ 
Balanced Saline Solution (HBSS) for 45 minutes at 37˚C with gentle shaking. The supernatant 
was collected, and the digestion reaction was stopped by addition of 5 mL Fetal Bovine Serum 
(FBS; Moregate Biotech, Queensland, Australia). FBS is a growth supplement that can be used 
to enrich cell culture solutions with growth factors and can also stop digestion reactions by 
supplying a competing source of protein. EVs are present in FBS, and were depleted by 
ultracentrifugation at 100,000 x g for 2 hours prior to use in any cell culture solutions. This 
digestion process was repeated 4-5 times to ensure complete digestion of cardiac tissue. 
Isolated cells were centrifuged at 1,000 x g for 4 minutes at 37˚C. Cell pellets were 
resuspended in EV-depleted 10% growth media (see Appendix 1) and plated in two T-25 falcon 
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flasks (in vitro technologies, Auckland, New Zealand). Cardiac fibroblasts were separated from 
other cardiac cell types by incubating for 1 hour at 37˚C, followed by two PBS washes to 
remove all non-adherent cells. Cardiac fibroblast were cultivated in a humid atmosphere with 
5% CO2/95% O2 at 37˚C until confluent. Cell culture media was changed every 48-72 hours, 
and cells were passaged using 0.25% Trypsin-EDTA Solution (Sigma-Aldrich, Missouri, United 
States) at 80% confluence.  Cell concentration was determined prior to passaging using Trypan 
Blue solution (Sigma-Aldrich).  
 
5.2.1.3 Characterisation of cardiac fibroblast by flow cytometry.  
The purity of the cardiac fibroblast population was assessed by flow cytometry. Briefly, cardiac 
fibroblasts were isolated by trypsinization (Sigma-Aldrich) from a single T-75 flask at passage 
3, resuspended in staining buffer (see Appendix 1), and incubated in Fc receptor blocking 
solution diluted 1:10 (Becton Dickinson, California, United States) for 10 minutes at room 
temperature. In parallel, peripheral blood mononuclear cells (PBMCs) were prepared as a 
positive control for CD45+/CD31+ expression. PBMCs were collected by density centrifugation 
from EDTA-anticoagulated whole blood from a single healthy volunteer, frozen at 1 x 106 cells 
in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% dimethyl sulfoxide 
(DMSO) and 10% FBS and stored in liquid nitrogen until use. PBMCs were thawed at 37˚C and 
washed in DMEM by centrifugation at 400 x g for 12 minutes at room temperature. PBMC 
pellets were resuspended in staining buffer, and incubated under the same conditions as 
cardiac fibroblasts in Fc receptor blocking solution.  
 
Following Fc block, all cell suspensions were washed in 100 µL PBS, centrifuged at 1,000 x g 
for 4 minutes at room temperature, and resuspended in 100 µL Zombie NIR™ Fixable Viability 
solution (Biolegend, California, United States; 1:2000 dilution). Samples were incubated at 
room temperature in darkness for 15 minutes, before being washed with 400 µL of staining 
buffer and centrifuged at 1,000 x g for 4 minutes at room temperature to remove supernatant.  
 
For cell surface staining, cell suspensions were incubated with anti-CD45-AF532 (clone HI30; 
Thermo Fisher Scientific, Massachusetts, United States; 1:100 dilution) and anti-CD31-
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APC/Cy7 (clone WM59; Biolegend, California, United States; 1:100 dilution) in staining buffer 
for 30 minutes at 4˚Cprior to fixation with 200 µL of 1% paraformaldehyde for 20 minutes at 
4˚C.  
 
For intracellular staining, cell suspensions were then permeabilized by addition of 200 µL of 
permeablization wash buffer (Biolegend, California, United States), samples were vortexed for 
1 minute, incubated for 20 minutes at 4˚C, and pelleted by centrifugation at 1000 x g for 4 
minutes. Cell pellets were resuspended in anti-vimentin-PE (clone RV202, Becton Dickinson, 
California, United States; 1:200 dilution) and αSMA-APC (clone 1A4, R&D Systems, Minnesota, 
United states: 1:200 dilution) in permeabilization wash buffer (Biolegend) and incubated for 
30 minutes at 4˚C. Cell suspensions were made up to a final volume of 250 µL in 
permeabilization wash buffer and incubated overnight at 4˚C prior to analysis.  
 
The flow cytometry gating strategy for cardiac fibroblast purity is shown in Figure 5-1. All flow 
cytometry was performed on the 3-laser (violet-blue-red) Cytek Aurora (Cytek Biosciences, 
California, United States), and data was analysed using FlowJo software (Tree star, Oregon, 
United States).  
  




Figure 5-1. Flow cytometry gating strategy for cardiac fibroblast populations. 
A and B) Doublet exclusion was performed based on forward scatter (FSC) and side scatter (SSC) properties. C) 
Live cells were gated on their negative expression of Zombie-NIR™. D) CD45- cardiac fibroblasts were identified 
based on E) CD45- expression in PBMC controls. F) CD45- cardiac fibroblasts were further gated on CD31-
negativity. G) Vimentin+ and αSMA+ cardiac fibroblast expression was identified.  
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5.2.1.4 In vitro stimulation of cardiac fibroblasts 
Cardiac fibroblasts at passage 2 were trypsinised (Sigma-Aldrich) and seeded into T-75 Falcon 
Flasks (in vitro technologies, Auckland, New Zealand) at a final density of 290,000 cells and 
incubated overnight. Following 24 hours of serum starvation, cells were treated in duplicate 
with either 0.1% bovine serum albumin (BSA; MP Biomedicals, California, United States) in 
ddH2O (control), 10 ng/mL TNFα (Thermo Fisher Scientific, Massachusetts, United States; Lot 
1998133) or 20 ng/mL TGFβ-1 (Thermo Fisher Scientific, Massachusetts, United States; Lot 
0519102219) in EV-depleted 2% growth media (see Appendix 1). This reduced 
supplementation of EV-depleted FBS was included in order to minimise the presence of 
external EVs. After 48 hours of incubation, cell culture media was collected and pooled from 
duplicate stimulation samples. Differential centrifugation for 10 minutes at 400 x g, followed 
by 10 minutes at 2000 x g was conducted to remove cellular debris. Cleared supernatant was 
stored at -80˚C for EV isolation. Cardiac fibroblast cells were then harvested for downstream 
analysis. An overview of experimental protocol is shown in Figure 5-2.  
 
5.2.1.5 Viability analysis 
Following in vitro stimulation, cell viability was assessed using Trypan Blue solution (Sigma-
Aldrich). Briefly, trypsinised cells were incubated in a 1:1 ratio with Trypan Blue and counted 
in duplicate on a haemocytometer. Percentage viability was calculated by the ratio of non-
viable to viable cells. Cell viability was confirmed by assessment using colorimetric analysis 
using Cell Counting Kit-8 (Dojindo, Rockville, USA) following manufacturer instructions. Briefly, 
cardiac fibroblasts at passage 3 were seeded in a 96-well plate at a concentration of 5000 
cells/well, and incubated overnight at 37˚C at 5% CO2. Following 24 hours of serum starvation, 
cells were treated with 0.1% BSA in ddH2O (control), 10 ng/mL TNFα or 20 ng/mL TGFβ-1 in 
EV-depleted 2% growth media in triplicate. Media only wells were also included to account 
for background reading measurements. After 45 hours, 10 µL of CCK-8 reagent was added to 
each well, and incubated for 3 hours in the dark. At 48 hours, absorbances were measured 
using Multiskan GO microplate spectrophotometer (Thermo Fisher Scientific) at 450 nm. An 
increase in absorbance indicated increased cell concentrations, and significance was 
determined by ANOVA analysis. 
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Figure 5-2. A schematic summary of the experimental protocol.   
Schematic overview of experimental protocol from cardiac fibroblast isolation through to RNA-sequencing analysis. Black indicates mainstream experimental 
work flow. Blue indicates additional experimentation to characterise cardiac fibroblast activity or EV phenotype. Orange indicates quality control (QC) of RNA-
sequencing methodology. Abbreviations: TNF-α, tumour necrosis alpha; TGF-β1, transforming growth factor beta 1; EV, extracellular vesicle; RNA, ribonucleic 
acid. This figure was created on Biorender.com, Toronto, Canada. 
Page | 167 
 
5.2.1.6 Confirmation of cardiac fibroblast stimulation 
RNA extraction. The RNeasy Mini Kit (Qiagen, Hilden, Germany) was employed to isolate total 
RNA from duplicates of cardiac fibroblasts stimulated under each experimental condition. The 
manufacturer’s protocol was undertaken, and is as follows. Cell pellets were lysed and 
homogenised by addition of Buffer RLT and vortexing at maximum speed for 1 minute. Freshly 
prepared 70% ethanol was added to the homogenized lysate in order to provide appropriate 
binding conditions. Samples were then transferred to an RNeasy spin column and centrifuged 
for 15 seconds at 8,000 x g at room temperature to allow for selective RNA binding to the silica 
column membrane. The RNeasy spin column was washed with Buffer RW1 by centrifuging 
under the same conditions. A further column wash was carried out by addition of Buffer RPE 
for 15 seconds at 8,000 x g at room temperature. This wash step was repeated with longer 
spin time of 2 minutes, followed by further centrifugation at full speed (12,900 x g) for 1 
minute at room temperature. These additional centrifugation steps were applied to ensure 
the silica column membrane was dried to prevent ethanol carry over during RNA elution. The 
RNeasy spin column was transferred to a 1.5 mL microcentrifuge tube and RNA was eluted in 
30 µL of nuclease-free water by incubating for 1 minute and followed by centrifugation at 
8,000 x g for 1 minute at room temperature. RNA purity and concentration was quantified 
using Nanodrop™ One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Fisher 
Scientific, Massachusetts, United States). RNA was standardised to 200 ng/µL and aliquots 
stored at -80˚C until required for further downstream analysis. 
 
cDNA synthesis. cDNA template was synthesised from cardiac fibroblast RNA using 
SuperScript™ IV VILO™ Master Mix with ezDNase™ Enzyme (Life Technologies, California, 
United States) according to manufacturer instructions. In detail, gDNA was digested by adding 
1 µg of RNA template to ezDNase buffer (10X) and enzyme. Digestion was initiated by gentle 
mixing and incubation at 37˚C for 2 minutes. Reverse transcription (RT) of the RNA template 
was achieved by addition of SuperScript™ IV VILO™ mastermix and nuclease-free water. To 
monitor genomic DNA contamination, a no-RT reaction was also created for each control 
duplicate by replacing SuperScript™ IV VILO™ master mix with SuperScript™ IV VILO™ no-RT 
master mix. Samples were gently mixed and incubated in the C1000 Touch Thermal Cycler 
(Bio-Rad Laboratories, California, United States) under the following conditions: 25˚C for 10 
minutes, 50˚C for 10 minutes and 85˚C for 5 minutes.  
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Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Immediately 
following cDNA synthesis, gene expression was quantified using Taqman® technology on the 
CFX384™ Real-Time PCR Detection System (Bio-Rad Laboratories, California, United States). 
Taqman® detects amplification of PCR products through measurement of fluorogenic probes. 
Specifically, Taqman® assay primers contain a sequence specific oligo which is covalently 
bound to a fluorescent reporter (5’ end) and a quencher (3’ end). When reporter and quencher 
are in close proximity to each other, fluorescent resonance energy transfer (FRET) occurs, and 
no increase in fluorescence intensity can be detected. However, when bound to a denatured 
cDNA sequence and during the extension phase of PCR amplification, Taq DNA polymerase 
cleaves and separates both molecules from the oligo sequence and this creates a permanent 
increase in fluorescent signal that is directly proportional to PCR product. Gene expression 
was quantified for cardiac fibroblast duplicates of each experimental stimulation condition by 
combining a 1/20 dilution of cDNA template with TaqMan® Fast Advanced Master Mix (2X), 
TaqMan® Assay Primers and nuclease-free water. Each Taqman® assay is specific to an mRNA 
target and the following targets were measured in this experiment: Interleukin-6 (IL-6; 
Hs00174131_m1; Thermo Fisher Scientific, California, United States), MMP-9 
(Hs00957562_m1; Thermo Fisher Scientific), Collagen type I (COL1A1; Hs00164004_m1; 
Thermo Fisher Scientific) and alpha-smooth muscle actin (ACTA2; Hs00426835_g1; Thermo 
Fisher Scientific). All mRNA targets were duplexed with housekeeper controls which 
comprised Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Hs99999905_m1; Thermo 
Fisher Scientific) and RNA Polymerase II Subunit A (POLR2A; Hs00172187_m1; Thermo Fisher 
Scientific).  Each RT-qPCR experiment was performed in duplicate and contained a no template 
and no-RT control. Samples were run under the following conditions: 50˚C for 2 minutes 
followed by 95˚C for 2 minutes, then 40 repeat cycles of 95˚C for 1 second and 60˚C for 20 
seconds.  
 
Following qPCR amplification, mRNA concentrations were quantified using quantification 
cycle (Cq) values. Cq values for housekeeper controls were averaged to obtain the geometric 
mean and used to normalise the target mRNA average Cq values. The relative expression for 
each sample was calculated by comparing TNFα and TGF-β1 stimulation conditions to the 
control by using the 2-ΔΔCt method [297].  
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5.2.2 Extracellular vesicles 
5.2.2.1 EV isolation from cardiac fibroblasts 
Stored cell culture media, isolated from in vitro stimulated cardiac fibroblasts, was defrosted 
at 37˚C and centrifuged for 10 minutes at 2,000 x g to remove any residual cellular debris. EVs 
were purified using IZON qEV10/70nm columns with an Automatic Fraction Collector (Izon 
Science, Oxford, UK). This methodology uses size exclusion chromatography (SEC) which 
separates molecules based on size into different collectable fractions. Initially smaller 
particles, including EVs, are eluted into solution and this is followed by larger contaminating 
particles. To ensure a purified population of EVs was collected, we eluted 10mL of cell culture 
media into four 5mL fractions, as recommended by the manufacturer to reduce protein 
contamination. This process was repeated twice for each stimulation condition in order to 
ensure EVs were collected from 20 mL cell culture media. Fractions were pooled together for 
each stimulation condition, and 8 mL was removed and concentrated to 150 uL using Amicon 
Ultra-15 Centrifugal Filter Units (Merck, New Jersey, United States) by centrifuging at 4,000 x 
g for 20 minutes. This concentrated product was stored at -80 for future size and 
concentration analysis using tunable resistive pulse sensing (TRPS). The remaining 32 mL 
sample was ultracentrifuged at 100,000 x g for 16 hours in order to concentrate the EVs. The 
supernatant was removed, and EV pellets were resuspended in 200 uL of Exosome 
Resuspension Buffer (Life Technologies, California, United States) and immediately processed 
for RNA extraction.  
 
5.2.2.2 EV size and concentration analysis 
The size and concentration of EVs were quantified by TRPS on a Nanopore 200 (NP200; Izon 
Science, Oxford, UK) which measures particles in the range of 85-500 nm using the qNano 
Gold (Izon Science, Oxford, UK). Calibration runs were performed with 200 nm diameter 
carboxylated polystyrene beads (Izon Science, Oxford, UK) after each run under the same 
experimental conditions. Concentration and size were determined using the product specific 
software (Izon Control Suite, version 3.3.2.2001, Izon Science, Oxford, UK).  
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5.2.2.3 EV RNA extraction 
EV RNA was extracted from samples by combining two isolation protocols using the Total 
Exosome RNA & Protein Isolation Kit (Life Technologies, California, United States) followed by 
RNA Clean & Concentrator™-5 Kit (Zymo Research, California, United States). Following 
addition of Exosome Resuspension Buffer (Life Technologies), EVs were incubated for 10 
minutes at room temperature to allow pellet dissolution. EVs were lysed by the addition of 2x 
Denaturing Solution (Life Technologies) and incubated on ice for 5 minutes. An equal volume 
of Acid-Phenol:Chloroform (Life Technologies) was added to the sample and was thoroughly 
mixed by vortexing for 1 minute. The solution was centrifuged at 12,900 x g for 5 minutes at 
room temperature to produce phase separation, with a lower organic phase, and inter-phase 
containing DNA and a upper-aqueous phase exclusively containing RNA. Three-quarters of the 
upper-aqueous phase was carefully transferred to a clean 1.5 mL microcentrifuge tube 
(Interlab, Wellington, New Zealand) in order to avoid DNA contamination. To this, 1.25 
volumes of 100% ethanol was added and mixed thoroughly with a pipette. Sample was 
transferred to a Zymo-Spin IC Column (Zymo Research) and centrifuged at 10,000 x g for 30 
seconds at room temperature. The flow-through was discarded and the sample was combined 
with RNA Prep Buffer (Zymo Research) to create sufficient RNA binding conditions. Following 
centrifugation at 10,000 x g for 30 seconds at room temperature, the flow-through was 
discarded and the sample was washed by the addition of RNA Wash Buffer (Zymo Research) 
using the same centrifugation conditions. A further wash was included and complete removal 
of contaminating ethanol was achieved by an increased centrifugation time of 1 minute. The 
zymo column was transferred to a nuclease-free lobind tube (Eppendorf, Hamburg, Germany) 
and RNA was eluted by the addition of 15 µL nuclease-free water which was incubated for 2 
minutes and centrifuged for 1 minute at 800 x g followed by 30 seconds at 12,000 x g. Eluted 
RNA was separated into an 11 µL aliquot for RNA library preparation and a 4 µL aliquot for 
RNA quality control analysis.  
 
5.2.2.4 EV RNA quality control 
Quality control (QC) was assessed by quantification of EV RNA using both fluorescent based 
measurement and RT-qPCR analysis. Quant-iT™ RiboGreen RNA reagent and kit (Thermo 
Fisher Scientific, California, United States) uses an ultrasensitive fluorescent nucleic acid stain 
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to bind to RNA in vitro and can be measured using a spectrofluorometric. Briefly, a 5 point 
standard curve was generated by diluting the 100 µg/mL RNA standard (Component C) 1000-
fold in Tris Buffered Saline (TBS) (Life Technologies, California, United States) to create the top 
standard, followed by 5-fold serial dilution. Samples were diluted 1:200 with TBS buffer, and 
plated alongside the standards in triplicate on a 96-well plate (Thermo Fisher Scientific, 
Massachusetts, United States). TBS buffer was used as a blank measurement. Quant-iT™ 
RiboGreen reagent (Component A) was diluted 200-fold in Tris-EDTA buffer and incubated in 
the dark for 5 minutes at room temperature.  Fluorescence was measured on Fluostar Optimal 
(Alphatech Systems Ltd, Auckland, New Zealand), and sample concentration was quantified 
by generation of a standard curve. RNA concentration is shown in Figure 5-3A.   
 
MicroRNA expression analysis was undertaken to further quantify EV RNA.  Briefly, cDNA 
template was generated using TaqMan™ Advanced miRNA cDNA Synthesis Kit (Life 
Technologies, California, United States) according to manufacturer instructions. In detail, 2 µL 
of EV RNA was combined with 10X Poly(A) Buffer, adenosine triphosphate (ATP), Poly(A) 
enzyme and nuclease-free water and incubated at 37˚C for 45 minutes followed by 65˚C for 
10 minutes to create a poly(A) tail. Adapter ligation was then performed by combining 5X DNA 
Ligase buffer, 50% PEG 8000 buffer, 25X ligation adaptor, RNase ligase and nuclease-free 
water and incubating for 60 minutes at 16˚C. Reverse transcription of the sample was 
performed by combining 5X RT Buffer, dNTP Mix, 20X Universal RT Primer, 10X RT Enzyme Mix 
and nuclease-free water under the following conditions: 42˚C for 15 minutes and 85˚C for 5 
minutes. RT-qPCR was performed by combining Taqman™ Fast Advanced Mastermix with 
Taqman microRNA probe hsa-miR-19a-3p (479228_miR; Thermo Fisher Scientific, 
Massachusetts, United States), which has been shown to be expressed by cardiac fibroblast 
EVs in previous studies [298]. Only samples with RNA expression levels of hsa-miR-19a-3p 
below a Cq value of 35 were used in further downstream analysis. Sample Cq values are shown 
in Figure 5-3B, and a representative RT-qPCR trace is shown in Figure 5-3C.  
  







Figure 5-3. Quality control (QC) measures of isolated EV RNA. 
A) Quantified RNA concentration using the Ribogreen assay. Concentration represents ng in 10 µL 
and is the input concentration for RNA library preparation. Dotted line represents 1 ng of RNA. B) 
Cq measurement of RNA samples using RT-qPCR. All samples had Cq levels < 35. C) Representative 
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5.2.2.5 RNA-sequencing of EV samples 
Small RNA libraries were prepared from isolated EV RNA using the NEXTFLEX® Small RNA-Seq 
Kit v3 (PerkinElmer, Massachusetts, United States) according to manufacturer instructions. 
Samples were prepared in lobind 96-well plates (Eppendorf, Hamburg, Germany) on ice, and 
all incubations were conducted using the C1000 Thermal Cycler (Bio-Rad Laboratories)  
 
Briefly, 10 µL of EV RNA was denatured by combining with nuclease-free water for total 
volume of 10.5 µL, and incubated at 70˚C for 2 minutes. RNA input concentration ranged from 
1.2 ng to 6.9 ng based on Ribogreen assay quantification (Figure 5-3A). As such, the input fell 
within the lower limit of the kit (1 - 50 ng), and additional adapter dilutions and PCR cycles 
were recommended by the manufacturer. Thus, 3’ 4N Adenylated Adapters were diluted ¼ 
with nuclease-free water and ligated to denatured RNA by addition of 3’ Ligation Buffer and 
Enzyme Mix and incubation at 25˚C for 2 hours. The 3’ 4N Adenylated Adapters are a 
population of DNA oligonucleotides that contain identical sequences excluding four 
nucleotides at the 5’ terminal which are randomized and degenerate.  This patent-pending 
adapter design reduces the inherent base-specific biases of RNA ligase, and provides a more 
accurate representation of small RNA species in the final sequencing product.  
 
Following 3’ adapter ligation, excess unligated adapters were removed from the sample using 
NEXTFLEX® Cleanup Beads. Removal of unligated adapters is critical for downstream 
sequencing processes, as they can form side products known as adapter dimers that can 
dominate the final sequencing product. Solid-phase reversible immobilization paramagnetic 
bead technology was performed to selectively bind nucleic acid products prior to a 70% 
ethanol wash to remove unbound products, such as adapters. Purified nucleic acids were 
eluted from the paramagnetic beads under aqueous conditions, and residual RNA ligase 
activity was inhibited by addition of Adapter Inactivation Buffer and Enzyme mix and 
incubation at 12˚C for 15 minutes followed by 50˚C for 20 minutes.   
 
5’ 4N Adapters were diluted ¼ with nuclease-free water and denatured by incubation at 70˚C 
for 2 minutes, prior to combining with 3’ 4N Adenylated Adapter Ligated RNA. Similar to the 
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3’ adapters, 5’ 4N Adapters also contain a four nucleotide region of degeneracy that reduces 
small RNA sequencing biases. 5’ Adapter Ligation was achieved by addition of 5’ Ligation 
Buffer and 5’ Enzyme Mix and incubation at 20˚C for 1 hour. Reverse transcription of the 5’ 
and 3’ Adapter Ligated RNA was undertaken in the presence of M-MuLV reverse transcriptase 
enzyme and NEXTFLEX® RT Buffer, which contains RT primer that is complementary to the 3’ 
adapter and serves as a template for first-stand synthesis.   
 
Following reverse transcription, a further NEXTFLEX® Bead Cleanup step was carried out to 
remove excess 5’ 4N Adapter from the sample prior to PCR amplification. NEXTFLEX® universal 
primer and small RNA PCR Master Mix was combined with the purified first-strand synthesis 
product along with a NEXTFLEX® barcoded primer. Barcoded primers contain a unique six 
base-pair index sequence that can be used to identify individual samples multiplexed together 
for sequencing. PCR amplification was performed by incubating samples for 2 minutes at 95˚C, 
followed by 25 cycles of 95˚C for 20 seconds, 60˚C for 30 seconds and 72˚C for 15 seconds, 
with a final incubation of 72˚C for 2 minutes. During PCR amplification, a double-stranded 
cDNA product is formed through binding of the universal primer and barcoded primer to the 
complementary 5’ and 3’ adapters, respectively.  
 
Due to the low yield nature of our PCR product, a Polyacrylamide Gel Electrophoresis (PAGE) 
size selection step was performed to improve sample purity. Briefly, samples were run on a 
10% Tris-borate-EDTA (TBE) gel (Thermo Fisher Scientific, Massachusetts, United States) in 1X 
TBE Buffer (Life Technologies, California, United States) at 200 V for 50 minutes. The gel was 
stained in SYBR™ gold (Thermo Fisher Scientific, Massachusetts, United States) diluted 50-fold 
in 1X TBE Buffer and incubated for 10 minutes before visualising on a UV transillluminator 
(Daihan Scientific Company Ltd, Wonju-si, South Korea). Bands were cut at 150 bp and placed 
into a clean 1.5 mL microcentrifuge tube. A pestle (Mediray, Auckland, New Zealand) was used 
to crush the gel slice containing the PCR product, prior to incubation with NEXTFLEX® Elution 
Buffer for 2 hours at room temperature. A final NEXTFLEX® Bead Cleanup was performed to 
remove any remaining contaminants and to purify the RNA library product.  
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RNA library quality was assessed using a Bioanalyzer 2100 (Agilent Technologies Inc; 
California, United States). Briefly, fluorescent dye was intercalated with the RNA-library 
product and the samples were electrophoretically separated by a microfluidic-based system 
in the bioanalyzer. Smaller fragments migrate faster than larger fragments, and sample can 
be detected by their fluorescent intensity which is translated into electropherograms (peaks). 
A single peak at the expected size of the sample indicates a purified product. RNA library 
quantity was assessed using the QIAseq Library Quant System (Qiagen, Hilden, Germany) 
according to manufacturer’s instructions. RNA library samples were pooled, and diluted to 1 
ng/mL prior to next generation sequencing (NGS) at The Otago Genomics Facility. Following 
an initial QC sequencing run performed on the MiSeq System (Illumina, California, United 
States), samples were sequenced (single-end 50 base pair read length) using HiSeq 2000 
(Illumina).  An overview of the RNA-sequencing library preparation protocol is shown in Figure 
5-4, and a representative PAGE gel and bioanlyzer trace are shown in Figure 5-5. All sample 
bioanalyzer traces are available in Appendix 2.  
 
  




Figure 5-5. Representative quality control (QC) results of prepared RNA libraries.  
A) Representative DNA gel showing 150 bp product (red arrows) using a 10% TBE gel in three paired samples. 
B) Representative Agilent 2100 Bioanalyzer trace of a single EV RNA library with y-axis measuring fluorescent 
units (concentration) and x-axis measuring fragment size (bp). A single peak at 150 bp is shown between the 
lower  DNA marker (35 bp) and the upper DNA marker (10,380 bp).  
 
Figure 5-4. Small RNA sample preparation flow chart.  
Total RNA was extracted from cardiac fibroblasts prior to construction of a small-non coding RNA 
library using the NEXTFLEX® Small RNA-Seq Kit v3. Sample quality was checked on the MiSeq System 




Page | 177 
 
5.2.3 Statistical analysis 
Bioinformatics was performed on NGS data by the Australian Genome Research Facility 
(AGRF). Briefly, the adapter sequences were trimmed using Trim_Galore! and according to the 
specific trimming parameters of the NEXTflex Small RNA Seq Kit v3. Specifically, each adaptor 
sequence and four randomised degenerate bases were trimmed from each sequence. The 
processed sequences were size filtered for sncRNA by removing reads shorter than 14 base 
pairs and longer than 38 base pairs. FastQC was performed on the processed reads to evaluate 
sequence quality. The sequence reads were aligned to the Homo sapien genome (Build version 
GRCh38, GCF_000001405.39) using the STAR aligner (v2.5.3a). The unitas pipeline [299] was 
undertaken for feature annotation and quantification. Differential gene expression (DGE) 
analysis was performed using edgeR (version 3.30.3) in R verison 4.0.3. This unique package 
can detect and quantity differential expression of genes between samples using a generalised 
linear model. A significant difference in gene expression was determined if the false-discovery 
rate (FDR), the adjusted p-value for multiple comparisons, was ≤ 0.05. Following 
bioinformatics analysis, standard statistical analysis was performed on samples. Continuous 
variables were assessed for normality using the Shapiro-Wilk test. Continuous variables were 
reported as mean ± SD and categorical variables were reported as frequencies (percentages). 
Statistical differences between cardiac fibroblast mRNA expression and viability were 
assessed using paired t-tests and one-way ANOVA, respectively. Volcano plots and heat maps 
of microRNA expression were constructed in GraphPad Prism Software v.7.0.4.  
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5.3 Results  
5.3.1 Cardiac fibroblasts isolated from cardiac tissue were a purified cell population.  
Flow cytometry was undertaken on samples included in RNA-sequencing to confirm the purity 
of cardiac fibroblasts isolated from right atrial appendage cardiac tissue. Sample purity was 
assessed using a panel comprised of five markers (Zombie-NIR, CD45, CD31, vimentin, αSMA). 
A combination of positive and negative marker expression was utilised in order to characterise 
cardiac fibroblast cells, as no single cell-specific marker for fibroblasts has been identified in 
the literature. Hematopoietic contamination, identified by expression of CD45, was less than 
1% (mean ± SD, 99.4 ± 0.4% CD45- cells). Similarly, endothelial contamination was low, with 
96.8 ± 1.5% of cells negative for CD31 . Double-negative (CD45-/CD31-) cells were assessed for 
expression of vimentin and αSMA, which are well-established markers of cardiac fibroblast 
and myofibroblast phenotypes, respectively.  97.2 ± 2.7% of CD45-/CD31- cells expressed both 
markers, demonstrating a purified population of cardiac fibroblasts.  
 
5.3.2 TNF-α and TGF-β1 in vitro stimulation has opposing effects on cardiac fibroblast mRNA 
expression.  
Cardiac fibroblast cells were stimulated with TNF-α (10 ng/mL) or TGF-β1 (20 ng/mL) for 48 
hours. Phase contrast microscopy images are shown in Figure 5-6A. Cardiac fibroblast viability 
was not significantly altered by TNF-α or TGF-β1 stimulation when compared to control 
conditions, as measured by Trypan Blue staining (Figure 5-6B) and CCK-8 assays (Figure 5-6C.). 
To investigate the effects of in vitro stimulation on cardiac fibroblast phenotype, mRNA targets 
representing inflammatory markers (IL-6 and MMP-9) and myofibroblast markers (COL1A1 & 
ACTA2) were assessed. When target levels were normalised to controls, a quantitatively 
higher fold-change of MMP-9 was observed in TNF-α stimulated cells compared to TGF-β1 
(n=4, 12.85  9.52 versus 1.69   1.80, p=ns; Figure 5-6D), and a similar, albeit smaller, effect 
was observed for IL-6 mRNA expression (n=4, 2.04  0.89 versus 1.30  0.54, p=ns; Figure 5-
6D). The opposite relationship was observed in pro-fibrotic marker expression, with 
significantly lower fold-change of COL1A1 (n=4, 0.94  0.3 versus 1.74  0.31, p<0.05; Figure 
5-6E) and ACTA2 (n=4, 0.39  0.24 versus 1.96  0.76, p<0.05; Figure 5-6E) in TNF-α stimulated 
cardiac fibroblasts compared to TGF-β1 stimulation.  
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Figure 5-6. Cardiac fibroblast activity under TNF-α and TGF-β1 stimulation in vitro.  
Cardiac fibroblasts were stimulated with 0.1% BSA in ddH2O (control), 10 ng/mL TNF-α or 20 ng/mL  TGF-
β1 for 48 hours. (A) Phase contrast microscopy of cardiac fibroblasts under experimental conditions. (B) 
Trypan blue cell staining and (C) CCK-8 assays were undertaken to assess cell viability. (D) Inflammatory 
marker expression (IL-6 & MMP-9) and (E) pro-fibrotic marker expression (COL1A1 & ACTA2) were 
assessed using RT-qPCR analysis. The dotted line indicates the control expression (fold change of 1). Data 
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5.3.3  Cardiac fibroblasts synthesise EVs under control, TNF-α and TGF-β1 stimulation 
conditions.  
EV size and concentration was examined using TRPS. EV characterisation was performed for 
one sample across the three stimulation groups to confirm EV expression in cardiac 
fibroblasts, and histograms of expression are shown in Figure 5-7. The size of EVs was 
quantitatively similar between stimulation groups (control 230 ± 66.6 nm; TNF-α 254 ± 133.8; 
& TGF-β1 255 ± 95.5). Similarly, the concentration of EVs was comparable between control 
(2.78e+07 particles/mL), TNF-α (9.00e+06 particles/mL) and TGF-β1 (2.49+07 particles/mL).  
 
  
Figure 5-7. Cardiac fibroblast-derived EV size and concentration. 
Histograms were generated for a sample under each stimulation condition using qNano Gold. The 
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5.3.4 RNA-sequencing QC 
RNA-sequencing quality was assessed by examining base calling accuracy. This type of QC uses 
Phred quality scoring (Q score) to determine the probability that a given base is called 
incorrectly by the sequencer. This is considered an important indicator of sample quality, and 
a Phred quality score > 30 indicates a base call accuracy of 99.99%. We confirmed that all of 
our samples met this standard, and the mean Phred score for all samples sequenced is shown 
in Figure 5-8A. In addition, all samples demonstrated similar sequenced library sizes as shown 
in Figure 5-8B. 
  
A. B. 
Figure 5-8. Quality control (QC) results of RNA-sequencing data.  
A) The distribution of the Phred quality score per base sequence using FastQC for each of the nine samples 
(green lines). Red background indicates a Phred quality score <20, orange indicates between 20-28, and green 
>28. D) Library size of the nine EV samples run on the HiSeq 2000 sequencer. 
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5.3.5 Cardiac fibroblast-derived EVs contain microRNAs 
MicroRNA was the only type of sncRNA identified in EV samples using the UNITAS sequencing 
pipeline. In total, 1050 unique microRNAs were identified across all of the samples (Figure 5-
9A). In control cardiac fibroblast EVs, 492 (46.9%) microRNAs were identified. Under TNF-α 
and TGF-β1 stimulation, 475 (45.2%) and 618 (58.9%) microRNAs were identified, respectively. 
To assess the microRNA diversity between stimulation conditions, we created a Venn diagram 
to explore microRNA composition (Figure 5-9B).  Of the total 1050 microRNAs, the expression 
of 164 was shared between the control and stimulation conditions. TGF-β1 stimulation had 
the largest number of exclusively expressed microRNAs (n, 307), while a similar number of 
microRNAs were observed in EVs from control and TNF-α stimulation conditions (n, 185 versus 
187). Control and TGF-β1 conditions shared 81 EV microRNAs, control and TNF-α stimulation 
conditions shared 60 EV microRNAs, and 66 EV microRNAs were shared between TNF-α and 













Figure 5-9. MicroRNA expression in cardiac fibroblast EV samples. 
sncRNA libraries were created using NEXTFLEX® Small RNA-Seq Kit v3 and RNA-sequencing was 
performed. (A) The number of microRNAs (n) identified in at least one sample under each stimulation 
condition. (B) A Venn diagram of microRNA targets shared between or exclusively expressed under 
each stimulation condition.  
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5.3.6 MicroRNAs are differentially expressed in cardiac fibroblast-derived EVs between 
stimulation conditions and controls 
To assess differential microRNA expression between control samples and stimulation 
conditions, edgeR analysis was performed. To reduce the incidence of false-positive results, 
microRNAs were only included in differential gene analysis if they were found in all samples 
within at least one experimental condition. A counts per million cut-off was also set to 0.5 in 
order to remove any microRNAs from analysis with very low counts. These cut-offs reduced 
the data set to 82 unique microRNAs. A significant difference in microRNA expression between 
analysed groups was identified if the false-discovery rate (FDR), the adjusted p-value for 
multiple comparisons, was ≤ 0.05 (Figure 5-10A). When TNF-α and TGF-β1 conditions were 
compared to the control, seven unique microRNAs were identified to be differentially 
expressed. These microRNA targets are shown in Table 5-1. 
 
When EVs from TNF-α stimulated cardiac fibroblasts were compared to controls, miR-26b-5p 
(log2 fold-change, 14.1) and miR-2278 (13.7) were significantly upregulated (Table 5-1 & 
Figure 5-10B & C). TGF-β1 stimulation significantly altered cardiac fibroblast EV composition 
with significantly upregulated levels of let-7i-5p (13.9), miR-203a-3p (13.9) and miR-181a-5p 
(13.3) when compared to control conditions (Figure 5-10B & C). In comparison, miR-221-3p (-
14.8) and miR-8085-3p (-13.8) were significantly decreased in EVs under TGF-β1 stimulation.  
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Table 5-1. EV microRNA targets differentially expressed in stimulation conditions compared to 
control. 
Comparison microRNA target Log2 fold-change FDR 
Control/TNF-α 
miR-26b-5p 14.1 0.04 
miR-2278-5p 13.7 0.04 
Control/TGF-β1 
miR-221-3p -14.8 0.03 
miR-8085-3p -13.8 0.03 
let-7i-5p 13.9 0.03 
miR-203a-3p 13.9 0.03 
miR-181a-5p 13.3 0.03 
Only FDR < 0.5 included in table. 
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Figure 5-10. MicroRNA regulation by in vitro stimulation with TNF-α and TGF-β1.  
RNA-sequencing data was subjected to differential gene expression analysis using edgeR. Each stimulation 
condition (TNF-α & TGF-β1) was compared to an untreated control group. A) Volcano plots demonstrate the 
expression profile of 82 microRNA targets, with red dots showing microRNA with FDR values <0.05. B) Heat maps 
demonstrate the logCPM of microRNA in each sample within a stimulation condition. Red indicates increased 
expression, while blue indicates lower expression. C) The log2 fold change of significantly regulated microRNA in 
each stimulation group.  
 
Control Control 
TNF-α TGF-β1 Control Control 
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5.3.7 Additional differentially expressed EV microRNA targets were identified by comparing 
TNF-α and TGF-β1 stimulation conditions  
When stimulation conditions were compared, there were nine significantly differentiated 
microRNAs, and these are shown in Table 5-2. Specifically, there were five significantly 
upregulated microRNAs (miR-26b-5p, 13.9; miR-485-3p, 13.6; miR-3665-5p, 12.3; miR-1469-
3p, 10.8 & miR-221-3p, 11.2; Figure 5-11A & B) and four significantly downregulated 
microRNAs (miR-203a-3p, -15.8; miR-181a-5p, -13.3; miR-24-1-3p, -11.3 & miR-24-39, -10.9, 
Figure 5-11A & B) under TGF-β1stimulation when compared toTNF-α. A quantitative 
comparison of significantly regulated microRNAs between each differential gene analysis 
condition is shown in Figure 5-11C. Notably, no significantly different microRNAs were shared 
between all analysed groups. miR-26b-5p was significantly upregulated under TNF-α 
stimulation when compared to both control and TGF-β1 conditions. miR-221-3p, miR-203a-3p 
and miR-181a-5p were all downregulated under TGF-β1 stimulation when compared to 
control and TNF-α conditions. No significantly altered microRNA were shared between control 
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Table 5-2. EV microRNA targets differentially expressed between stimulation conditions 
Comparison microRNA target Log2 fold-change FDR 
TGF-β1/TNF-α 
miR-203a-3p 15.77637 0.03 
miR-181a-5p 13.29472 0.03 
miR-24-1-3p 11.30667 0.03 
miR-24-3p 10.86893 0.04 
miR-26b-5p -13.9236 0.04 
miR-485-3p -13.5815 0.05 
miR-3665-5p -12.2794 0.05 
miR-1469-3p -10.7935 0.05 
miR-221-3p -11.1584 0.05 
Only FDR <0.05 included in table. Fold change was TGF-β1 compared to TNF-α stimulation.  
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Figure 5-11. Differential microRNA expression between TNF-α and TGF-β1 stimulation groups.  
A) Heat maps demonstrate the expression level of microRNA in each sample within a stimulation condition. Red 
indicates increased expression, while blue indicates lower expression. B) Log2 fold-change of significantly different 
microRNAs. C) A Venn diagram of significantly altered microRNA targets shared between, or exclusively within, 
differential gene analysis conditions. Red arrow and text demonstrates decreased expression and green arrow and 
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5.4 Discussion 
Cardiac fibroblasts are the primary source of ECM in the myocardium, and consequently drive 
collagen-scar formation in repair and cardiac fibrosis in disease. In this study, EVs were 
isolated from human primary cardiac fibroblasts that had been untreated or stimulated with 
TNF-α or TGF-β1 in vitro. Using RNA-sequencing and differential gene expression analysis, 12 
unique EV microRNA targets were identified as differentially expressed across stimulation 
conditions. These findings may represent putative novel targets that may be potentially useful 
for future biomarker research in CVD.  
 
Effective cardiovascular function relies on the co-ordinated interplay of resident cardiac cells, 
which is facilitated by paracrine EV signalling [219]. Indeed, cardiac fibroblast-derived EVs 
have been implicated in modulating cellular activity in vitro [221, 300], and findings from these 
studies suggest a role for EVs in propagating repair processes following AMI. Understanding 
what changes exist in EV composition during cardiac repair is an initial step towards 
elucidating potential novel targets for measuring repair processes in vivo. Similar to cardiac 
repair phases, cardiac fibroblasts have an early pro-inflammatory phenotype followed by an 
enriched pro-fibrotic profile post-MI [301]. In this study, we have attempted to replicate these 
phenotypic states in vitro by polarizing cardiac fibroblasts with either TNF-α or TGF-β1. This 
study chose to treat cardiac fibroblasts separately under these conditions, instead of 
sequentially with TNF-α followed by TGF-β1, as this provided an opportunity to assess novel 
biomarker targets under each condition. Thus, we were able to ascertain if candidate 
biomarkers were associated with pro-inflammatory or pro-fibrotic processes, respectively.  
 
TNF-α is a potent pro-inflammatory stimulus, and is significantly upregulated following AMI 
[302]. TNF- α has a polarizing effect on cardiac fibroblast activity in vitro, demonstrated by 
increased pro-inflammatory cytokine secretion and MMP synthesis [212, 213]. Here, we 
demonstrate for the first time that the microRNA composition of cardiac fibroblast-derived 
EVs is altered under TNF-α stimulation. Specifically, we identified a significant increase in miR-
26b-5p and miR-2278-5p expression when compared to unstimulated conditions. 
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The role of miR-26b-5p in CVD is newly emerging within the literature. Jakob et al. [303] 
previously demonstrated that decreased circulating levels of miR-26b-5p were significantly 
associated with development of MACE, defined as cardiovascular related death and re-
infarction, within 1 year of AMI onset. Additionally, this study further showed that miR-26b-
5p had an increased sensitivity to predict MACE beyond that of the traditional risk-associated 
markers high-sensitivity troponin T and NT-proBNP [303]. In addition to its relationship with 
MACE, increased circulating levels of miR-26b-5p have also been identified in hypertensive 
patients with left ventricular hypertrophy (LVH) when compared to healthy volunteers [304]. 
These observational studies suggest a dichotomous role for miR-26b-5p in CVD that may be 
associated with ventricular remodelling processes. Indeed, Tang et al. [305] has previously 
shown that miR-26b-5p expression significantly inhibits collagen synthesis, αSMA and 
connective tissue growth factor (CTGF) production in murine cardiac fibroblasts in vitro, and 
this effect could be rescued by the expression of circRNA_000203 which is a direct binding 
target of miR-26b-5p. These findings indicate an anti-fibrotic role for miR-26b-5p in cardiac 
fibroblasts, and supports its upregulation under pro-inflammatory conditions. Alongside miR-
26b-5p, miR-2278-5p was also significantly upregulated in EVs from cardiac fibroblasts under 
TNF-α stimulation. These findings are novel, as to the best of our knowledge miR-2278-5p has 
not previously been linked to CVD.  
 
Expansion of cardiac fibroblasts and differentiation into their matrix-synthetic phenotype is 
essential for cardiac repair following ischaemic injury. TGF-β1 signalling is a critical stimuli for 
myofibroblast formation [306]. In this study, we demonstrated that in vitro stimulation of 
cardiac fibroblasts with TGF-β1 for 48 hours could induce a myofibroblast-like phenotype, as 
observed by increased collagen type I synthesis and αSMA expression. In addition, we also 
demonstrated that TGF-β1 stimulation could alter EV microRNA composition. Specifically, we 
identified five differentially expressed EV microRNA targets. 
 
Let-7i-5p, miR-203a-3p and miR-181a-5p were all significantly upregulated when compared to 
control conditions. The Let-7 family comprises 13 highly conserved members and is closely 
linked to CVD development and progression [307]. Let-7i-5p is a central regulator of 
inflammation and fibrosis in angiotensin II induced cardiac remodelling. Specifically, Wang et 
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al. [308] demonstrated that intravenous administration of let-7i-5p could dramatically 
attenuate inflammatory cell infiltration and myocardial fibrosis mechanisms in the murine 
myocardium in vivo following angiotensin II infusion. In this same study, let-7i-5p was primarily 
synthesised by cardiac fibroblasts and negatively regulated the expression of inflammatory 
and collagen-specific factors [308]. Combined, these findings indicate an important role for 
let-7i in modulating myocardial remodelling, and these actions may be mediated by the 
cardiac fibroblast.  
 
Levels of miR-203a-3p and miR-181a-5p were also significantly upregulated in EVs from 
cardiac fibroblasts under TGF-β1 stimulation. Previous experimental studies have implicated 
both microRNA in myocardial remodeling processes post-MI [309, 310]. Zhang et al. [309] has 
previously shown that murine miR-203 overexpression in the myocardium, a comparative 
microRNA to human miR-203a-3p, can significantly improve cardiac function and reduce 
infarct size following experimental MI. The mechanism of action was associated with 
attenuation of mitochondria-mediated apoptosis of cardiomyocytes, suggesting a cardio-
protective role for miR-203 expression. Chen et al. [310] has recently shown that miR-181a is 
increased in the murine myocardium following experimental MI, and is closely associated with 
myocardial fibrosis. When over-expressed in murine cardiac fibroblasts in vitro, miR-181a 
increased cellular proliferation and synthesis of collagen and fibronectin, which was mediated 
by the interaction between miR-181a and TGF-β receptor III expression [310]. Thus, unlike 
miR-203a, increased expression of miR-181a may play a detrimental role in cardiac fibrosis 
progression. This suggests that EV enriched microRNA under TGF-β1 stimulation have 
potentially dichotomous roles in cardiac repair.  
 
TGF-β1 stimulated cardiac fibroblasts also had downregulated expression of miR-221-3p and 
miR-8085-3p when compared to unstimulated conditions. miR-221 has been well investigated 
in cardiac disease. Specifically, in vivo miR-221 mimic injections were shown to reduce 
collagen accumulation and myofibroblast differentiation in the murine myocardium post-MI 
[311], while pharmacological inhibition of miR-221 increased angiotensin II induced fibrosis 
and LV dysfunction in pressure-overload model of heart failure [312]. Cardiac fibroblasts are 
suggested to be the main cellular source of miR-221 in the myocardium [312]. In addition, 
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miR-221 expression negatively regulates TGF-β signalling within the cardiac fibroblast, by 
reducing ECM synthesis and myofibroblast differentiation. Taken together, findings from 
experimental studies indicate that miR-221 expression is anti-fibrotic and is closely linked to 
TGF-β signalling, supporting the reduced expression observed under TGF-β1 stimulation. 
 
When TNF-α and TGF-β1 stimulation conditions were compared, nine differentially expressed 
EV microRNAs were observed. Four of these EV microRNAs were previously identified as 
differentially expressed when control conditions were compared to stimulation conditions. 
These included miR-203a-3p, miR-181a-5p, miR-26b-5p and miR221-3p. Of the remaining five 
microRNAs, two belonged to the miR-24 family, mir-24-3p and miR-24-1-3p. This family of 
microRNAs have previously been linked to CVD [313]. A murine model of MI demonstrated 
that in vivo delivery of lentivirus-miR-24 improved heart function by reducing myocardial 
infarct size and cardiac fibrosis [314]. In this same study, in vitro culture of cardiac fibroblasts 
demonstrated that miR-24 transfection reduced collagen synthesis and myofibroblast 
transdifferentiation, and this was likely associated with its upstream regulatory role in TGF-β1 
signalling [314]. This suggests a pro-fibrotic role for miR-24 expression, and this supports its 
upregulation under TGF-β1 stimulation when compared to TNF-α conditions. Additionally, 
miR-485-3p, miR-3665-5p and miR-1469-3p were downregulated in TGF-β1 stimulated EVs 
compared to TNF-α stimulation. These microRNAs are newly emerging within the literature, 
and further research is required to identify their mechanistic activity in CVD.  
 
In this study, cardiac fibroblasts were isolated from human myocardial tissue and cultured in 
vitro to examine EV sncRNA composition. The use of primary cell culture provided an 
opportunity to assess cardiac fibroblast activity that closely resembled cellular physiology 
within the human myocardium. In addition, experiments were conducted during an early 
cellular passage in order to reduce divergence from in vivo morphology and function. A further 
strength of this study was the cellular source of cardiac fibroblasts, which were collected from 
CAD patients. Therefore, cells included in this study had been exposed to an in vivo 
microenvironment associated with the development and progression of CAD, ensuring these 
cells were biologically relevant to investigate in the context of AMI. A further strength 
associated with this study was the use of a mono-cellular culture system. Unlike measuring 
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EVs from plasma, this creates certainty that EVs sequenced were derived from a single cell 
population. Consequently, findings in this Chapter support previous literature demonstrating 
cardiac fibroblast associated microRNA expression, such as let-7i-5p and miR-181a-5p [310, 
314]. In addition, this experimental design also provides an opportunity to characterise novel 
microRNA targets previously unlinked to cardiac fibroblasts, such as miR-2278-5p and miR-
3365-5p. 
 
While these findings are exciting and novel, the next step for experimentation is validation of 
these results. RNA-sequencing has become a powerful tool for quantification and discovery of 
transcriptome targets, and advances in sequencing technology and bioinformatics have 
increased the reliability of this technique. Indeed, a recent study conducted by Everaert et al. 
[315] demonstrated a high concordance between RNA-sequencing data and RT-qPCR 
validation, with only 1.8% of total genes identified as severely non-concordant. However, the 
context of the current study must be taken into consideration when evaluating the benefit of 
independent validation, and the unique analysis of sncRNAs in EVs suggests external validation 
should be undertaken. Thus, we intend to perform RT-qPCR on the 12 differentially expressed 
EV microRNA targets identified in this study. Specifically, we will measure gene expression in 
the three samples included in RNA-sequencing, as a well as an additional three samples 
treated under the same experimental conditions. This will provide an opportunity to confirm 
technical reproducibility of the RNA-sequencing results, as well as identify if these transcripts 
show the same trends in similar biological samples.  
 
The term EV encompasses all extracellular membrane-enclosed vesicles. However, EVs can be 
further classified into sub-groups based on cellular biogenesis and particle size [217]. 
Exosomes are the smallest vesicles (~30 to 100 nm) and are generated intracellularly, 
microvesicles are mid-sized particles (~100 to 1,000 nm) and are formed by plasma membrane 
budding, while apoptotic bodies are the largest vesicles (~800 to 5,000 nm) and are formed 
by cells undergoing apoptosis [217]. In this study, we captured all EVs synthesised by cardiac 
fibroblasts in vitro and have not delineated the specific sub-types that may be present. This 
was an appropriate methodology for an initial discovery approach. However, future studies 
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incorporating size and imaging analysis could be undertaken to assess the types of EVs 
produced by cardiac fibroblasts under the differential stimulation conditions.  
 
Complementary to particle size is EV classification by surface protein expression. The minimal 
information for studies of extracellular vesicles (MISEV) guidelines [316] recommends the 
measurement of at least three positive protein markers, including transmembrane or lipid-
bound proteins and cytosolic proteins, as well as the measurement of a negatively expressed 
protein marker, such as calnexin. In addition, MISEV also recommends inclusion of cryo-
transmission electron microscopy (TEM), which allows for the visualisation of the double 
membrane phospholipid bilayer of EVs. Unfortunately due to sample restrictions and COVID-
19, these analyses was not completed within the time constraints of this thesis, but will be 
prioritised for completion following thesis submission. Fortunately, EV experimentation is well 
established within our laboratory and EV purity has previously been confirmed.   
 
In addition to standard surface markers, parental cell markers can also be measured to 
phenotype EV origin. This is of significance for measuring EVs in circulation, as the EV 
microRNA targets identified within this study may also be expressed by additional cell types. 
Thus, surface marker phenotyping could provide increased assurance that the EV origin for 
these targets were derived from fibroblast cells when measured in circulation. One 
methodology for measuring surface marker EV expression is flow cytometry [317]. Indeed, a 
number of studies have demonstrated the ability of endothelial-associated EVs, identified by 
CD31+ surface expression, to predict adverse cardiovascular outcomes in ACS patients [296, 
318]. In this study, we have characterised cardiac fibroblasts by the absence of endothelial 
(CD31-) and haematopoietic (CD45-) marker expression and positivity for vimentin and αSMA. 
We propose these same criteria could be applied to EV sized particles for measurement of EVs 
in circulation.  
 
We utilised size-exclusion chromatography, which separates particles based on size as they 
flow through a gel-based column, to isolate EVs from cell culture samples. This methodology 
has been shown to minimally alter EV characteristics when compared to other isolation 
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techniques [319], and has been demonstrated to produce pure EVs with minimal protein 
contamination [320]. The combination of sample purity with the additional scalability, 
reproducibility and time efficiency of this technique [321], makes this methodology 
transferable to a clinical setting. Thus, further emphasising the clinical utility of findings from 
this Chapter.  
 
 
This thesis has created a roadmap for good experimental design for examining biomarkers in 
AMI. Therefore, we propose to investigate the role of candidate EV microRNAs in the setting 
of AMI using a similar path described in Chapters 2 to 4. Specifically, we are interested in 
identifying if these microRNA candidates are differentially expressed in healthy volunteers and 
AMI patients, and if they are useful for predicting adverse ventricular remodeling processes. 
Prior research has demonstrated that some of the candidate microRNAs are differentially 
expressed in dilated cardiomyopathy [311, 322], heart failure [323, 324] and CAD [325, 326] 
when compared to healthy volunteers. However, this research is mostly saturated by miR-
26b-5p, let-7i-5p, miR-181a-5p and miR-221-3p, and the remaining differentially expressed EV 
microRNAs remain largely unexplored. Additionally, the literature linking these specific 
candidate microRNAs to clinical outcomes in CVD have focused on free-circuiting levels, and 
minimal attention has been given to microRNA encapsulated in EVs. 
 
EVs are powerful biomarker tools that are stably expressed in the circulation with microRNA 
cargo protected from degradation by the EV phospholipid bilayer membrane [327]. Indeed, 
Jansen et al. [296] demonstrated in a cohort of stable CAD patients that miR-126 and miR-
199a were predictive of MACE, defined as cardiac related death, revascularisation and re-
infarction within 6 years, only when measured in EVs. Consequently, examination of how the 
12 EV microRNA candidates identified in this study perform as biomarkers in adverse 
remodelling is of significant interest.  
 
In Chapter 4, we examined the prognostic utility of traditional ECM biomarkers to predict 
development of systolic and diastolic dysfunction in AMI patients. We propose that measuring 
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EV targets in plasma from this cohort is an appropriate clinical endpoint for future 
examination. Furthermore, in Chapter 2 we demonstrated two statistical techniques capable 
of combining biomarkers together, EFA and cluster analysis. We demonstrated some success 
for combined analysis of ECM biomarkers in predicting the development of systolic 
dysfunction. Jakob et al. [303] has previously shown that a combination of microRNAs, 
specifically miR-26b-59, miR-660-5p and miR-320a, yielded increased prognostic utility to 
predict MACE in AMI patients when compared to single microRNA analysis. Thus, single and 
combined analysis of candidate EV microRNA targets would be appropriate for future studies.  
Additionally, another potential avenue for biomarker research would be investigating the 
longitudinal profile of candidate EV microRNA targets in AMI patients. Using the cohort 
examined in Chapter 3, we could assess if EV targets demonstrated a biphasic pattern that 
matched in vitro stimulation conditions. This type of assessment would be particularly useful 
to examine the potential prognostic utility of cardiac fibroblast-derived EVs to non-invasively 
the cardiac repair profile of patients following AMI.  
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5.5 Limitations 
There are some limitations associated with in vitro cell culture and the methodology 
undertaken in this study that should be addressed. A common phenomena identified in the 
literature suggests isolated cardiac fibroblasts spontaneously adopt a myofibroblast 
phenotype in 2-dimensional cell culture [328]. This was confirmed in our current study using 
flow cytometry, which demonstrated that unstimulated cardiac fibroblasts were 
approximately 97% positive for αSMA. However, through RT-qPCR analysis we showed that 
stimulation with TNF-α or TGF-β1 appropriately polarized cardiac fibroblasts in the direction 
we expected regardless of original marker expression. Additionally, in vitro assessment still 
remains the most appropriate non-invasive tool to investigate human cellular physiology. The 
myocardial microenvironment contains a number of molecular factors that influence cardiac 
fibroblast phenotype in combination [141]. In this experiment, we stimulated cells with a 
single pro-inflammatory or pro-fibrotic stimulus, and this unlikely replicates the exact in vivo 
phenotype. However, we were able to demonstrate that genetic marker expression of IL-6, 
MMP-9, collagen type I and αSMA appropriately matched the literature under differential 
stimulation conditions. In addition, a well-accepted limitation of EV research is a lack of an 
ideal methodology for pure EV isolation [329]. As a result, isolated EV fractions may still 
contain contaminating proteins or lipids un-associated with target EVs. We have mitigated this 
limitation by using SEC, which is a superior methodology for EV purification compared to 
traditional differential centrifugation techniques  [330]. A further limitation associated with 
this study, is the FBS component included in cell culture media which also contains non-human 
contaminating EVs. While this does not create an issue for RNA-sequencing, as results are 
aligned to the human genome, the addition of external EVs may alter cellular physiology. 
Therefore, to mediate the effects of FBS-associated EVs we firstly depleted EVs from the FBS 
using ultracentrifugation prior to creating cell culture media. In addition, we also used a low 
concentration of FBS supplemented media during experimentation. Despite undertaking 
sncRNA sequencing, only microRNAs were identified in our sample and additional species, 
such as PIWI-interacting RNAs, were not shown. The reason for this may be associated with 
low sample diversity due to the context of measuring sncRNAs in EVs from primary cells. 
However, further data investigations using additional sequencing pipelines, such as the 
exceRpt pipeline, may be warranted to confirm these findings 
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5.6 Conclusion 
We have demonstrated that cardiac fibroblasts synthesise EVs in vitro, and microRNA 
composition is altered under TNF-α and TGF-β1 stimulation. These findings suggest that 
cardiac fibroblasts differentially regulate EV microRNA expression under certain pro-
inflammatory and pro-fibrotic conditions. We suggest that these 12 differentially expressed 
EV microRNA targets could be useful as potential novel biomarkers in AMI. However, further 
validation and investigation is warranted in order to assess their prognostic utility.  
 
  













 Summary and future directions. 
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6.1 Summary   
Initially in this thesis, we were interested in investigating the feasibility of combining 
circulating ECM biomarkers. Specifically, in Chapter 2 we aimed to use EFA and cluster analysis 
to investigate the interrelationships between biomarkers and their ability to separate patients 
into specific ECM clusters, respectively. We measured plasma levels of FGFb, MMP-2, -3, -8, -
9, periostin, PINP, osteopontin, TGF-β1, TIMP-1, -4 and VEGF in a cohort of 140 AMI patients 
on day three following hospital admission. Of the 10 detectable biomarkers measured, EFA 
grouped eight into a two-factor solution, which comprised three biomarkers in Factor 1 and 
five biomarkers in Factor 2. Interestingly, ECM biomarkers were not separated based on 
biological function alone. Using cluster analysis, patients were separated into three distinct 
clusters based on ECM biomarker levels. Cluster One had increased levels of MMP-8, MMP-9, 
and TGF-B1. Cluster Two had elevated levels of MMP-2, MMP-3, osteopontin, periostin and 
TIMP-1, and increased high-sensitivity troponin T and GRACE scores. Cluster Three had 
decreased levels of ECM biomarkers. Combined, these findings demonstrate that circulating 
ECM biomarkers contain collinear relationships and combination using cluster analysis, which 
can account for these complex interrelationships, separated patients into distinct ECM profiles 
that were associated with differential patient risk.  
 
In Chapter 3, we explored the variability of circulating ECM biomarker levels in a prospective 
cohort of 23 AMI patients with biomarker measurements recorded across four-time points 
between hospital admission and six months following AMI onset. We aimed to assess if 
differences existed between biomarker levels in AMI patients when compared to 12 healthy 
volunteers, and showed that levels of MMP-8, MMP-9, PINP and TIMP-1 were elevated at one 
or more of the time points measured, while levels of MMP-3 and periostin were significantly 
lower across all hospitalisation measurements. In addition, MMP-2, MMP-8 and TIMP-1 
remained elevated at the six-month time point, and this potentially reflects continued 
molecular activity beyond acute cardiac repair. Additionally, this Chapter aimed to assess if 
biomarker levels were temporally altered across measured time points in AMI patients. While 
temporal variation was observed in some biomarkers, there was no clear trend in maximal 
and minimum levels within or between circulating biomarkers. Finally, this study aimed to 
identify if clinical characteristics and cardiac function parameters were associated with ECM 
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biomarker levels in AMI patients. Clinical characteristics explained some, but not all, of the 
variance observed in ECM biomarker levels, while AUC Troponin T was only associated with 
MMP-3 levels and baseline LVEF was inversely associated with MMP-2 and periostin.  Overall, 
findings from this Chapter identified a panel of seven ECM biomarkers that were significantly 
different in AMI patients compared to healthy volunteers, and while some variation could be 
described by clinical parameters, this study suggests a majority of variation remained 
unexplained.  
 
Following the identification of a combined biomarker methodology in Chapter 2 and a panel 
of potential ECM biomarkers in Chapter 3, we were then interested in identifying the 
prognostic utility of ECM biomarkers in Chapter 4. Specifically, the aim of this Chapter was to 
assess if EFA or cluster analysis of MMP-2 -3, -8, -9, periostin, PINP and TIMP-1 could predict 
the development of systolic or diastolic dysfunction in AMI patients. In this Chapter, we 
showed that assignment into Cluster One, MMP-8 levels, EFA Factor 1 scores, as well as 
prescription of ACE inhibitors at discharge, peak troponin levels above median levels and 
current smoking were univariate predictors of impaired systolic function measured within 1 
year post-MI. Upon multivariate analysis, Cluster One assignment and clinical variables 
remained independent predictors of systolic dysfunction development. Furthermore, when 
diastolic dysfunction was examined in a subgroup of 100 AMI patients, neither single 
biomarkers nor combined biomarker analysis could differentiate between patients with 
normal function, diastolic dysfunction or indeterminate function. Here, we demonstrate 
improved prognostic utility of cluster analysis when compared to single biomarker analysis for 
the assessment of systolic dysfunction development in AMI patients. However, this combined 
biomarker technique was not transferable to diastolic dysfunction, and superior novel 
biomarkers may need to be investigated for improved assessment.  
 
One approach for investigating novel biomarkers in AMI was to explore biomarkers that may 
potentially represent cellular activity. Thus, in the final experimental chapter of this thesis we 
aimed to examine if the sncRNA composition of EVs isolated from human primary cardiac 
fibroblasts were altered under TNF-α or TGF-β1 stimulation in vitro. Using RNA-sequencing, 
we identified 12 microRNAs differentially expressed between stimulation conditions. 
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Specifically, miR-26b-5p and miR-2278-5p were significantly upregulated in EVs under TNF-α 
stimulation compared to control conditions. In comparison, Let-7i-5p, miR-203a-3p and miR-
181a-5p were upregulated in EVs under TGF-β1 conditions compared to controls, while miR-
221-3p and miR-8085-3p were significantly downregulated. When TNF-α and TGF-β1 
stimulation conditions were compared, miR-221-3p, miR-203a-3p, miR-181a-5p and miR-26b-
5p were further identified as differentially regulated, along with miR-485-3p, miR-3665-5p, 
miR-1469-3p, miR-24-1-3p and miR-24-3p. To the best of our knowledge, this is the first study 
to investigate cardiac fibroblast derived-EV sncRNA composition under stimulation conditions 
which reflect the cardiac repair microenvironment. Subsequently, these findings provide a list 
of putative targets for future investigation in CVD biomarker research.  
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6.2 Limitations  
While limitations were minimised in this thesis by careful planning and experimental 
execution, some overarching limitations remain and should be acknowledged. All of the AMI 
cohorts included in this thesis (Chapters 2-4) were observational in nature. Although this 
provided an opportunity to include ‘real world’ patients that reflect a true New Zealand AMI 
population, it limited our ability to control for differences in patient management and this 
potentially introduced confounding variance into our studies.  
 
Chapters 2 to 4 of this thesis focused on circulating ECM biomarkers in AMI, and inherent 
limitations exist with this type of research. While we have asserted that circulating ECM 
biomarker levels reflect intra-cardiac biological changes, this has not been proven within this 
thesis. Indeed, the word ‘biomarkers’ is a portmanteau for biological markers, and describes 
a surrogate measure for molecular activity [75]. This limitation is further confounded by the 
non-specific nature of the ECM proteome, which participates in systemic wound repair 
processes in the human body [331]. Thus, while the ECM biomarkers included in this study are 
firmly cemented as important regulators of cardiac repair and remodelling (see Chapter 1, 
Section 1.4), we have not specifically linked peripheral levels to intra-cardiac activity. 
Addressing this limitation was beyond the scope of this thesis, as measurement of intra-
cardiac ECM activity was both clinically and ethically not appropriate in these study cohorts. 
However, we mediated this limitation as best we could by carefully selecting patient cohorts 
that excluded for conditions that may influence peripheral ECM biomarker levels. For 
example, all three AMI cohorts excluded patients with chronic heart failure in order to 
mitigate potential prior LV remodelling. In addition, the prospectively recruited cohort in 
Chapter 3 also excluded patients with evidence of significant baseline systolic dysfunction. 
 
This thesis included a finite number of biomarkers to characterise ECM activity in AMI. These 
markers were carefully selected based on previous experimental and clinical literature. 
However, cardiac repair and remodelling processes are performed by a myriad of ECM 
molecular factors, of which we only scratched the surface. While we measured a diverse group 
of ECM biomarkers that comprised growth factors, collagen propeptides, ECM turnover 
enzymes and matricellular proteins, we cannot account for the possibility that a more optimal 
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set of biomarkers could have been measured. As such, proteomic techniques could have been 
employed to overcome this limitation, and these are discussed in more detail in Section 6.3. 
 
Study populations included in this thesis were of moderate size. For single time point studies 
conducted in Chapters 2 and 4, cohort sizes were ≥ 100 participants. For the longitudinal time 
point study in Chapter 3, a smaller prospective cohort of 23 AMI patients and 12 healthy 
volunteers was included. Single time point studies were of sufficient size to investigate 
statistical techniques for biomarker combination (Chapter 2) as well as relationships with 
systolic or diastolic dysfunction (Chapter 4), while the longitudinal study (Chapter 3) was of an 
appropriate size to investigate trends in biomarker levels across four measured time points. 
However, in some instances these modest populations reduced our ability to investigate 
associations between specific ECM biomarkers and clinical factors. Of significance, all three 
studies were unable to meaningfully examine the relationship between biomarkers and 
ethnicity. As described in Chapter 1, Māori and Pacific people are disproportionately 
represented in CVD statistics and are at increased risk for adverse secondary outcomes 
following AMI [5]. Therefore, cohort sizes enriched for these at risk-groups should be 
prioritised in future studies.  
 
Biomarker measurements were undertaken using three biochemical assay techniques, which 
included ELISA, Luminex and CBA. Luminex and CBA are both multiplexing assay techniques 
that allow for the simultaneous measurement of multiple analytes within a single sample. 
Utilising these types of assays is of significance in the setting of biomarker research, as it 
provides more effective use of time and precious sample. While ELISAs are more time 
consuming to undertake, they commonly provide more sensitive measurements. In this study, 
multiplexing assays were prioritised due to the emphasis of combined biomarker research, 
and ELISA were undertaken in analytes that could not be included in multiplexing assays due 
to cross-reactivity (TIMP-1 & TIMP-4), pre-sample preparation requiring acidification and 
neutralisation (TGF-B1) or analyte unavailability (PINP). Importantly, all of the assays included 
in this thesis were commercially sourced and validated for use in plasma samples. However, 
in instances where analytes were unmeasurable, specifically FGFb and VEGF, we did not 
investigate alternative measurement techniques, and therefore cannot rule out the possibility 
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that these assays suffered from sensitivity or specificity issues. However, developing accurate 
measurement tools was not the purpose of this thesis. Instead, we were interested in using 
commercially available pre-existing tools and applying them to a clinical context.   
 
This study included two statistical methodologies to combine biomarkers in AMI, EFA and 
cluster analysis. While both techniques capture complexity of collinear data, EFA categorises 
variables based on correlations and cluster analysis categorises cases based on distance 
matrices. Thus, groupings identified within a population are specific to internal variable 
relationships, and may not be transferrable to a generalised worldwide population. 
Unfortunately, this is a common limitation for statistical techniques that rely on 
interrelationships within a population. However, we have mitigated this limitation by selecting 
cohorts that are reflective of a generalised NZ population in regards to patient presentation, 
ethnicity, risk factors and medication and management.  
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6.3 Future directions 
Findings from this thesis have highlighted the potential clinical utility of ECM biomarkers and 
techniques for combining biomarkers in the setting of AMI. Additionally, novel putative 
targets have also been identified for future potential clinical application. 
 
As described in the limitations section, we characterised ECM activity in AMI patients based 
on the levels of 12 carefully selected biomarkers. A key advantage of undertaking biochemical 
assays is their immediate clinically applicability. However, commercially available assays are 
limited by the number of analytes that can be measured and are biased towards more popular 
and well investigated markers. Thus, while this strategy was valid for application in this thesis, 
alternative methodologies exist for biomarker identification. Specifically, proteomics is an 
unbiased platform that utilises mass spectrometry techniques to identify an entire population 
of proteins within a sample [332]. In this thesis, we were unable to delineate between normal 
diastolic function, diastolic dysfunction or indeterminate function using single or combined 
biomarker analysis. Thus, potentially a more optimal biomarker panel could have been 
highlighted by undertaking a proteomics based technique in this cohort. This methodology is 
not currently appropriate for clinical implementation but has the advantage of detecting novel 
proteins within a sample.  
 
In Chapter 4, we characterised ventricular function in a cohort of AMI patients who received 
echocardiogram measurements within 1 year following symptom onset. The development of 
systolic and diastolic dysfunction is a clinically meaningful endpoint in CVD research, and 
describes the manifestations of long-term adverse remodelling. As suggested in the discussion 
of Chapter 5, a future experiment could investigate the relationship between these endpoints 
and the putative EV microRNA targets differentially expressed in cardiac fibroblasts in vitro. 
However, we have also demonstrated in this thesis the potential benefit of combined 
biomarker analysis in predicting systolic dysfunction in AMI patients. Thus, a future direction 
for research could be the combination of EV microRNA targets identified in Chapter 5 with 
traditional ECM biomarkers measured in Chapter 4. This would provide an opportunity to 
measure a group of circulating parsimonious factors that comprise cellular activity along with 
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the ECM proteome, and may more comprehensively capture ECM repair and remodelling 
processes.  
 
While we successfully predicted systolic dysfunction in AMI patients at a univariate and 
multivariate level, these findings were not replicated for diastolic dysfunction. The reason for 
this prognostic discrepancy remains undetermined, but may be associated with the 
pathophysiology of diastolic dysfunction, which is biologically distinct from systolic 
dysfunction [68]. Potentially measuring an alternative endpoint that precedes long-term LV 
remodelling is a more optimal strategy for developing prognostic biomarker tools. cMRI is the 
gold-standard imaging technique to visualise injured myocardium with high spatial and 
temporal resolution [333]. Myocardial salvage can distinguish between the ischaemic 
myocardium distal to the infarct artery, termed the area at risk, and the final necrotic 
myocardium [334]. Previous studies have demonstrated the prognostic utility of the 
myocardial salvage index, which describes the proportion of non-necrotic myocardium within 
the area at risk, to predict adverse outcomes and LV remodelling when measured acutely 
following AMI [335, 336]. To date, no studies have examined the relationship between ECM 
biomarkers and myocardial salvage index, and we propose this combination is a future 
direction for this research. Using a similar design to Chapter 4, we could assess the relationship 
between ECM biomarkers measured during patient hospitalisation and myocardial salvage 
index assessed acutely post-MI. Establishing an association between ECM biomarkers and 
improved or reduced myocardial salvage index would provide an opportunity to identify a 
high-risk population that may go on to develop adverse outcomes or long-term LV 
remodelling.  
 
In considering the results from Chapter 5, it would be interesting to examine how cardiac 
fibroblast EVs modulate resident cardiac cell activity in vitro. This is of significance in the 
context of cardiac repair, as we have demonstrated differentially expressed cardiac fibroblast-
derived EVs under pro-inflammatory and pro-fibrotic conditions of which represent early 
inflammatory and proliferative repair phases, respectively. Thus, examining how resident 
cardiac cell activity is altered by differentially expressed EVs could elucidate a temporally 
diverse role for cardiac fibroblasts during AMI. To investigate this, we propose to measure the 
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most abundant cardiac resident cells within the myocardium of which include cardiomyocytes, 
cardiac fibroblasts, endothelial cells and VSMC. The types of activity investigated would be 
cellular specific, but may include broad physiological processes such as proliferation, 
migration and invasion. If altered activity were identified in one or more cardiac cell types, we 
would propose to next elucidate the specific microRNA responsible by introducing mimics and 
silencing RNA inhibitors. These are commonly used within the literature [305, 308] and 
provide an opportunity to overexpress or knockdown specific microRNA targets in order to 
determine the precise mechanistic role of paracrine signalling. While this type of research is 
not directly linked to biomarker development, it does provide an opportunity to examine how 
cardiac fibroblasts could modulate the myocardial microenvironment during AMI, and 
subsequently, could provide more specific EV microRNA targets associated with abhorrent or 
cardio-protective signalling.  
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6.4 Conclusion 
Together, findings from this thesis suggest that a combined biomarker approach may more 
optimally capture ECM activity than single biomarkers following AMI. Specifically, using EFA 
we demonstrated that circulating ECM biomarkers were collinear and could not be separated 
based on biological function alone. Application of cluster analysis identified distinct ECM 
profiles in AMI patients with differential risk associations. In addition, when cluster analysis 
was applied to a cohort of patients with echocardiograms within 1 year of AMI onset, cluster 
assignment was superior to single biomarker analysis for independently predicting 
development of systolic dysfunction. However, neither combined biomarker analysis, nor 
single biomarker analysis could distinguish between patients with normal diastolic function, 
diastolic dysfunction and indeterminate function. Thus, the final experimental study in this 
thesis examined a more novel approach for measuring ECM activity by investigating cardiac 
fibroblast-derived EVs under stimulation conditions that represented early myocardial repair. 
A selection of 12 EV microRNAs were identified as differentially expressed across untreated, 
pro-inflammatory and pro-fibrotic stimulation conditions, and we suggest these may 
represent a novel group of putative targets for future biomarker research in AMI. Combined, 
this thesis explores robust methodologies for combining measurements that represent a 
complex pathophysiological system. We suggest that these methodologies could be applied 
to further complex biological processes in AMI, such as inflammation or oxidative stress. 
Alternatively, concepts within this thesis could also be applied to additional 
pathophysiological conditions orchestrated by complex networks of immune and molecular 
factors, such as cancer or tissue-specific fibrotic diseases.  
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Chapter 2 - Reagents 
 
1x Wash Buffer (v/v), pH 7.2-7.4  
Reagent Conc. (%) Source 
PBS 99.9 
Sigma-Aldrich, Missouri, United States 
Tween-20 0.1 
Abbreviations: PBS, phosphate-buffered saline 
 
 
1x Blocking Buffer (w/v) 
Reagent Conc. (%) Source 
PBS 98.0 Sigma-Aldrich, Missouri, United States 
Skim Milk Powder 2.0 
Thermo Fisher Scientific, Massachusetts, United 
States 
Abbreviations: PBS, phosphate-buffered saline 
 
 
Reagent Diluent (w/v)  
Reagent Conc. (%) Source 




MP Biomedicals New Zealand Ltd, Auckland, New 
Zealand 
Abbreviations: PBS, phosphate-buffered saline 
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Substrate Solution (v/v) 
Reagent Conc. Source 
Na-Acetate, 0.11 M, 
pH 5.5 
108 mM 
Sigma-Aldrich, Missouri, United States 
TMB (in DMSO)  0.41 mM 
H2O2, 3% 0.003% 
Thermo Fisher Scientific, Massachusetts, United 
States 
Abbreviations: TMB, 3,3′,5,5′-Tetramethylbenzidine; DMSO, Dimethyl sulfoxide; H2O2, Hydrogen peroxide 
 
 
Stop Solution  
Reagent Conc.  Source 
H2SO4 1.8 M Sigma-Aldrich, Missouri, United States 
Abbreviations: H2SO4, Sulphuric acid 
 
Chapter 5 - Reagents 
 
EV-depleted 10% Growth Media (v/v), filter-sterilized using 0.22 µM  




Thermo Fisher Scientific, Massachusetts, United 
States 
Fetal Bovine Serum 10.0 Moregate Biotech, Bulimba, Australia 
L-Glutamine 1.0 In vitro technologies, Auckland, New Zealand 
Penicillin/ 
Streptomycin 
1.0 Life Technologies, California, United States 
Amphotericin 0.1 
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EV-depleted 2% Growth Media (v/v), filter-sterilized using 0.22 µM  




Thermo Fisher Scientific, Massachusetts, United 
States 
Fetal Bovine Serum 2.0 Moregate Biotech, Bulimba, Australia 
L-Glutamine 1.0 In vitro technologies, Auckland, New Zealand 
Penicillin/ 
Streptomycin 
1.0 Life Technologies, California, United States 
Amphotericin 0.1 
Thermo Fisher Scientific, Massachusetts, United 
States 
 
Staining Buffer (v/v) 
Reagent Conc.  Source 




MP Biomedicals New Zealand Ltd, Auckland, New 
Zealand 
Sodium azide 0.1 % Sigma-Aldrich, Missouri, United States 
EDTA  5 mM 
Thermo Fisher Scientific, Massachusetts, United 
States 






















Appendix Figure 1. Elbow method for Cluster Analysis in Chapter 2 demonstrates a three 
cluster solution. The elbow method plots total within sum of squares (y axis), which measures 
cluster compactness, against cluster number (x axis). The bend within the graph demonstrates 
optimal cluster size, and this is shown using the dotted line. Elbow graphs were generated 
using the NbClust package in R version 4.0.2.  












Appendix Figure 2. Elbow method for Cluster Analysis of Systolic Dysfunction patients in Chapter 4 
demonstrates a two cluster solution. The elbow method plots total within sum of squares (y axis), which 
measures cluster compactness, against cluster number (x axis). The bend within the graph demonstrates 
optimal cluster size, and this is shown using the dotted line. Elbow graphs were generated using the 
NbClust package in R version 4.0.2.   
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Appendix Figure 3. Elbow method for Cluster Analysis of Diastolic Dysfunction patients in Chapter 4 
demonstrates a two cluster solution. The elbow method plots total within sum of squares (y axis), which 
measures cluster compactness, against cluster number (x axis). The bend within the graph demonstrates 
optimal cluster size, and this is shown using the dotted line. Elbow graphs were generated using the 
NbClust package in R version 4.0.2. 


























Sample One - Control 
Sample One - TNF-α 
Sample One - TGF-β1 






Sample Two - Control 
Sample Two - TNF-α 
Sample Two - TGF-β1 






Sample Three - Control 
Sample Three - TNF-α 
Sample Three - TGF-β1 











Appendix Figure 4. Agilent 2100 Bioanalyzer traces for all of the prepared library samples 
included in RNA-sequencing in Chapter 5. The y-axis measures the fluorescent units 
(concentration) and the x-axis measures fragment size (bp). The library sample is shown at 
~150 bp and is in-between the lower DNA marker (35 bp) and the upper DNA marker 
(10,380 bp). The sample and stimulation condition is recorded for each bioanalyzer trace.  
